UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2021

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________ to

Commission File Number 000-52985

SANUWAVE Health, Inc.
(Exact name of registrant as specified in its charter)

Nevada
 
20-1176000
(State or other jurisdiction of incorporation or organization)
 
(I.R.S. Employer Identification No.)

3360 Martin Farm Road, Suite 100
Suwanee, GA
 
30024
(Address of principal executive offices)
 
(Zip Code)

(770) 419-7525
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which
registered
Common Stock, par value $0.001
SNWV
 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    ☐  Yes  ☒ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    ☐ Yes ☒  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act (Check one):

 
Large accelerated filer ☐
Accelerated filer ☐
 
Non-accelerated filer ☒
Smaller reporting company  ☒
   
Emerging growth company  ☐
 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐  Yes  ☒  No

 As of December 8, 2021 there were issued and outstanding 481,619,621 shares of the registrant’s common stock, $0.001 par value.

SANUWAVE Health, Inc. shares of common stock are traded on the OTC Expert Market under the symbol SNWV.



 SANUWAVE Health, Inc.

Table of Contents

   
Page
     
PART I – FINANCIAL INFORMATION
 
     
Item 1.
4
     
  4
     
 
5
     
 
6
     
 
7
     
 
8
     
Item 2.
20
     
Item 3.
24
     
Item 4.
24
     
PART II – OTHER INFORMATION
 
Item 1.
26
     
Item 1A.
26
     
Item 2.
26
     
Item 3.
26
     
Item 4.
26
     
Item 5.
26
     
Item 6.
27
     
  28

Special Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q of SANUWAVE Health, Inc. and its subsidiaries (“SANUWAVE” or the “Company”) contains forward-looking statements.  All statements in this Quarterly Report on Form 10-Q, including those made by the management of the Company, other than statements of historical fact, are forward-looking statements. Examples of forward-looking statements include statements regarding: the potential impact of the COVID-19 pandemic on our business, results of operations, liquidity, and operations, including the effect of governmental lockdowns, restrictions and new regulations on our operations and processes, including the execution of clinical trials; the Company’s future financial results, operating results, and projected costs;  market acceptance of and demand for UltraMIST, dermaPACE and our product candidates; management’s plans and objectives for future operations; industry trends; regulatory actions that could adversely affect the price of or demand for our approved products; our intellectual property portfolio; our business, marketing and manufacturing capacity and strategy; estimates regarding our capital requirements, the anticipated timing of the need for additional funds, and our expectations regarding future capital-raising transactions, including through investments by strategic partners for market opportunities, which may include strategic partnerships or licensing agreements, or raising capital through the conversion of outstanding warrants or issuances of securities; product liability claims; economic conditions that could adversely affect the level of demand for or cost of our products; timing of clinical studies and eventual FDA approval of our products; financial markets; the competitive environment; supplier and customer disputes; and our plans to remediate our material weaknesses in our disclosure controls and procedures and our internal control over financial reporting.  These forward-looking statements are based on management’s estimates, projections and assumptions as of the date hereof and include the assumptions that underlie such statements.  Forward-looking statements may contain words such as “may,” “will,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential” and “continue,” the negative of these terms, or other comparable terminology.  Any expectations based on these forward-looking statements are subject to risks and uncertainties and other important factors, including those discussed in the reports we file with the Securities and Exchange Commission (the “SEC”), specifically the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed on October 21, 2021.  Other risks and uncertainties are and will be disclosed in the Company’s prior and future SEC filings. These and many other factors could affect the Company’s future financial condition and operating results and could cause actual results to differ materially from expectations based on forward-looking statements made in this document or elsewhere by the Company or on its behalf.  The Company undertakes no obligation to revise or update any forward-looking statements. The following information should be read in conjunction with the financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed on October 21, 2021.

Except as otherwise indicated by the context, references in this Quarterly Report on Form 10-Q to “we,” “us” and “our” are to the consolidated business of the Company.

PART I -- FINANCIAL INFORMATION
Draft 12/2/2021
ITEM 1.
FINANCIAL STATEMENTS

SANUWAVE HEALTH, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
(In thousands except share data)

   
March 31, 2021
   
December 31, 2020
 
ASSETS
           
Current Assets:
           
Cash
 
$
96
   
$
2,437
 
Accounts receivable, net of allowance for doubtful accounts of $475 in 2021 and $343 in 2020
   
1,727
     
2,356
 
Inventory
   
2,935
     
2,956
 
Prepaid expenses and other current assets
   
405
     
179
 
Total Current Assets
   
5,163
     
7,928
 
Property and Equipment, net
   
531
     
471
 
Right of Use Assets, net
   
685
     
795
 
Other Intangible Assets, net
   
6,369
     
6,545
 
Goodwill
   
7,260
     
7,260
 
Other Assets
   
271
     
28
 
Total Assets
 
$
20,279
   
$
23,027
 
                 
LIABILITIES
               
Current Liabilities:
               
Senior secured promissory note payable, in default
 
$
10,903
   
$
10,676
 
Convertible promissory notes payable, in default
   
4,000
     
4,000
 
Convertible promissory notes, related parties, in default
   
1,596
     
1,596
 
Accounts payable
   
5,728
     
4,454
 
Accrued expenses
   
2,492
     
2,127
 
Accrued employee compensation
   
2,463
     
2,541
 
Warrant liability
   
6,191
     
8,855
 
Current portion of SBA loans
   
464
     
321
 
Accrued interest
   
981
     
1,021
 
Accrued interest, related parties
   
124
     
77
 
Current portion of lease liabilities
   
414
     
451
 
Current portion of contract liabilities
   
32
     
32
 
Other
   
-
     
23
 
Total Current Liabilities
   
35,388
     
36,174
 
Non-current Liabilities
               
SBA loans
   
1,033
     
143
 
Lease liabilities
   
319
     
391
 
Contract liabilities
   
156
     
37
 
Deferred tax liability
   
16
     
-
 
Total Non-currrent Liabilities
   
1,524
     
571
 
Total Liabilities
   
36,912
     
36,745
 
                 
Contingencies
               
                 
STOCKHOLDERS’ DEFICIT
               
                 
Preferred Stock, par value $0.001, 5,000,000 shares authorized; 6,175, 293, 90 and 8 shares designated Series A, Series B, Series C and Series D, respectively; no shares issued and outstanding at March 31, 2021 and December 31, 2020
   
-
     
-
 
Common Stock, par value $0.001, 800,000,000 shares authorized; 481,619,621 and 470,694,621 issued and outstanding at March 31, 2021 and December 31, 2020, respectively
   
482
     
471
 
Additional Paid-in Capital
   
144,582
     
142,563
 
Accumulated Deficit
   
(161,627
)
   
(156,690
)
Accumulated Other Comprehensive Loss
   
(70
)
   
(62
)
Total Stockholders’ Deficit
   
(16,633
)
   
(13,718
)
Total Liabilities and Stockholders’ Deficit
 
$
20,279
   
$
23,027
 

The accompanying notes to condensed consolidated financial
statements are an integral part of these statements.

SANUWAVE HEALTH, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(UNAUDITED)
(In thousands except share data)

   
Three Months Ended March 31,
 
   
2021
   
2020
 
             
Revenues:
           
Product
 
$
253
   
$
75
 
Accessory and parts revenue
   
1,825
     
63
 
License fees and other
   
38
     
11
 
Total Revenues
   
2,116
     
149
 
                 
Cost of Revenues
   
1,055
     
130
 

               
Gross Margin
   
1,061
     
19
 
                 
Operating Expenses:
               
Research and development
   
354
     
287
 
Selling and marketing
   
1,780
     
608
 
General and administrative
   
3,321
     
1,920
 
Total Operating Expenses
   
5,455
     
2,815
 
                 
Operating Loss
   
(4,394
)
   
(2,796
)
                 
Other Income (Expense), net
               
Change in fair value of warrant liability
   
635
     
-
 
Interest expense
   
(1,122
)
   
(19
)
Interest expense, related party
   
(47
)
   
(183
)
Loss on foreign currency exchange
   
7
     
(4
)
Other Income (Expense), net
   
(527
)
   
(206
)
                 
Net Loss before Income Taxes
   
(4,921
)
   
(3,002
)
                 
Provision for Income Taxes
   
16
     
-
 
                 
Net Loss
   
(4,937
)
   
(3,002
)
                 
Other Comprehensive Loss
               
Foreign currency translation adjustments
   
(8
)
   
5
 
                 
Total Comprehensive Loss
 
$
(4,945
)
 
$
(2,997
)
                 
Loss per Share:
               
Net loss per share, basic and diluted
 
$
(0.01
)
 
$
(0.01
)
                 
Weighted average shares outstanding, basic and diluted
   
518,490,225
     
296,061,866
 

 The accompanying notes to condensed consolidated financial
 statements are an integral part of these statements.

SANUWAVE HEALTH, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT
(UNAUDITED)
(In thousands except share data)

 
Preferred Stock
   
Common Stock
                         
   
Number of
Shares
Issued and
Outstanding
   
Par Value
   
Number of
Shares
Issued and
Outstanding
   
Par Value
   
Additional Paid-
in Capital
   
Accumulated
Deficit
   
Accumulated
Other
Comprehensive
Loss
   
Total
 
                                                 
Balances as of December 31, 2020
   
-
   
$
-
     
470,694,621
   
$
471
   
$
142,563
   
$
(156,690
)
 
$
(62
)
 
$
(13,718
)
Cashless warrant exercise
   
-
     
-
     
10,925,000
     
11
      (11
)
   
-
     
-
      -  
Reclassification of warrant liability due to cashless warrant exercise
   
-



-



-



-



2,030



-



-



2,030  
Net loss
   
-
     
-
     
-
     
-
     
-
     
(4,937
)
   
-
     
(4,937
)
Foreign currency translation adjustment
   
-
     
-
     
-
     
-
     
-
     
-
     
(8
)
   
(8
)
Balances as of March 31, 2021
   
-
   
$
-
     
481,619,621
   
$
482
   
$
144,582
   
$
(161,627
)
 
$
(70
)
 
$
(16,633
)
                     
-
                                         
Balances as of December 31, 2019
   
-
   
$
-
     
293,780,400
   
$
294
   
$
115,458
   
$
(125,752
)
 
$
(62
)
 
$
(10,062
)
Proceeds from warrant exercise
   
-
     
-
     
1,000,000
     
1
     
9
     
-
     
-
     
10
 
Shares issued for services
   
-
     
-
     
1,000,000
     
1
     
199
     
-
     
-
     
200
 
Stock-based compensation
   
-
     
-
     
-
     
-
     
21
     
-
     
-
     
21
 
Conversion of short term notes
   
-
     
-
     
1,820,461
     
2
     
262
     
-
     
-
     
264
 
Conversion of advances from related parties
   
-
     
-
     
62,811
     
-
     
3
     
-
     
-
     
3
 
Net loss
   
-
     
-
     
-
     
-
     
-
     
(3,002
)
   
-
     
(3,002
)
Foreign currency translation adjustment
   
-
     
-
     
-
     
-
     
-
     
-
     
4
     
4
 
Balances as of March 31, 2020
   
-
   
$
-
     
297,663,672
   
$
298
   
$
115,952
   
$
(128,754
)
 
$
(58
)
 
$
(12,562
)

 The accompanying notes to condensed consolidated financial
 statements are an integral part of these statements.

SANUWAVE HEALTH, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(In thousands)

   
Three Months Ended March 31,
 
   
2021
   
2020
 
Cash Flows - Operating Acivities:
           
Net loss
 
$
(4,937
)
 
$
(3,002
)
Adjustments to reconcile net loss to net cash used by operating activities
               
Amortization of intangibles
   
176
     
-
 
Depreciation
   
94
     
53
 
Bad debt expense
   
132
     
83
 
Share-based payment
   
-
     
222
 
Deferred taxes
   
16
     
-
 
Change in warrant valuation
    (635
)
   
-
 
Amortization of debt issuance costs and original issue discount
   
228
     
-
 
Accrued interest
   
(40
)
   
2
 
Interest payable, related parties
   
47
     
183
 
Changes in operating assets and liabilities
               
Accounts receivable - trade
   
489
     
(111
)
Inventory
   
21
     
24
 
Prepaid expenses
   
(444
)
   
(104
)
Other assets
   
(24
)
   
(1
)
Operating leases
   
(6
)
   
(3
)
Accounts payable
   
1,274
     
(323
)
Accrued expenses
   
365
     
65
 
Accrued employee compensation
   
(78
)
   
289
 
Contract liabilties
   
(22
)
   
(23
)
Net Cash Used by Operating Activities
   
(3,344
)
   
(2,646
)
                 
Cash Flows - Investing Activities
               
Purchases of property and equipment
   
(101
)
   
(5
)
Net Cash Flows Used by Investing  Activities
   
(101
)
   
(5
)
                 
Cash Flows - Financing Activities
               
Proceeds from sale of convertible preferred stock
   
-
     
2,250
 
Proceeds from SBA loan
   
1,033
     
-
 
Proceeds from warrant exercises
   
-
     
10
 
Proceeds from related party deposits
   
125
     
-
 
Payments of principal on finance leases
   
(46
)
   
(28
)
Net Cash Flows Provided by Financing Activities
   
1,112
     
2,232
 
                 
Effect of Exchange Rates on Cash
   
(8
)
   
5
 
                 
Net Change in Cash During Period
   
(2,341
)
   
(414
)
                 
Cash at Beginning of Period
   
2,437
     
1,761
 
Cash at End of Period
 
$
96
   
$
1,347
 
     
         
Supplemental Information:
               
Cash paid for interest
 
$
934
   
$
-
 
                 
Non-cash Investing and Financing Activities:
               
Cashless warrant exercise
 
$
2,030
   
$
-
 
Conversion of short-term notes payable to equity
   
-
     
264
 
Conversion of advamces from related parties to equity
   
-
     
2
 
Additions to right of use assets from new finance lease liabilities
   
-
     
128
 

 The accompanying notes to condensed consolidated financial
 statements are an integral part of these statements.

SANUWAVE HEALTH, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
March 31, 2021

1.
Nature of the Business and Basis of Presentation

SANUWAVE Health, Inc. and Subsidiaries (“SANUWAVE” or the “Company”) is focused on the research, development, and commercialization of its patented noninvasive and biological response activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. The Company’s lead regenerative product in the United States is the dermaPACE® device used for treating diabetic foot ulcers.

Through the Company’s acquisition, on August 6, 2020, of the UltraMIST® assets from Celularity, Inc. (“Celularity”), SANUWAVE now combines two highly complementary and market-cleared energy transfer technologies and two human tissue biologic products, which creates a platform of scale with an end-to-end product offering in the advanced wound care market.

Basis of Presentation – The accompanying unaudited Condensed Consolidated Financial Statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X.  Accordingly, these Condensed Consolidated Financial Statements do not include all the information and disclosures required by U.S. GAAP for comprehensive financial statements. The financial information as of March 31, 2021 and for the three months ended March 31, 2021 and 2020 is unaudited; however, in the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2021 are not necessarily indicative of the results that may be expected for any other interim period or for the year ending December 31, 2021.

The Condensed Consolidated Balance Sheet at December 31, 2020 has been derived from the audited Consolidated Financial Statements at that date but does not include all of the information and disclosures required by U.S. GAAP for comprehensive financial statements.  These financial statements should be read in conjunction with the Company’s December 31, 2020 Annual Report on Form 10-K filed with the SEC on October 21, 2021 (the “2020 Annual Report”).

Reclassifications – Certain accounts in the prior period Condensed Consolidated Financial Statements have been reclassified to conform to the presentation of the current year Condensed Consolidated Financial Statements.  Accessory and parts revenue for the quarter ended March 31, 2020 contains $63 thousand of revenue that was reclassified from other revenue.  In addition, $41 thousand of depreciation expense related to rental devices was reclassified from operating expenses to cost of revenues for the quarter ended March 31, 2020.   These reclassifications had no effect on the previously reported operating results.

Covid-19 – The worldwide spread of the COVID-19 virus has resulted and is expected to result in a global slowdown of economic activity which has, and is likely to continue to, decrease demand for a broad variety of products, including from our customers, while also disrupting supply channels and marketing activities for an unknown period of time until the disease is contained.  Also, the pandemic may cause continued or additional actions by hospitals and clinics such as limiting elective procedures and treatments and limiting clinical trial activities and data monitoring.  We expect all of these factors to continue to have a negative impact on our sales and our results of operations, the size and duration of which we are currently unable to predict.

2.
Going Concern

Our recurring losses from operations and dependency upon future issuances of equity or other financing to fund ongoing operations have raised substantial doubt as to our ability to continue as a going concern. We will be required to raise additional funds to finance our operations and remain a going concern; we may not be able to do so, and/or the terms of any financings may not be advantageous to us.

The continuation of our business is dependent upon raising additional capital. We expect to devote substantial resources for the commercialization of the dermaPACE system and will continue to research and develop the non-medical uses of the PACE technology, both of which will require additional capital resources.  The operating losses and the events of default on the Company’s notes payable indicate substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve months from the filing of this Form 10-Q.

The continuation of our business is dependent upon raising additional capital to fund operations.  Management’s plans are to obtain additional capital in 2022 through investments by strategic partners for market opportunities, which may include strategic partnerships or licensing arrangements, or raise capital through the conversion of outstanding warrants, issuance of common or preferred stock, securities convertible into common stock, or secured or unsecured debt.  These possibilities, to the extent available, may be on terms that result in significant dilution to our existing shareholders.  In addition, there can be no assurances that our plans to obtain additional capital will be successful on the terms or timeline we expect, or at all.  Although no assurances can be given, management believes that potential additional issuances of equity or other potential financing transactions as discussed above should provide the necessary funding for us. If these efforts are unsuccessful, we may be required to significantly curtail or discontinue operations or, if available, obtain funds through financing transactions with unfavorable terms.

The accompanying Condensed Consolidated Financial Statements have been prepared in conformity with U.S. GAAP, which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the Condensed Consolidated Financial Statements do not necessarily purport to represent realizable or settlement values. The Condensed Consolidated Financial Statements do not include any adjustment that might result from the outcome of this uncertainty. Our Condensed Consolidated Financial Statements do not include any adjustments relating to the recoverability of assets and classification of assets and liabilities that might be necessary should we be unable to continue as a going concern.

3.
Summary of Significant Accounting Policies

Significant accounting policies followed by the Company are summarized below and should be read in conjunction with those described in Note 3 to the Consolidated Financial Statements in our 2020 Annual Report.

Estimates – These Condensed Consolidated Financial Statements have been prepared in accordance with U.S. GAAP.  Because a precise determination of assets and liabilities, and correspondingly revenues and expenses, depend on future events, the preparation of consolidated financial statements for any period necessarily involves the use of estimates and assumptions.  Actual amounts may differ from these estimates.  These Condensed Consolidated Financial Statements have, in management’s opinion, been properly prepared within reasonable limits of materiality and within the framework of the accounting policies summarized herein.

Significant estimates include the recording of allowances for doubtful accounts, the net realizable value of inventory, useful lives of long-lived assets, fair value of goodwill and other intangible assets, the determination of the valuation allowances for deferred taxes and the estimated fair value of warrants.

Concentration of credit risk and limited suppliersMajor customers are defined as customers whose accounts receivable or sales individually consist of more than ten percent of total trade receivables or total sales, respectively.  The percentage of accounts receivable and sales from major customers of the Company for the periods indicated were as follows:

   
March 31, 2021
   
December 31, 2020
 
Accounts Receivable:
           
Customer A
   
15
%
   
46
%
                 
   
Three Months Ended
 
   
March 31, 2021
   
March 31, 2020
 
Revenue:
               
Customer B
   
n/a
     
66
%

The Company currently purchases most of its product component materials from single suppliers and the loss of any of these suppliers could result in a disruption in our production.  The percentage of purchases from major vendors of the Company that exceeded ten percent of total purchases for the three months ended March 31, 2021 and 2020 were as follows:

   
Three Months Ended
 
   
March 31, 2021
   
March 31, 2020
 
Purchases:
           
Vendor A
   
55
%
   
n/a
 
Vendor B
   
13
%
   
n/a
 
Vendor C
   
n/a
     
35
%
Vendor D
   
n/a
     
22
%
Vendor E
   
n/a
     
11
%

Goodwill and Other Intangible Assets – Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed. The Company accounts for goodwill under ASC Topic 350, Intangibles-Goodwill and Other. The Company tests goodwill for impairment annually, or more frequently whenever events or circumstances indicate impairment may exist. Goodwill is stated at cost less accumulated impairment losses. The Company completes its goodwill impairment test annually in the fourth quarter. Intangible assets arising from the Company’s acquisition are amortized on a straight‑line basis over the estimated useful life of each asset. Customer relationships have a useful life of seven years. Patents and tradenames have a useful life of nineteen years. At December 31, 2020, the Company determined that intangible assets related to certain customer relationships was impaired.  No additional impairment was indicated at March 31, 2021.

Recent Accounting Pronouncements – In August 2020, Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies the accounting for convertible instruments by removing the separation models for (1) convertible debt with a cash conversion feature and (2) convertible instruments with a beneficial conversion feature and simplifies the guidance for determining whether a conversion feature is a derivative. As a result, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost. These changes will reduce reported interest expense and increase reported net income for entities that have issued a convertible instrument that was bifurcated according to previously existing rules. In addition, ASU 2020-06 requires the application of the if-converted method for calculating diluted earnings per share and the treasury stock method will be no longer available. The new guidance is effective for fiscal years beginning after December 15, 2021, with early adoption permitted no earlier than fiscal years beginning after December 15, 2020. Effective January 1, 2021, the Company elected to early adopt ASU 2020-06 using the modified retrospective method.  The adoption of ASU 2020-06 had no impact previously reported financial position or operating results.

In May 2021, the FASB issued ASU 2021-04, Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40). This ASU reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. This ASU provides guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic. It specifically addresses: (1) how an entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; (2) how an entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; and (3) how an entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange. This ASU will be effective for all entities for fiscal years beginning after December 15, 2021. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted, including adoption in an interim period. The adoption of ASU 2021-04 is not expected to have a material impact on the Company’s financial statements or disclosures.

In December 2019, the FASB issued ASU 2019-12 Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. ASU 2019-12 simplifies the accounting for income taxes in several areas including calculating taxes in an interim period, clarifying how to account for taxes that are partially based on income and requiring an entity to reflect the effect of an enacted change in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date.  This amendment is effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company adopted ASU 2019-12 effective January 1, 2021 with no impact on previously reported financial position or operating results.

In January 2017, the FASB issued ASU 2017-04, Intangibles—Goodwill and Other (Topic 350) Simplifying the Test for Goodwill Impairment. The amendments in ASU 2017-04 modified the testing that an entity should perform for its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider income tax effects from any tax-deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. This amendment is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted ASU 2017-04 effective January 1, 2021.  The adoption of this guidance did not impact our results of operations or financial position.

4.
Loss per Share

The net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares outstanding for the three months ended March 31, 2021 and 2020.  In accordance with ASC Topic 260-10-45-13, Earnings Per Share, the weighted average of number of shares outstanding includes outstanding common stock and shares issuable for nominal consideration.  Accordingly, warrants issued with a $0.01 per share exercise price, are included in weighted average shares outstanding as follows:

   
2021
   
2020
 
Weighted average shares outstanding
           
Common shares
   
481,619,621
     
296,061,866
 
Common shares issuable assuming excercise of nominally priced warrants
   
36,870,604
     
-
 
Weighted average shares outstanding
   
518,490,225
     
296,061,866
 

Diluted net loss per share would be computed by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding. To the extent that securities are “anti-dilutive,” they are excluded from the calculation of diluted net loss per share.  As a result of the net loss for the three months ended March 31, 2021 and 2020, all potentially dilutive shares were anti-dilutive and therefore excluded from the computation of diluted net loss per share.  Anti-dilutive equity securities consist of the following at March 31, 2021 and 2020, respectively:

   
2021
   
2020
 
Common stock options
   
31,864,385
     
34,403,385
 
Common stock purchase warrants
   
142,265,576
     
8,374,091
 
Convertible notes payable
   
60,328,907
     
-
 
Short-term notes payable
   
-
     
2,250,000
 
Convertible preferred stock
   
-
     
16,071,429
 
     
234,458,868
     
61,098,905
 

5.
Inventory

Inventory consists of the following at March 31, 2021 and December 31, 2020 (in thousands):

   
2021
   
2020
 
Inventory - finished goods
 
$
2,270
   
$
2,276
 
Inventory - parts and accessories
   
665
     
680
 
Total inventory
 
$
2,935
   
$
2,956
 

6.
Accrued Expenses

Accrued expenses consist of the following at March 31, 2021 and December 31, 2020 (in thousands):

   
2021
   
2020
 
Outside services
 
$
191
   
$
347
 
License fees
   
298
     
336
 
Board of director’s fees
   
380
     
320
 
Registration penalties
   
1,055
     
264
 
Commissions
   
-
     
239
 
Legal and professional fees
   
139
     
197
 
Warranty reserve
   
180
     
180
 
Inventory purchases
   
72
     
91
 
Other
   
177
     
153
 
   
$
2,492
   
$
2,127
 

There was no activity in the warranty reserve during the three months ended March 31, 2021.

7.
Revenue

Disaggregation of Revenue - The disaggregation of revenue is based on geographical region. The following table presents revenue from contracts with customers for the three months ended March 31, 2021 and 2020 (in thousands):

   
Three Months Ended March 31, 2021
   
Three Months Ended March 31, 2020
 
   
United States
   
International
   
Total
   
United States
   
International
   
Total
 
Product
 
$
41
   
$
212
   
$
253
   
$
34
   
$
41
   
$
75
 
Accessories and parts
   
1,689
     
136
     
1,825
     
63
     
-
     
63
 
License fees and other
   
33
     
5
     
38
     
1
     
10
     
11
 
   
$
1,763
   
$
353
   
$
2,116
   
$
98
   
$
51
   
$
149
 

Contract liabilities - As of March 31, 2021 and December 31, 2020, the Company has contract liabilities from contracts with customers as follows (in thousands):

   
March 31,
2021
   
December 31,
2020
 
Service agreements
 
$
63
   
$
69
 
Deposit on future equipment purchases
   
125
     
-
 
Total contract liabilities
   
188
     
69
 
Less: current portion
   
(32
)
   
(32
)
Non-current contract liabilities
 
$
156
   
$
37
 

During the three months ended March 31, 2021 and 2020, the Company recognized revenue related to these contract liabilities of $8 thousand and $22 thousand, respectively, that were in the beginning contract liability balances for each of those periods.

8.
Debt with Related Parties

Debt with related parties at March 31, 2021 and December 31, 2020 consisted of the following (in thousands):

   
2021
   
2020
 
Maturity Date
 
Stated Interest
Rate
   
Incremental
Default
Interest
 
Convertible promissory notes (HealthTronics), related parties, in default
 
$
1,372
   
$
1,372
 
In default
   
12.0
%
   
+2.0
%
Convertible promissory notes (Stolarski), related parties, in default
   
224
     
224
 
In default
   
12.0
%
   
+2.0
%
Total debt with related parties
 
$
1,596
   
$
1,596
                   

Convertible promissory notes payable (HealthTronics), in default – On August 6, 2020, the Company issued to HealthTronics, Inc. a convertible note payable in the amount of $1.4 million (the “HealthTronics Note”). The HealthTronics Note matured on August 6, 2021 and was not repaid. The Company’s failure to pay the outstanding principal balance when due constituted an event of default under the terms of the HealthTronics Note and, accordingly, it began accruing additional interest of 2.0% in addition to the 12.0% stated interest rate, as of the date of the default. The convertible promissory note is expressly subordinate to the Senior Secured Notes (as defined in Note 9).

As the Seller Note (as defined in Note 9) was not repaid prior to January 1, 2021, HealthTronics may elect to convert the outstanding principal amount plus any accrued but unpaid interest thereon into shares of the Company’s common stock, at a conversion price of $0.10 per share. The Company evaluated embedded conversion features within the convertible promissory note and determined that the conversion feature does not require to be bifurcated.  Upon adoption of ASC 2020-6 effective January 1, 2021, the convertible promissory note is accounted for as a single liability due to the elimination of the beneficial conversion feature accounting model.

Convertible promissory notes payable (Stolarski), in default – On August 6, 2020, issued to A. Michael Stolarski, a member of the board of directors and an existing shareholder, a convertible promissory note in the principal amount of $223 thousand (the “Stolarski Note”). The Stolarski Note matured on August 6, 2021 and was not repaid. The Company’s failure to pay the outstanding principal balance when due constituted an event of default under the terms of the Stolarski Note and, accordingly, it began accruing additional interest of 2.0% in addition to the 12.0% initial rate, as of the date of the default. On March 31, 2021 and December 31, 2020 accrued interest of $17 thousand and $11 thousand, respectively, remained outstanding on the Stolarski Note.

As the Stolarski Note was not repaid prior to January 1, 2021, the holder may elect to convert the outstanding principal amount plus any accrued by unpaid interest thereon into shares of common stock at a conversion price of $0.10 per share. The Company evaluated embedded conversion features within the convertible promissory note and determined that the conversion feature does not require to be bifurcated.  Upon adoption of ASC 2020-6 effective January 1, 2021, the convertible promissory note is accounted for as a single liability due to the elimination of the beneficial conversion feature accounting model.

9.
Debt with Unaffiliated Parties

Debt with unaffiliated parties at March 31, 2021 and December 31, 2020 consisted of the following (in thousands):

   
2021
   
2020
 
Maturity Date
 
Stated Interest
Rate
   
Incremental
Payment in
Kind Interest
   
Incremental
Default Interest
 
Senior secured promissory note payable, in default::
                               
Principal
 
$
15,000
   
$
15,000
                     
Debt issuance costs
   
(1,440
)
   
(1,520
)
                   
Debt discount
   
(2,657
)
   
(2,804
)
                   
     
10,903
     
10,676
 
In default
   
12.25
%
   
+3.00
%
   
+5.00
%
Convertible promissory note payable, in default
   
4,000
     
4,000
 
In default
   
12.00
%
   
n/a
     
+5.00
%
SBA loan #1
   
464
     
464
 
May 28, 2022
   
1.00
%
   
n/a
     
n/a
 
SBA loan #2
   
1,033
     
-
 
February 20, 2026
   
1.00
%
   
n/a
     
n/a
 

   
16,400
     
15,140
                           
Less: current maturities including notes in default
   
(15,367
)
   
(14,997
)
                         
Debt with unafffiliated parties, long-term
 
$
1,033
   
$
143
                           

Senior secured promissory note payable, in default (“Senior Secured Note”) -  On August 6, 2020, the Company entered into a Note and Warrant Purchase and Security Agreement (the “NWPSA”), with NH Expansion Credit Fund Holdings LP, as noteholder and agent. In accordance with the NWPSA, the Company issued a $15 million Senior Secured Promissory Note Payable (the “Senior Secured Note”) and a warrant exercisable into shares of the Company’s common stock (the “NH Expansion Warrant”) in exchange for cash to support operations, repay outstanding debt and close on the acquisition of the UltraMIST assets from Celularity, among other transactions.  As of December 31, 2020, the Company was in default of the minimum liquidity provisions on the Senior Secured Note. As of March 31, 2021, the Company remains in default of the minimum liquidity provisions on the Senior Secured Note, and, as a result, it is classified in current liabilities in the accompanying Condensed Consolidated Balance Sheets. As a result of the default, the Company is accruing interest at the default interest note of an incremental 5%.

The debt issuance costs and debt discount related to the Senior Secured Note were capitalized as a reduction in the principal amount and are being amortized to interest expense over the life of the Senior Secured Note.  The amortization of the debt issuance costs and debt discount for the three months ended March 31, 2021 was $228 thousand and is included in interest expense. Accrued interest related to the Senior Secured Note was $666 thousand and $642 thousand at March 31, 2021 and December 31, 2020, respectively.  Interest expense on the Senior Secured Note was $760 thousand for the three months ended March 31, 2021.

Convertible promissory notes payable, in default (“Seller Note”) - On August 6, 2020, the Company entered into an asset purchase agreement with Celularity to acquire Celularity’s UltraMIST assets. A portion of the aggregate consideration of $24 million paid for the assets included the issuance of a promissory note to Celularity in the principal amount of $4 million (the “Seller Note”). The Seller Note matured on August 6, 2021 and was not repaid. The Company’s failure to pay the outstanding principal balance when due constituted an event of default under the terms of the Seller Note and, accordingly, it began accruing additional interest of 5.0% in addition to the 12.0% initial rate, as of the date of the default. As of March 31, 2021 and December 31, 2020, the Seller Notes had outstanding accrued interest of $312 thousand and $192 thousand, respectively.

The Company evaluated embedded conversion features within the convertible promissory note and determined that the conversion feature does not require to be bifurcated.  Upon adoption of ASC 2020-6 effective January 1, 2021, the convertible promissory note is accounted for as a single liability due to the elimination of the beneficial conversion feature accounting model.

SBA Loan #1 - The Company received a letter from the Small Business Administration (“SBA”) dated August 27, 2021 forgiving approximately $454 thousand of the SBA Loan #1 principal and $6 thousand of interest.   As of March 31, 2021, all of the $464 thousand balance outstanding is classified as current.  As of December 31, 2020, $320 thousand is classified as current and $142 thousand is classified as non-current.

SBA Loan #2 – On February 20, 2021, the Company received proceeds from a second SBA loan (“SBA Loan #2”) in the amount of $1.03 million from Northeast Bank, as lender, pursuant to the Paycheck Protection Program (“PPP”) under the CARES Act. SBA Loan #2 is evidenced by a promissory note that matures on February 20, 2026 and bears interest of 1% per annum. Equal monthly payments of principal and interest commence in June 2022, after both a 24-week “covered period” and a 10-month “deferment period,” as defined in the promissory note and current SBA regulations. The SBA Loan #2 contains customary events of default relating to, among other things, payment defaults and breaches of representations, warranties and covenants. The SBA Loan #2 may be prepaid by the Company at any time prior to maturity with no penalties.

All or a portion of SBA Loan #2 may be fully or partially forgiven by the SBA upon application by the Company not later than June 2022 in accordance with SBA regulations.  The ultimate forgiveness of SBA Loan #2 is also contingent upon regulatory authorities concurring with management’s good faith assessment that the current economic uncertainty made the loan request necessary to support ongoing operations. If, despite the Company’s good-faith belief that given the circumstances the Company satisfied all eligibility requirements for SBA Loan #2, the Company is later determined to have violated any applicable laws or regulations or it is otherwise determined that the Company was ineligible to receive SBA Loan #2, the Company may be required to repay SBA Loan #2 in its entirety and/or be subject to additional penalties. In the event SBA Loan #2, or any portion thereof, is forgiven pursuant to the PPP, the amount forgiven is applied to outstanding principal.  As of March 31, 2021, the entire $1,033 thousand loan balance outstanding is included in non-current liabilities in the accompanying Condensed Consolidated Balance Sheets.

10.
Warrants

A summary of the warrant activity during the three months ended March 31, 2021 is as follows:

Warrant class
 
Outstanding
December 31,
2020
   
Exercised
   
Outstanding
March 31,
2021
   
Exercise
price/share
 
 Expiration
date
Class E Warrants
   
141,091,485
     
-
     
141,091,485
   
$
0.25
 
August 2023
Class O Warrants
   
909,091
     
-
     
909,091
     
0.11
 
 January 2022
Class P Warrants
   
265,000
     
-
     
265,000
     
0.20
 
June 2024
LGH Warrant
   
35,000,000
     
(11,400,000
)
   
23,600,000
     
0.01
 
June 2025
NH Expansion Warrant
   
13,091,160
     
-
     
13,091,160
     
0.01
 
 August 2030
Total
   
190,356,736
     
(11,400,000
)
   
178,956,736
              

On February 3, 2021, the Company issued 10,925,000 shares of its common stock to LGH upon the cashless exercise of 11,400,000 of the LGH Warrants under the terms of the warrant agreement.  After this cashless exercise, 23,600,000 of LGH Warrants remain outstanding.

11.
Warrant Liabilities

A summary of the warrant liability activity for the three months ended March 31, 2021 is as follows:

   
Warrants
Outstanding
   
Fair Value
per Share
   
Fair Value
 
Balance December 31, 2020
   
48,091,160
   
$
0.18
   
$
8,855,379
 
Cashless exercise of LGH Warrants
   
(11,400,000
)
   
0.18
     
(2,030,025
)
Gain on remeasurement of warrant liability
                   
(634,672
)
Balance March 31, 2021
   
36,691,160
   
$
0.17
   
$
6,190,682
 

NH Expansion Warrants -- Significant Black Scholes valuation model inputs related to the NH Expansion Warrants at March 31, 2021 and December 31, 2020 are as follows:

Black Scholes option pricing model
   
March 31,2021
   
December 31, 2020
 
Exercise Price(1)
 
$
0.01
   
$
0.01
 
Warrant Expiration Date (1)
 
August 6, 2030
   
August 6, 2030
 
Interest Rate (annual) (2)
   
0.70
%
   
0.65
%
Volatility (annual) (3)
   
145.04
%
   
143.94
%
Time to Maturity (Years)
   
9.4
     
9.6
 
Calculated fair value per share
 
$
0.1700
   
$
0.1891
 

(1) Based on the terms provided in the warrant agreement to purchase common stock of the Company dated August 6, 2020.

(2) Interest rate for U.S. Treasury Bonds, as of each presented period ending date, as published by the U.S. Federal Reserve.

(3) Based on the historical daily volatility of the Company as of each presented period ending date.

LGH Warrants – On June 5, 2020, the Company entered into a securities purchase agreement with investor LGH Investments LLC ("LGH") for warrants entitling LGH to acquire 1,075,000 shares of common stock (the “LGH Warrants”), among other things.  The LGH Warrants contain certain ratchet provisions with respect to subsequent issuances of securities by the Company at a price below the exercise price of such warrants. As a result of certain dilutive issuances of securities by the Company on August 6, 2020, the exercise price of the LGH Warrants decreased to $0.01 per share and the number of shares subject to the LGH Warrants increased to 35,000,000 shares. As a result, the Company determined that these warrants meet the definition of a derivative liability. The fair value of the LGH Warrant liabilities was determined using the Black-Scholes option pricing model which approximates the binomial pricing model. Significant inputs into the model at March 31, 2021 and December 31, 2020 are as follows:

Black Scholes option pricing model
   
March 31, 2021
   
December 31, 2020
 
Exercise Price(1)
 
$
0.01
   
$
0.01
 
Warrant Expiration Date (1)
 
June 5, 2025
   
June 5, 2025
 
Interest Rate (annual) (2)
   
0.37
%
   
0.36
%
Volatility (annual) (3)
   
100.16
%
   
99
%
Time to Maturity (Years)
   
4.2
     
4.4
 
Calculated fair value per share
 
$
0.1680
   
$
0.1823
 

  (1)
Based on the terms provided in the warrant agreement to purchase common stock of the Company dated August 6, 2020.
  (2)
Interest rate for U.S. Treasury Bonds, as of each presented period ending date, as published by the U.S. Federal Reserve.
  (3)
Based on the historical daily volatility of the Company as of each presented period ending date.

12.
Leases

The following is a summary of the Company’s right of use assets and lease liabilities at March 31, 2021 and December 31, 2020 (in thousands):

   
March 31, 2021
   
December 31, 2020
 
    
Operating
Leases
   
Financing
Leases
   
Total
   
Operating
Leases
   
Financing
Leases
   
Total
 
Right of use assets
 
$
725
   
$
644
   
$
1,369
   
$
725
   
$
644
   
$
1,369
 
Less: Accumulated amortization
   
(396
)
   
(288
)
   
(684
)
   
(339
)
   
(235
)
   
(574
)
Right of use assets, net
 
$
329
   
$
356
   
$
685
   
$
386
   
$
409
   
$
795
 
                                                 
Lease liabilities
 
$
352
   
$
381
   
$
733
   
$
415
   
$
427
   
$
842
 
Less: current portion
   
(214
)
   
(200
)
   
(414
)
   
(257
)
   
(194
)
   
(451
)
Lease Liabilities
 
$
138
   
$
181
   
$
319
   
$
158
   
$
233
   
$
391
 

Total lease costs for the three months ended March 31, 2021 and 2020 are as follows (in thousands):

   
2021
   
2020
 
Finance lease costs:
           
Amortization of right-of-use assets
 
$
53
   
$
41
 
Interest on lease liabilities
   
13
     
12
 
Operating lease costs
   
83
     
52
 
Total lease costs
 
$
149
   
$
105
 

The following summarizes cash paid for amounts included in the measurement of lease liabilities as well as the related right-of-use assets obtained for the three months ended March 31, 2021 and 2020 (in thousands):

   
2021
   
2020
 
Cash paid for amouonts included in measurement of lease liabilities:
           
Operating cash flows from finance leases
 
$
(59
)
 
$
(40
)
Operating cash flows from operating leases
 
$
(83
)
 
$
(55
)


Operating Leases - As of March 31, 2021, the maturities of the Company’s operating lease liability, which have initial or remaining lease terms in excess of one year, consist of the following (in thousands):

   
Amount
 
Year ending December 31,
     
2021 (remainder of year)
 
$
210
 
2022
   
94
 
2023
   
65
 
2024
   
8
 
2025
   
3
 
Total lease payments
   
380
 
Less: Present value adjustment
   
(28
)
Lease liability
 
$
352
 

As of March 31, 2021, the Company’s operating leases had a weighted average remaining lease term of 1.9 years and a weighted average discount rate of 10.0%.

Rent expense for the three months ended March 31, 2021 and 2020 was $83 thousand and $52 thousand, respectively.

Financing Lease - As of March 31, 2021, the maturities of the Company’s financing lease liability, which have initial or remaining lease terms in excess of one year, consist of the following (in thousands):

   
Amount
 
Year ending December 31,
     
2021 (remainder of year)
 
$
176
 
2022
   
200
 
2023
   
18
 
Total lease payments
   
394
 
Less: Present value adjustment
   
(13
)
Lease liability
 
$
381
 

As of March31, 2021, the Company’s financing leases had a weighted average remaining lease term of 2.0 years based on annualized base payments expiring through 2023 and a weighted average discount rate of 13.2%.

As of March 31, 2021, the Company did not have additional operating or financing leases that have yet commenced.

13.
Contingencies

Supplier disputes - In May 2021, the Company received notification alleging that it is not in compliance with the license agreement with Celularity entered into in connection with the acquisition of the UltraMIST assets.  The Company has responded and asserted that the Company is not in breach and that the supplier has breached various agreements.  It is too early to determine the outcome of this matter.  Any potential impact to the Company cannot be fully determined at this time and there is no guarantee that the dispute will be resolved in a manner beneficial to the Company or at all.

As part of the Asset Purchase Agreement on August 6, 2020, the Company assumed obligations for a purchase order for UltraMIST devices from Celularity’s vendor Minnetronix. This purchase order had a remaining purchase commitment of approximately $1.1 million. The purchase order also calls for production delay fees of 1.25% of the committed inventory if the Company delays production.  There is also a cancelation clause of 20% of the remaining balance in the event that the Company delays production for more than six months. On September 23, 2021, Minnetronix notified the Company that it was cancelling the purchase order for the UltraMIST devices as a result of the Company delaying production more than six months. This notification includes fees and charges for the cancellation of the purchase order of an additional $320 thousand. The Company expects to be able to resume production upon paying this obligation. While the Company is disputing certain aspects of this termination notice and is continuing to engage with Minnetronix regarding resolution of this matter, including reinstatement of the purchase order, there is no guarantee that the dispute will be resolved in a manner beneficial to the Company or at all.

14.
Related Party Transactions

On February 13, 2018, the Company entered into an Agreement for Purchase and Sale, Limited Exclusive Distribution and Royalties, and Servicing and Repairs with Premier Shockwave Wound Care, Inc., a Georgia Corporation (“PSWC”), and Premier Shockwave, Inc., a Georgia Corporation (“PS”). Each of PS and PSWC is owned by A. Michael Stolarski, a member of the Company’s board of directors and an existing shareholder of the Company  The agreement provides for the purchase by PSWC and PS of dermaPACE System and related equipment sold by the Company along with limited but exclusive distribution rights to provide dermaPACE Systems to certain governmental healthcare facilities and the agreement contains provisions whereby in the event of a change of control of the Company (as defined in the agreement), the stockholders of PSWC have the right and option to cause the Company to purchase all of the stock of PSWC, and whereby the Company has the right and option to purchase all issued and outstanding shares of PSWC, in each case based upon certain defined purchase price provisions and other terms.

During the three months ended March 31, 2021 and 2020, the Company recorded $8 thousand and $13 thousand, respectively, in revenue from an entity owned by this related party.  In addition, contract liabilities includes a balance of $63 thousand at March 31, 2021 and $69 thousand at December 31, 2020 from this related party.

In March 2021, PSWC paid the Company $125 thousand as a deposit for future purchase of new medical equipment.  Please see Note 16 – Subsequent Events in the accompanying Condensed Consolidated Financial Statements for discussion of advances from directors in October 2021.

15.
Income Taxes
 
The provision for income taxes of $16 thousand and deferred tax liability are related to the goodwill of $7.3 million recorded as part of the acquisition of the Celularity assets and is known as a “naked credit”. The goodwill was assigned an indefinite life for book purposes but is deductible for income tax purposes over a fifteen-year life.  As a result, the deferred tax liability has an indefinite life and cannot be used as a source of taxable income to support the realization of other deferred tax assets.
 
16.
Subsequent Events

April 2021 Securities Purchase Agreement and Warrants (In default) -  On April 20, 2021, the Company entered into a Securities Purchase Agreement (the “Leviston Purchase Agreement”), with Leviston Resources, LLC, an accredited investor (“Leviston”) for the sale by the Company in a private placement (the “Private Placement”) of (i) the Company’s future advance convertible promissory note in an aggregate principal amount of up to $3.4 million (the “Leviston Note”) and (ii) a warrant to purchase an additional 16,666,667 shares of common stock of the Company (the “Leviston Warrant”). The Leviston Warrant has an exercise price of $0.18 per share and a four-year term. The closing of the Private Placement occurred on April 20, 2021 (the “Leviston Closing Date”).

As noted above, on April 20, 2021, the Company issued the Leviston Note to the Purchaser in an aggregate principal amount of up to $3.4 million (the “Aggregate Amount”), which shall be advanced in disbursements by the Purchaser (“Leviston Disbursements”), as set forth in the Leviston Note. On May 14, 2021, the Leviston Note was amended to increase the Aggregate Amount to $4.2 million. On April 21, 2021, the Purchaser advanced a Leviston Disbursement of $750 thousand, which is net of an original issue discount of 8%. Subsequent to April 21, 2021 the Purchaser made two additional disbursements, net of 8% original issue discounts, totaling $1.0 million, $750 thousand on May 14, 2021 and $250 thousand on September 3, 2021. The remaining disbursements up to the Aggregate Amount are subject to the satisfaction of certain terms and conditions set forth in the Leviston Note. Leviston Disbursements bear an interest at a rate of five percent (5%) per annum and have a maturity date of twelve (12) months from the date of issuance. The Leviston Note is convertible at the option of the holder into shares of the common stock of the Company at a conversion price per share equal to the lesser of (i) $0.18, and (ii) ninety percent (90%) of the closing price for a share of common stock reported on the OTCQB on the effective date of the Registration Statement (as defined below).

The Leviston Note contains customary events of default and covenants, including limitations on incurrences of indebtedness and liens.

Pursuant to the Leviston Purchase Agreement, the Company has agreed, within a reasonable period of time following the Leviston Closing Date, and in any event prior to any Leviston Disbursement under the Leviston Note subsequent to the initial Leviston Disbursement, to enter into a security agreement in favor of the Leviston, securing the Company’s obligations under the Leviston Note.

The rights of Leviston to receive payments under the Leviston Note are subordinate to the rights of North Haven Expansion pursuant to a subordination agreement, that the Company and Leviston entered into with North Haven Expansion on April 20, 2021, in connection with the Private Placement (the “Subordination Agreement”).

In connection with the Leviston Purchase Agreement, the Company entered into a registration rights agreement with the Leviston on April 20, 2021 (the “Leviston Registration Rights Agreement”) pursuant to which the Company agreed to file a registration statement (the “Registration Statement”) with the SEC no later than thirty days following the Leviston Closing Date for the registration of 100% of the maximum number of the shares issuable upon conversion of the Leviston Note and exercise of the Leviston Warrants issued pursuant to the Leviston Purchase Agreement (the “Leviston Registrable Securities”). The Company shall use its best efforts to keep the Registration Statement continuously effective under the Securities Act of 1933, as amended (the “Securities Act”), until all Leviston Registrable Securities have been sold, or may be sold without the requirement to be in compliance with Rule 144(c)(1) of the Securities Act and otherwise without restriction or limitation pursuant to Rule 144 of the Securities Act, as determined by the counsel to the Company.  The Company has yet to file the Registration Statement and, under the terms of the Leviston Registration Rights Agreement, it is obligated to pay in cash a one-time aggregate amount of $250 thousand to the holders of the Leviston Notes, plus 1% of the outstanding principal for each 30-day period during which the Company continues not to have in-place an effective Registration Statement.

On August 31, 2021, Leviston notified the Company that it was in default of the Leviston Purchase Agreement effective June 11, 2021 for failure to timely file a Registration Statement. From the date of the default, interest on the amounts due to Leviston is calculated at the default interest rate of 15% in addition to the registration penalties stated above.

June 2021 Accounts Receivable Factoring Agreement – On June 17, 2021, the Company entered into a factoring agreement with Goodman Capital Finance (“Goodman”), an unrelated third party, pursuant to which the Company may sell certain of its accounts receivable to Goodman for 86.25% of the value of the receivable. Advances available under the facility are capped at the lesser of $3.0 million or a formula amount, as defined in the agreement. The agreement’s term is one month and automatically renews for additional one-month periods, unless either party provides 30 days’ notice of termination. The accounts receivable are sold with recourse back to the Company, which means that the Company bears the risk of non-payment by the account debtor.

September 2021 Securities Purchase Agreement and Warrants (In default) - On September 3, 2021, the Company entered into Securities Purchase Agreements (the “September 2021 Purchase Agreements”), with certain accredited investors (collectively, the “September 2021 Purchasers”) for the sale by the Company in a private placement (the “September 2021 Private Placement”) of (i) the Company’s future advance convertible promissory notes in an aggregate principal amount of up to $543 thousand (the “September 2021 Notes”) and (ii) warrants to purchase an additional 2,777,779 shares of common stock of the Company (the “September 2021 Warrants”). The September 2021 Warrants have an exercise price of $0.18 per share and a five-year term. The closing of the September 2021 Private Placement occurred on September 7, 2021 (the “September 2021 Purchasers Closing Date”).

Under the terms of the September 2021 Purchase Agreements, the aggregate principal amount of the September 2021 Notes of up to $543 thousand (the “Aggregate Amount”), may be advanced in disbursements by the September 2021 Purchasers (“September 2021 Purchasers Disbursements”), as set forth in the September 2021 Notes. The September 2021 Purchasers Disbursements bear an interest at a rate of five percent (5%) per annum and have a maturity date of twelve (12) months from the date of issuance. Each September 2021 Note is convertible at the option of the holder into shares of common stock of the Company at a conversion price per share equal to (A) until the date of effectiveness of the Registration Statement, $0.18 and (B) after the date of effectiveness of the Registration Statement, the lesser of (i) $0.18, (ii) ninety percent (90%) of the closing price for a share of common stock reported on the OTCQB on the effective date of the Registration Statement or (iii) 75% of the lowest volume weighted average price, as defined,, which shall be no lower than $0.01. The September 2021 Notes contain customary events of default and covenants, including limitations on incurrences of indebtedness and liens.

Pursuant to each September 2021 Purchase Agreement, the Company entered into a security agreement in favor of the applicable September 2021 Purchaser, securing the Company’s obligations under the applicable September 2021 Note. The rights of each September 2021 Purchaser to receive payments under their respective note is subordinate to the rights of North Haven Expansion pursuant to a Subordination Agreement, that the Company and each September 2021 Purchaser entered into with North Haven Expansion in connection with the September 2021 Private Placement.

In connection with each September 2021 Purchase Agreement, the Company entered into a registration rights agreement with the September 2021 Purchasers on September 3, 2021 (the “September 2021 Purchasers Registration Rights Agreement”) pursuant to which the Company has agreed to file a Registration Statement no later than ninety (90) days following the September 2021 Purchasers Closing Date for the registration of 100% of the maximum number of the shares issuable upon conversion of the September 2021 Notes and exercise of the September 2021 Warrants issued pursuant to such September 2021 Purchase Agreement (the “September 2021 Purchasers Registrable Securities”). The Company shall use its best efforts to keep the Registration Statement continuously effective under the Securities Act of 1933, as amended, until all September 2021 Purchasers Registrable Securities have been sold, or may be sold without the requirement to be in compliance with Rule 144(c)(1) of the Securities Act and otherwise without restriction or limitation pursuant to Rule 144 of the Securities Act, as determined by the counsel to the Company.

The September 2021 Notes were in default as of October 25, 2021 and, accordingly, on that date, interest began accruing at the default rate of 15% in addition to registration penalties per the September 2021 Purchasers Registration Rights Agreement.
 
The Company has yet to file the Registration Statement, and under the terms of the September 2021 Registration Rights Agreement, it is obligated to pay in cash a one-time aggregate amount of $250 thousand  to the holders of the September 2021 Notes, plus 1% of the outstanding principal for each 30-day period during which the Company continues not to have in-place an effective Registration Statement. As a result of this breach of the September 2021 Registration Rights Agreement, interest on the September 2021 Notes accrues at the default interest rate of 15%.

September 2021 Advances on Future Receipts Financing – On September 27, 2021, the Company received $703 thousand in cash proceeds related to its entry into a non-recourse agreement for the sale of $1.0 million of future receipts to GCF Resources LLC (“GCF”).   In conjunction with the 24-week agreement, the Company is obligated to remit to GCF a minimum of $59 thousand of receipts each week, with the sum of the first four payments occurring at closing, which was September 27, 2021.  After taking into account the payments made at closing, the Company will record an initial liability of $763 thousand and a debt discount of approximately $60 thousand, which represents the original issue discount and the fees paid in conjunction with the financing.  The debt discount will be amortized to interest expense over the life of the agreement.  The Company began making the required minimum weekly October 25, 2021 and is obligated to continue through March 7, 2022.

October 2021 Advances from Directors - On October 27, 2021 the Company received $50 thousand in advances from related parties; $25 thousand from NightWatch Capital Advisors, LLC, a company controlled by John Nemelka, a shareholder and member of the Company’s board of directors, (the “Nemelka Advance”) and $25 thousand from A. Michael Stolarski, also a shareholder and member of the Company’s board of directors (the “Stolarski Advance”).

In exchange for the Nemelka Advance, the Company issued to NightWatch Capital Advisors, LLC a promissory note in the principal amount of $25 thousand (the “Nemelka Note”). The Nemelka Note matures on June 30, 2022 and accrues interest at a rate equal to 15.0% per annum.  In exchange for the Stolarski Advance, as well as the $125 thousand deposit received in March 2021 by the Company (see Note 14), the Company issued to Mr. Stolarski a promissory note in the principal amount of $150 thousand (“Stolarski Note #2”). Stolarski Note #2 matures on June 30, 2022 and accrues interest at a rate equal to 15.0% per annum.

Item 2.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
 
You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated financial statements and the related notes appearing elsewhere in this report, and together with our audited consolidated financial statements, related notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” as of and for the year ended December 31, 2020 included in our Annual Report on Form 10-K, filed with the SEC on October 21, 2021 (the “2020 Annual Report”).

Overview
 
We are a shock wave technology company using a patented system of noninvasive, high-energy, acoustic shock waves for regenerative medicine and other applications. Our initial focus is regenerative medicine utilizing noninvasive, acoustic shock waves to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures.
 
Our lead regenerative product in the United States is the dermaPACE® device, used for treating diabetic foot ulcers (“DFU”), which was subject to two double-blinded, randomized Phase III clinical studies. On December 28, 2017, the U.S. Food and Drug Administration (“FDA”) granted the Company’s request to classify the dermaPACE® System as a Class II device via the de novo process. As a result of this decision, the Company was able to immediately market the product for the treatment of DFU as described in the de novo request, subject to the general control provisions of the Food, Drug and Cosmetic Act and the special controls identified in this order.
 
On August 6, 2020, we entered into an asset purchase agreement (the “Asset Purchase Agreement” or “Acquisition”) with Celularity Inc. (“Celularity”) pursuant to which we acquired Celularity’s UltraMIST assets (“UltraMIST” or the “Assets”). The UltraMIST® System provides through a fluid mist a low-frequency, non-contact, and pain free ultrasound energy deep inside the wound bed that promotes healing from within. The ultrasound acoustic waves promote healing by reducing inflammation and bacteria in the wound bed, while also increasing the growth of new blood vessels to the area. The UltraMIST® System treatment must be administered by a healthcare professional. This proprietary technology has been cleared by the FDA for the promotion of wound healing through wound cleansing and maintenance debridement combined with ultrasound energy deposited inside the wound that stimulated tissue regeneration.
 
In connection with the Asset Purchase Agreement, on August 6, 2020, we entered into a license and marketing agreement with Celularity pursuant to which Celularity granted to the Company a license to the Celularity wound care biologic products, Biovance® and Interfyl® (the “License Agreement”). The License Agreement provides the Company with an exclusive license to use, market, distribute and sell Biovance® in the “Field” and “Territory” (each as defined in the License Agreement), and a non-exclusive license to use, market, distribute and sell Interfyl® in the Field and in the Territory. The License Agreement has an initial five-year term, after which it automatically renews for additional one-year periods, unless either party gives written notice at least 180 days prior to the expiration of the current term. In May 2021, the Company received notification alleging that it is not in compliance with the License Agreement with Celularity. See further discussion in Note 13 - Contingencies in the accompanying Condensed Consolidated Financial Statements.
 
Critical Accounting Policies and Estimates

Management’s Discussion and Analysis of Financial Condition and Results of Operations is based on our Condensed Consolidated Financial Statements, which have been prepared in accordance with U.S. GAAP. The preparation of our Condensed Consolidated Financial Statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses.

On an ongoing basis, we evaluate our estimates and judgments, including those related to the recording of the allowances for doubtful accounts, net realizable value of inventory, useful lives of long-lived assets, fair value of goodwill and other intangible assets, the determination of the valuation allowance for deferred taxes, the estimated fair value of the warrants, and the estimated fair value of stock-based compensation. We base our estimates on authoritative literature and pronouncements, historical experience and on various other assumptions that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Our actual results may differ from these estimates under different assumptions or conditions. The results of our operations for any historical period are not necessarily indicative of the results of our operations for any future period.

Our significant accounting policies are more fully described in Note 3 to our Consolidated Financial Statements filed with our 2020 Annual Report. For a description of recent accounting policies and the impact on our financial statements, refer to Note 3 in the accompanying Condensed Consolidated Financial Statements.

Financial Overview
 
Since inception in 2005, our operations have primarily been funded from the sale of capital stock, notes payable, and convertible debt securities. We have devoted and expect to continue to devote substantial resources for the commercialization of the dermaPACE® System and will continue to research and develop the non-medical uses of the PACE technology, both of which will require additional capital resources.  We also expect to require additional working capital as sales of our UltraMIST product continue to grow.
 
We incurred net losses of $30.9 million and $10.4 million for the years ended December 31, 2020 and 2019, respectively, and additional losses of approximately $4.9 million in the first quarter of 2021. These factors and the events of default on the notes promissory discussed above create substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve months from the financial statement issuance date. See Note 16 – Subsequent Events to the accompanying Condensed Consolidated Financial Statements for a discussion of the various events of default.
 
Our operating losses create substantial doubt about our ability to continue as a going concern. Although no assurances can be given, we believe that potential additional issuances of equity, debt or other potential financing may provide the necessary funding for us to continue as a going concern for the next year. See “Liquidity and Capital Resources” for further information regarding our financial condition.
 
The continuation of our business is dependent upon raising additional capital to fund operations. Management’s plans are to obtain additional capital in 2022 through investments by strategic partners for market opportunities, which may include strategic partnerships or licensing arrangements, or raise capital through the conversion of outstanding warrants, the issuance of common or preferred stock, securities convertible into common stock, or secured or unsecured debt. These possibilities, to the extent available, may be on terms that result in significant dilution to our existing shareholders. In addition, there can be no assurances that our plans to obtain additional capital will be successful on the terms or timeline we expect, or at all. Although no assurances can be given, management believes that potential additional issuances of equity or other potential financing transactions as discussed above should provide the necessary funding for us for the next twelve months. If these efforts are unsuccessful, we may be required to significantly curtail or discontinue operations or, if available, obtain funds through financing transactions with unfavorable terms.
 
The accompanying Condensed Consolidated Financial Statements have been prepared in conformity with U.S. GAAP, which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The Condensed Consolidated Financial Statements do not include any adjustment that might result from the outcome of this uncertainty. Our Condensed Consolidated Financial Statements do not include any adjustments relating to the recoverability of assets and classification of assets and liabilities that might be necessary should we be unable to continue as a going concern.
 
Since our inception, we have incurred losses from operations each year. As of December 31, 2020, we had an accumulated deficit of $156.7 million. Although the size and timing of our future operating losses are subject to significant uncertainty, we anticipate that our operating losses will continue over the next few years as we continue to incur expenses related to commercialization of our dermaPACE® system for the treatment of DFU in the United States. If we are able to successfully commercialize, market and distribute the dermaPACE® system, then we believe we may able to partially or completely offset these losses in the future with revenues from sales of our UltraMist systems and applicators. Although no assurances can be given, we believe that potential additional issuances of equity, debt or other potential financing, as discussed above, may provide the necessary funding for us to continue as a going concern for the next twelve months. We cannot reasonably estimate the nature, timing and costs of the efforts necessary to complete the development and approval of, or the period in which material net cash flows are expected to be generated from, any of our products, due to the numerous risks and uncertainties associated with developing and marketing products, including the uncertainty of:
 
• the scope, rate of progress and cost of our clinical trials;
 
• future clinical trial results;
 
• the cost and timing of regulatory approvals;
 
• supplier and customer disputes;
 
• the establishment of successful marketing, sales and distribution channels and partnerships, including our efforts to expand our marketing, sales and distribution reach through joint ventures and other contractual arrangements;
 
• the cost and timing associated with establishing reimbursement for our products;
 
• the effects of competing technologies and market developments; and
 
• the industry demand and patient wellness behavior.
 
Any failure to complete the development of our product candidates in a timely manner, or any failure to successfully market and commercialize our product candidates, would have a material adverse effect on our operations, financial position and liquidity. A discussion of the risks and uncertainties associated with us and our business are set forth under the section entitled “Risk Factors – Risks Related to Our Business” in our 2020 Annual Report.
 
The worldwide spread of the COVID-19 virus has resulted and is expected to continue to result in a global slowdown of economic activity which is likely to continue to decrease demand for a broad variety of products, including from our customers, while also disrupting supply channels and marketing activities for an unknown period of time. Also, the pandemic may cause continued or additional actions by hospitals and clinics such as limiting elective procedures and treatments and limiting clinical trial activities and data monitoring. We expect all of these factors to continue to have a negative impact on our sales and our results of operations, the size and duration of which we are currently unable to predict.
 
Results of Operations
 
Revenues and Cost of Revenues
 
Revenues for the three months ended March 31, 2021 were $2.1 million compared to $149 thousand for the same period in 2020, an increase of nearly $2.0 million.  The increase was primarily driven by 2021 sales of UltraMIST devices and single-use accessories.  The Company’s UltraMIST business began with the August 6, 2020 Acquisition. Please see Note 13 - Contingencies in the accompanying Condensed Consolidated Financial Statements for a description of a supplier dispute relating to UltraMIST.
 
Cost of revenues for the three months ended March 31, 2021 were $1.1 million versus $130 thousand for the same period of the prior year.  Gross margin as a percentage of revenues was 50% for the 2021 first quarter and 13% for the 2020 first quarter.  The increase in gross margin percentage was driven by sales of UltraMIST products and accessories, which have higher gross margin percentages than do DuraPACE products and accessories.
 
Research and Development Expenses
 
Research and development expenses increased to $354 thousand from $287 thousand during the first quarter of 2021 compared with the first quarter of 2020, respectively.  The 24% increase was driven by higher employee compensation and benefits costs incurred by the larger, post-Acquisition organization, though these costs were partially offset by lower amounts paid to external parties for clinical studies and other research and development.
 
Selling and Marketing Expenses
 
Selling and marketing expenses increased $1.2 million or 193% from $608 thousand to $1.8 million from the three months ended March 31, 2020 to the three months ended March 31, 2021.  The expense increase was primarily driven by higher employee compensation, commissions, benefits costs incurred by the larger, post-Acquisition organization as well as higher levels of revenues.  Contributing to the expense increase were higher sales-related technology, equipment and supply costs, which were also the result of the larger, post-Acquisition organization.
 
General and Administrative Expenses
 
General and administrative expenses increased from $1.9 million to $3.3 million or 73% from the quarter ended March 31, 2020 to the quarter ended March 31, 2021.  The $1.4 million increase was primarily the result of approximately $791 thousand in expenses related to Registration Statement penalty accruals as well as smaller increases in bad debt expenses and expenses for professional fees and consultants.  Approximately $176 thousand of the increase relates to first quarter 2021 amortization of intangible assets related to the acquisition on August 6, 2020.
 
Liquidity and Capital Resources
 
We expect to devote substantial resources for the commercialization of the dermaPACE® System and intend continue to research and develop the next generation of our technology as well as the non-medical uses of the PACE technology, both of which will require additional capital resources. We incurred a net loss of $30.9 million and $10.4 million for the years ended December 31, 2020 and 2019, respectively, and incurred additional net losses in the first quarter of 2021 of approximately $5.0 million. These factors and the events of default on the promissiory notes discussed above create substantial doubt about the Company’s ability to continue as a going concern for a period of at least twelve months from the financial issuance date. See Note 16 – Subsequent Events to the accompanying Condensed Consolidated Financial Statements for a discussion of the various events of default. Historically, our operations have primarily been funded from the sale of capital stock, notes payable, and convertible debt securities. The continuation of our business is dependent upon raising additional capital to fund operations; we may not be able to do so, and/or the terms of any financings may not be advantageous to us.
 
During the three months ended March 31, 2021, cash used by operating activities totaled approximately $3.3 million, which was driven largely by the net loss for the quarter and was partially offset by increases in accounts payable and accrued expenses as well as decreases in accounts receivable.  Cash used by investing activities during the 2021 first quarter consisted of purchases of property and equipment of $101 thousand.  Cash provided by financing activities for the quarter consisted primarily of $1.1 million of proceeds from SBA Loan #2 as well as $125 thousand in proceeds from deposits from related parties and were offset by $46 thousand of principal payments on financing leases.
 
Cash used in operations averaged $1.1 million per month for the first quarter of 2021 and management anticipates cash usage for operations to be approximately $300 thousand to $500 thousand per month during the second quarter and $250 thousand to $400 thousand per month for the second half of 2021 as resources are devoted to the commercialization of the dermaPACE and UltraMIST products including hiring of new employees, expansion of our international business and continued research and development of the next generation of our technology as well as non-medical uses of our technology. Management’s plans are to obtain additional capital in 2022 through investments by strategic partners for market opportunities, which may include strategic partnerships or licensing arrangements, or raise capital through the conversion of outstanding warrants, issuance of common or preferred stock, securities convertible into common stock, or secured or unsecured debt. These possibilities, to the extent available, may be on terms that result in significant dilution to our existing shareholders. Although no assurances can be given, management believes that potential additional issuances of equity or other potential financing transactions as discussed above should provide the necessary funding for us for the next twelve months. If these efforts are unsuccessful, we may be required to significantly curtail or discontinue operations or, if available, obtain funds through financing transactions with unfavorable terms.

Segment and Geographic Information

We have determined that we have one operating segment.  Our revenues are generated from sales in United States, Europe, Canada, Middle East, Central America, South America, Asia and Asia/Pacific.  All significant expenses are generated in the United States and all significant assets are located in the United States.

Contractual Obligations

Our major outstanding contractual obligations relate to our financing leases for rental equipment, operating leases for our facilities and office equipment, purchase and supplier obligations for product component materials and equipment, and our outstanding debt.  Please see our 2020 Annual Report for additional discussions of these obligations.

Off-Balance Sheet Arrangements

Since inception, we have not engaged in any off-balance sheet activities, including the use of structured finance, special purpose entities or variable interest entities.

Effects of Inflation

Due to the fact that our assets are, to an extent, liquid in nature, they are not significantly affected by inflation.  However, the rate of inflation, which has been increasing, affects expenses such as employee compensation, office space leasing costs and research and development charges, which may not be readily recoverable during the period of time that we are bringing the product candidates to market.  To the extent inflation results in rising interest rates and has other adverse effects on the market, it may adversely affect our consolidated financial condition and results of operations.

Item 3.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not required under Regulation S-K for “smaller reporting companies.”
 
Item 4.
CONTROLS AND PROCEDURES
 
Evaluation of Disclosure Controls and Procedures
 
We maintain disclosure controls and procedures, as defined in Rule 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are designed to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

We carried out an evaluation under the supervision and with the participation of our management, including our Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial officer and accounting officer), of the effectiveness of the design and operation of our disclosure controls and procedures as of October 11, 2021. Based on this evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not operating effectively as of March 31, 2021. Our disclosure controls and procedures were not effective because of the “material weakness” described below under “Management’s Annual Report on Internal Control over Financial Reporting.”
 
Management’s Annual Report on Internal Control over Financial Reporting
 
Management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) for the Company.  The Company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP.
 
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance of achieving their control objectives.
 
 Management, with the participation of the Chief Executive Officer (principal executive officer) and the Chief Financial Officer (principal financial and accounting officer), evaluated the effectiveness of the Company’s internal control over financial reporting as of October 11, 2021. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control — Integrated Framework (2013).

We previously reported three material weaknesses in our internal control over financial reporting process resulting from a lack of internal expertise and resources to analyze and properly apply U.S. GAAP to complex and non-routine transactions such as complex financial instruments and derivatives and complex sales distribution agreements, a lack of internal resources to analyze and properly apply U.S. GAAP to accounting for equity components of service agreements with select vendors and cybersecurity breaches from email spoofing in 2019. The Company remedied the cybersecurity breaches and email spoofing in 2020.

As of March 31, 2021 the Company has still identified the following material weaknesses:


The Company lacks expertise and resources to analyze and properly apply U.S. GAAP to complex and non-routine transactions such as complex financial instruments and derivatives and complex sales distribution agreements.

The Company lacks internal resources to analyze and properly apply U.S. GAAP to accounting for financial instruments included in service agreements with select vendors.

The Company has failed to design and implement controls around all of its accounting and IT processes and procedures and, as such, it believes that all of its accounting and IT processes and procedures need to re-designed and tested for operating effectiveness.

As a result, management concluded that its internal control over reporting was not effective as of March 31, 2021.
 
Remediation Plan
 
During 2021, we engaged external consultants with appropriate experience applying GAAP technical accounting guidance, and we have hired additional accounting personnel both internal and external. We engaged external consultants to review revenue recognition for new products, lease agreements, internal controls and related procedures and review of documentation of internal controls in addition to new equity and debt financing arrangements. Accounting memos were produced for all technical issues during 2020 and reviewed with management. The Company will continue to implement and review new controls to address these issues.

We have also implemented cybersecurity training for all employees and redesign of procedures that cyber security breaches may impact and worked with our third-party IT vendor to develop a training plan for all existing and new employees related to cyber and implemented related controls around information technology infrastructure. In addition, an additional employee was hired to assist with the management of IT controls and enhance internal IT resources. Going forward, this employee will monitor our third-party IT vendor’s testing and monitoring efforts and where necessary implement new controls as the Company grows. These internal controls have been documented and procedures implemented.

There is no assurance that the measures described above will be sufficient to remediate the previously identified material weaknesses.
 
Changes in Internal Control over Financial Reporting
 
There have been no changes in our internal control over financial reporting that occurred during the quarter ended March 31, 2021 that materially affect, or are reasonably likely to materially affect, our internal control over financial reporting, except as disclosed in “Remediation Plan” above.
 
PART II — OTHER INFORMATION

Item 1.
LEGAL PROCEEDINGS.

From time to time, the Company is subject to various legal actions, claims and proceedings arising in the ordinary course of business, including claims related to breach of contracts and intellectual property matters resulting from our business activities. As with most actions such as these, an estimation of any possible and/or ultimate liability cannot always be determined. The Company believes that all pending claims, if adversely decided, would not have a material adverse effect on our business, financial position or results of operations.

Item 1A.
RISK FACTORS.
As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide the information required under this item.  A discussion of the risks and uncertainties associated with us and our business are set forth under the section entitled “Risk Factors – Risks Related to Our Business” in our 2020 Annual Report.

Item 2.
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.
 Not applicable.

Item 3.
DEFAULTS UPON SENIOR SECURITIES.
 Not applicable.

Item 4.
MINE SAFETY DISCLOSURES.
Not applicable.

Item 5.
OTHER INFORMATION.
 Not applicable.

Item 6.
EXHIBITS

Exhibit No.
Description
   
Promissory Note by and between SANUWAVE Health, Inc. and Northeast Bank, dated February 20, 2021.
   
Factoring Agreement by and between SANUWAVE Health, Inc. and Goodman Capital Finance dated June 17, 2021.
   
Future Receivables Agreement by and between GCF Resources LLC and SANUWAVE, Inc. dated September 27, 2021.
   
Promissory Note by and between SANUWAVE Health, Inc. and A. Michael Stolarski, dated October 27, 2021.
   
Promissory Note by and between SANUWAVE Health, Inc. and NightWatch Capital Advisors, LLC, dated October 27, 2021.
   
Letter Agreement Amendment dated May 14, 2021 to the April 20, 2021 Securities Purchase Agreement by and between the Company and Leviston Resources, LLC
   
Rule 13a-14(a)/15d-14(a) Certification of the Principal Executive Officer.
   
Rule 13a-14(a)/15d-14(a) Certification of the Chief Financial Officer.
   
Section 1350 Certification of the Principal Executive Officer.
   
Section 1350 Certification of the Chief Financial Officer.
   
101.INS*†
XBRL Instance.
   
101.SCH*†
XBRL Taxonomy Extension Schema.
   
101.CAL*†
XBRL Taxonomy Extension Calculation.
   
101.DEF*†
XBRL Taxonomy Extension Definition.
   
101.LAB*†
XBRL Taxonomy Extension Labels.
   
101.PRE*†
XBRL Taxonomy Extension Presentation.


* Filed herewith.
** Furnished herewith.
† XBRL-related documents are not deemed filed for purposes of section 11 of the Securities Act of 1933, as amended, section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject the liabilities of these sections, and are not part of any registration statement to which they relate.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 
SANUWAVE HEALTH, INC.
   
Dated:  December 13, 2021
By: /s/ Kevin A. Richardson, II
 
Name: Kevin A. Richardson, II
 
Title:   Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:
 
Signatures
 
Capacity
 
Date
         
By: /s/ Kevin A. Richardson, II
Name: Kevin A. Richardson, II
 
Chief Executive Officer and Chairman of the Board of Directors
 (principal executive officer)
 
December 13, 2021
         
By: /s/ Lisa E. Sundstrom
Name: Lisa E. Sundstrom
 
Chief Financial Officer        (principal financial and accounting officer)
 
December 13, 2021


28


Exhibit 10.1

 
NOTE
 
 
SBA Loan#
 
1964668500
 
SBA Loan Name
 
Paycheck Protection Program Loan
 
Date
 
02/20/2021
 
Loan Amount
 
$ 1033005.0
 
Interest Rate
 
Fixed rate equal to one percent (1.00%) per annum
 
Borrower
 
SANUWAVE, Inc.
 
Lender
 
Northeast Bank, a banking corporation organized under the laws of the State of Maine

1.
PROMISE TO PAY:
 
FOR VALUE RECEIVED, SANUWAVE,Inc.  (th"Borrower") here by promises to pay as necessary and in accordance with the Paycheck Protection Program under 13 CFR Part 120 (the "PPP", as may be amended or supplemented by further guidance issued by the SBA) to the order of Northeast Bank (the "Lender") or subsequent holders of this Promissory Note (the "Note") the principal amount of  one million, thirty-three thousand and Dollars (I $ 1033005.0 ) (the "Loan"), together with all accrued interest thereon, which amount shall not exceed 1.00% per annum, as provided in this Note.
 
2.
DEFINITIONS:
 
"Loan" means the loan evidenced by this Note.
 
"Loan Documents" means the documents related to this Loan signed by Borrower or anyone who pledges collateral.

"SBA" means the Small Business Administration, an Agency of the United States of America.
 
"Deferment Period" means (i) the period from the Disbursement Date to the month that the SBA determines loan forgiveness, provided the forgiveness  application was made within ten (10) months of the end of the loan forgiveness covered period, or (ii) ten (10) months from the end of the  loan forgiveness covered period in the event no application for forgiveness is made (or such other period as amended by further PPP guidance issued by the SBA).
 
"Disbursement Date" means the date on which the Loan was fully funded.


3.
PAYMENTTERMS:
 
Borrower must make all payments at the place Lender designates. The payment terms for this Note are:


A.
Maturity Date: Unless forgiven in writing or otherwise modified in compliance with the terms of the PPP or other applicable SBA requirements, this Note matures five (5) years from the date of disbursement of the Loan (the "Maturity Date").

B.
Interest Rate: Principal amounts outstanding under this Note shall bear interest at a rate per annum (the "Interest Rate") equal to 1.00%.  All computations of interest hereunder  shall be made on the  basis of  a year of 365/365 and the actual number of days elapsed. Interest shall begin to accrue on the Disbursement Date.

C.
Use of Proceeds: Borrower shall use the proceeds of this Loan only for eligible expenses under the terms of the PPP.

D.
Payment: Borrower must pay principal and interest payments (as calculated by Lender using an amortization schedule based on the number of  months remaining in the term of the Loan at the  end of the  Deferment Period through the Maturity Date and a 1.00% interest rate, accounting  for any  Deferred  Interest) commencing on the first Payment Date in the month immediately following the Deferment Period  and continuing monthly on each Payment Date thereafter  and ending on the Maturity Date. Payments must be made on the same day as the Disbursement Date (such date hereinafter the "Payment Date") in the months they are due and must be made in US dollars. Borrower's repayment obligation will be reduced by the amount of any loan forgiveness granted under the terms of the PPP. While no payments are due on this Loan for the Deferment Period, interest will continue to accrue during the Deferment Period (such interest the "Deferred Interest"). All outstanding principal and accrued and unpaid interest shall be due and payable on the Maturity Date.  Lender will apply each installment  payment  first to  pay Deferred Interest, then to  interest  accrued to the day Lender received the payment, then to principal. Any payment received after default, demand or acceleration shall be applied in accordance with SBA servicing guidelines.

E.
Deferment Period: No payments are due on this Loan for the earlier of (i) the period from the Disbursement Date to the month that the SBA determines loan forgiveness, provided the forgiveness application was made within ten (10) months of the end of the  loan forgiveness  covered  period, or (ii) ten (10) months from end of the  loan forgiveness covered period in the event no application for  forgiveness is made (or such other period as amended by further PPP guidance issued by the SBA). Interest will continue to accrue during the Deferment Period.

F.
Loan Prepayment:   Notwithstanding any provision in this Note to  the contrary, Borrower  may prepay this Note at any time without penalty.

G.
Loan Forgiveness: Borrower may apply to Lender for forgiveness of the amount due on this Loan in an amount in accordance with the requirements of the Paycheck Protection Program.

H.
Manner of Payment: All payments of principal and interest shall be made in US dollars on the date on which such payment is due. Such payments shall be made by ACH, cashier's check, certified check, or  wire transfer of immediately available funds to the holder of the Note ("Noteholder"). For purposes of this Note, the term Noteholder shall refer to the original Noteholder, or any assignee.



4.
DEFAULT:
 
Borrower is in default under this Note if Borrower does not make a payment when due under this Note {unless forgiven under the terms of this Note and the terms of the PPP}, or if Borrower:
 

A.
Fails to do anything required by this Note and other Loan Documents;
 

B.
Defaults on any other government guaranteed loan;
 

C.
Does not disclose, or anyone acting on their behalf does not disclose, any material fact to Lender or SBA;
 

D.
Makes, or anyone acting on their behalf makes, a materially false or misleading representation to Lender or SBA;
 

E.
Reorganizes, merges, consolidates, or otherwise changes ownership or business structure without Lender's prior written consent;or
 

F.
Becomes the subject of a civil or criminal action that that impacts Borrower's eligibility under PPP.

5.
LENDER'S RIGHTS IF THERE IS A DEFAULT:
 
Without notice or demand and without giving up any of its rights, Lender may:
 

A.
Require immediate payment of all {non-forgiven} amounts owing under this Note;
 

B.
Collect all amounts owing from any Borrower; or
 

C.
File suit and obtain judgment.

 
6.
LENDER'S GENERAL POWERS:
 
Without notice and without Borrower's consent, Lender may:
 

A.
Incur expenses to collect amounts due under this Note and enforce the terms of this Note or any other Loan Document. If Lender incurs any collection-related expenses, it may demand immediate repayment from Borrower or add the expenses to the principal balance;
 

B.
Release anyone obligated to pay this Note; and
 

C.
Take any action necessary to collect amounts owing on this Note.

7.
GOVERNING LAW; WHEN FEDERAL LAW APPLIES:

This Note and the obligations of Borrower hereunder shall be governed by and interpreted and determined in accordance with the laws of the Commonwealth of Massachusetts and/or all applicable federal regulations under the PPP Loan program.
 
When SBA is the holder, this Note will be interpreted and enforced under federal law, including SBA regulations. Lender or SBA may use state or local procedures for filing papers, recording documents, giving notice, foreclosing liens, and other purposes. By using such procedures, SBA does not waive any federal immunity from state or local control, penalty, tax, or liability. As to this Note, Borrower may not claim or assert against SBA any local or state law to deny any obligation, defeat any claim of SBA, or preempt federal law.



8.
SUCCESSORS AND ASSIGNS; ASSIGNMENT:
 
Under this Note, Borrower includes its successors, and Lender includes its successors and assigns. This Note may be assigned or transferred by Lender to  any individual, corporation, company, limited liability company, trust, joint venture, association, partnership, unincorporated organization, governmental authority, or other entity without the prior consent of or notice to any other person.

9.
GENERAL PROVISIONS:
 

A.
All individuals and entities signing this Note are jointly and severally liable.
 

B.
Borrower waives all suretyship defenses.
 

C.
Borrower must sign all documents necessary at any time to comply with the Loan Documents.
 

D.
Lender may exercise any of its rights separately or together, as many times and in any order it chooses. Lender may delay or forgo enforcing any of its rights without giving up any of them.
 

E.
Borrower may not use an oral statement of Lender or SBA to contradict or alter the written terms of this Note. No term of this Note may be waived, modified, or amended, except by an instrument in writing signed by the Borrower and the Lender, unless the SBA permits otherwise.   Any waiver of the terms hereof shall be effective only in the specific instance and for the specific purposes given.
 

F.
If any term or provision of this Note is invalid, illegal, or unenforceable in any jurisdiction, such invalidity, illegality, or un enforceability shall not affect any other term or provision of this Note or render such term or provision invalid or unenforceable in any other jurisdiction.
 

G.
To the extent allowed by law, Borrower waives all demands and notices in connection with this Note, including presentment, demand, protest, and notice of dishonor.

10.
NON-RECOURSE:
 
Lender and SBA shall have no recourse against any individual shareholder, member or partner of Borrower for non-payment of the Loan, except to the extent that such shareholder, member or partner uses the loan proceeds for an unauthorized purpose. Borrower is solely responsible for providing Lender with evidence that the Loan proceeds have been used for an authorized purpose, and such evidence shall be subject to Lender's review and approval in its sole and absolute discretion. Should Borrower fail to provide such evidence, the Loan may be full recourse to the Borrower.
 
11.
INDEMNIFICATION: The Borrower will indemnify and hold harmless Lender and any Noteholder (and their respective employees, directors, agents, affiliates and representatives) from and against any cost, loss or liability including interest, penalties, reasonable attorneys' fees and expenses resulting from the Borrower's misrepresentation in the application for this Loan or otherwise or breach of warranty, default or breach of any covenant in this Note.


12.
NOTICES. All notices and other communications relating to this Note shall be in writing and shall be deemed given upon the first to occur of (a) deposit with overnight courier service, properly addressed and shipping prepaid; (b) transmittal by e-mail properly addressed (with written acknowledgement from the intended recipient such as "return receipt requested" function, return e-mail, or other written acknowledgment); or (c) actual receipt by an employee or agent of the other party. Notices hereunder shall be sent to the following addresses, or to such other address as such party shall specify in writing:
 
If to the Borrower:

Name : SANUWAVE, Inc.


Phone Number: (678) 549-0449
Address:   3360 Martin Farm Rd., Ste 100 ,Suwanee, GA, 30(
 
Attention: Lisa Sundstrom
 
E-Mail:     lisa.sundstrom@sanuwave.com

If to Northeast Bank:
 
Name:
Northeast Bank
 

Phone: 800-284-5989
Address: PO Box 171769, Boston, MA 02117

Attention: Loan Servicing Department
 
E-Mail: sbaloans@northeastbank.com
 
13.
REPRESENTATIONS AND WARRANTIES. The Borrower represents and warrants to the Lender as follows:
 
A.   Existence. If the Borrower is an entity, the Borrower is duly incorporated/formed/organized, validly existing, and in good standing under the laws of the state of its organization. The Borrower has the requisite power and authority to own, lease, and operate its property, and to carry on its business.
 
B.   Compliance with Law. The Borrower is in compliance with all laws, statutes, ordinances, rules, and regulations applicable to or binding on the Borrower, its property, and business.
 
C.    Power and Authority. The Borrower has the requisite power and authority to execute, deliver and perform its obligations under this Note.
 
D.    Authorization; Execution and Delivery. The execution and delivery of this Note by the Borrower executing this Note is done in accordance with applicable law and with all necessary authority having been granted to Borrower to assure performance and bind the entity to its obligations.
 
E.    Information is True and Accurate. The information and certifications provided in all supporting documents and forms to obtain this Loan are true and accurate in all material respects. The Borrower (and any individual who provided information for the application of this Loan) understands that knowingly making a false statement to obtain this Loan from SBA is punishable under the law, including under 18 USC 1001 and 3571 by imprisonment of not more than five years and/or a fine of up to $250,000; under 15 USC 645 by imprisonment of not more than two years and/or fine of not more than $5,000; and, if submitted to a federally insured institution, under 18 USC 1014 by imprisonment of not more than thirty years and/or a fine of not more than $1,000,000.

14.
STATE-SPECIFIC PROVISIONS. None



15.
INTEGRATION. This Note constitutes the entire contract between the Borrower and the Lender with respect to the subject matter hereof and supersedes previous agreements and understanding, oral or written, with respect thereto.

16.
CONSENT TO USE ELECTRONIC SIGNATURE. In order to receive the Loan amount, the Lender must provide the Borrower with certain disclosures required by law. By submitting the Borrower's application and agreeing to the terms of this Note, which the Borrower collectively adopts as its electronic signature, the Borrower consents and agrees that: (i) the Lender and any Noteholder can provide all disclosures required by law and other information about the Borrower's legal rights and duties to the Borrower electronically, including by e-mail, a website portal or mobile phone application; (ii) the Borrower's electronic signature on agreements and documents has the same effect as if the Borrower signed them in ink and is evidence of the Borrower's intention to be bound by this Note; (iii) Electronic disclosures have the same meaning and effect as if the Borrower were provided paper disclosures; (iv) Disclosures are considered received by the Borrower within 24 hours of the time posted to Lender's or any Noteholders website, or within 24 hours of the time emailed to the Borrower unless the Lender or Noteholder receives notice that the email was not delivered; (v) Lender or the Noteholder reserves the right to cancel this electronic disclosure service, change the terms of use of this service or send disclosures in paper form at any time; (vi) the Lender or Noteholder is responsible for sending notice of the disclosures to the  Borrower electronically, but Lender or Noteholder are not responsible for any delay or failure in the Borrower's receipt or review of the email notices.  The Borrower agrees and confirms that the Borrower has access to the necessary equipment to receive, access and print any disclosures that may be provided in electronic form. The Borrower will not seek to withdraw the Borrower's consent for electronic signature and disclosures while the Borrower has an outstanding Loan balance.

17.
NO, WAIVER; CUMULATIVE REMEDIES. No failure by Lender or any subsequent Noteholder to exercise and no delay in exercising any right, remedy, or power hereunder shall operate as a waiver thereof; nor shall any single or  partial exercise of  any right, remedy, or power hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, or power. The rights, remedies, and powers herein provided are cumulative and not exclusive of any other rights, remedies, or powers provided by law.

18.
COUNTERPARTS.   This Note and any amendments, waivers, consents, or supplements hereto may be executed in counterparts, each of which shall constitute an original, but all of which taken together shall constitute as single contract.

19.
THIRD-PARTY BENEFICIARY. Any assignee of this Note shall be deemed to be a third-party beneficiary to this Note and is entitled to the rights and benefits hereunder and may enforce the  provisions hereof as if  they were a party hereto.

20.
ERRORS AND OMISSIONS; COOPERATION. The undersigned Borrower for and in consideration of the Lender funding the closing of this Loan agrees, if requested by Lender or its assignees, to fully cooperate and adjust for clerical errors, any or all Loan closing documentation if deemed necessary or desirable in the reasonable discretion of the Lender or its assignees. Borrower shall furnish the Lender with such other information as the Lender may reasonably request  from time to time, including but  not  limited to  any documentation  necessary to comply with the terms of the PPP.

21.
DISBURSEMENT. The undersigned hereby authorizes the Lender to disburse the entire amount of the Loan proceeds of the Note to Borrower.



22.
BORROWER CERTIFICATION. Borrower understands, acknowledges and agrees that Lender is relying solely on Borrower's representations, warranties, certifications, confirmations or other statements of, and information from, the Borrower and/or any of its affiliates, officers, directors, owners, principals, agents, and/or controlling persons as to the Borrower, its business or activities, its eligibility for the proposed Loan, its use of the proceeds or any other benefits of the Loan, the existence of any hardship or other condition, or any other matters of compliance with the PPP or SBA requirements without limitation or without Lender's examination of any other information not included in the Borrower's Loan application which may be in Borrower's possession. Borrower hereby recertifies all certifications made by Borrower in its Loan application.

23.
EQUAL EMPLOYMENT OPPORTUNITY. Borrower hereby acknowledges the receipt of a copy of the Equal Employment Opportunity Poster (SBA Form 722) and will display such poster at Borrower's place of business where it is clearly visible to employees, job applicants, and the general public.

(signatures on following page)



THE UNDERSIGNED BORROWER ACKNOWLEDGES THAT (i) HE/SHE IS THE AUTHORIZED REPRESENTATIVE OF THE APPLICANT AND HAS SIGNIFICANT RESPONSIBILITY FOR MANAGING THE BORROWER, (ii) HE/SHE HAS PROVIDED TO LENDER THE NAME, ADDRESS, DATE OF BIRTH, AND SOCIAL SECURITY NUMBER OF EACH INDIVIDUAL, WHO, DIRECTLY OR INDIRECTLY, THROUGH ANY CONTRACT, ARRANGEMENT, UNDERSTANDING, RELATIONSHIP OR OTHERWISE, OWNS 20% OR MORE OF THE BORROWER, (iii) HE/SHE HAS COMPLIED WITH ALL REQUIREMENTS OF THE PAYCHECK PROTECTION PROGRAM, AND (iv) HAVING READ ALL OF THE PROVISIONS OF THIS NOTE, AGREES TO ITS TERMS. THE BORROWER FURTHER ACKNOWLEDGES THAT ITS EXECUTION OF THIS NOTE DOES NOT CONSTITUTE A COMMITMENT TO FUND ON THE PART OF LENDER. THE LOAN REMAINS SUBJECT TO THE FINAL REVIEW OF THE LENDER AND THIS NOTE SHALL NOT BE BINDING ON THE PART OF THE LENDER UNTIL THE LOAN IS FULLY APPROVED AND DISBURSED.

IN WITNESS WHEREOF, the Borrower has executed this Note as of the date set forth above.

[ADD BORROWER'S NAME HERE]

By: 
/s/ Lisa Sundstrom
 
     
Name: Lisa Sundstrom  
     
Title: Chief Financial Officer  
 




Exhibit 10.2

FACTORING AGREEMENT
 
This FACTORING  AGREEMENT  (as amended, this "Agreement"), dated as of  the Effective  Date (as  defined  below), is by and between Goodman Capital Finance, a division of Independent Bank (and hereinafter referred to as "Goodman") and the entities from time to time party hereto as a client (collectively, the "Client"). All capitalized terms used in this Agreement are defined in the body or in the last Section of this Agreement.
 
For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed as follows:
 
I.            Factoring of Accounts
 
(a)          Purchase and Sale of Accounts. Client agrees to ofTer to sell to Goodman existing  and  future Accounts of Client. Each such offer shall be made on a schedule, in a form acceptable to Goodman. delivered to Goodman electronically or  by such other means as Goodman  may from time to time designate.   Goodman's purchase of an Account ofTercd for sale hereunder will be efTective upon itreceipt of such schedule  for such Account, without further act or instrument. At the time an Account is presented to Goodman for purchase,  the Client shall also deliver  to Goodmaa copy of all invoices relating to the Account together with evidence of the delivery and performance of the goods and services giving rise to such Account.

(b)          Payment of Purchase Price. As consideration for the assignment and sale of an Account to Goodman hereunder, Goodman shall pay to Client the Purchase Price for such Account on the Settlement Date for such Account by crediting such Purchase Price to the Reserve Account or applying the proceeds of such Purchase Price against the outstanding Advances.
 
(c)          Credit Risk. Except as expressly provided in this subsection with respect to Non-Recourse Accounts, all Accounts purchased  by Goodman hereunder are with  full recourse to Client and  without risk to Goodman of non-payment  for any reason. Without limiting the foregoing, Goodman may, in its sole discretion at the request of Client, agree to assume the Credit Risk on an Account by written notice from Goodman to Client, which written notice may be in the form of an-email, expressly stating that such Account is purchased by Goodman without recourse to the Client (any such Account for which Goodman has so notified the Client, a "Non-Recourse  Account"')The purchase by Goodman of a Non-Recourse  Account shall be without  recourse to Client for losses sustained due to Credit Risk except to the extent such Credit Risk is terminated in accordance with the terms hereof. Notwithstanding anything to the contrary herein, Goodman's Credit Risk on a Non-Recourse Account shall immediately terminate and such Account shall immediately cease to constitute a Non-Recourse Account hereunder,  in each case without any further action or notice, if (i) such Account is at any time subject to Dispute, (ii) any representation or warranty made by Client hereunder with respect to such Account is untrue, incorrect or misleading in any respect, (iii) any covenant or agreement made by Client hereunder with respect to such Account is breached, or (iv) this Agreement is terminated by Client.
 
(d)          Advances. At Client's request, but in Goodman's sole discretion. Goodman may make loans to Client (collectively, "Advances") up to an aggregate amount at any time outstanding not to exceed  thlesser of  the "Facility  Maximum" set forth on Schedule A and the Formula Amount. All Advances are payable upon demand and may be charged by Goodman to the Reserve Account at any time.  Without limiting the foregoing, if at any time the aggregate outstanding Advances exceeds the lesser of the Facility Maximum and the Formula Amount, Client shall immediately repay to Goodman such excess Advances.
 
(e)          Reserve AccountGoodman shall credit the Reserve Account with the Purchase Price of Accounts sold to Goodman hereunder as and when payable hereunder and debit the Reserve Account for all payment Obligations of Client as and when due hereunder. Goodman shall, upon request of Client and so long as no Event of Default exists, remit to Client any positive balance in the Reserve Account provided that Goodman may withhold from the Reserve Account such amounts as it deems necessary as security for the payment and performance of the Obligations, to enhance the likelihood of repayment of the Obligations or to reflect events, conditions, contingencies or risks which might adversely affect the Collateral or the business of Client. If at any time the Reserve Account is negative, Client shall immediately repay the deficiency to Goodman.
 
(f)          Account Stated. Client agrees to log on, no less frequently than monthly, to any internet accessible website made available to Client by Goodman to review all transactions posted to Client's account with Goodman. Each transaction posted to the Reserve Account or appearing in a statement received by Client from Goodman in connection herewith shall be subject to subsequent adjustment by Goodman but shall, absent manifest error, be conclusively presumed to be correct and accurate and constitute an account stated between Client and Goodman unless Client delivers to Goodman a written objection to such transaction, describing the error or errors allegedly contained therein, within thirty (30) days after the earlier of the posting of such transaction to the Reserve Account or delivery to Client of a statement reflecting such transaction.
 
(g)          Chargebacks. Goodman shall have the right to chargeback to Client the full amount of an Account. even if Goodman has already remitted payment of the Purchase Price therefor, if such Account (i) is or becomes subject to Dispute, (ii) is a Non-Recourse Account for which the Credit Risk of  Goodman  is terminated  in accordance with the terms here of or (iii) is not a Non-Recourse Account. In the event an Account for which Goodman has already remitted payment of the Purchase Price is charged back to Client in accordance with the terms hereof, Client shall repurchase such Account by paying to Goodman an amount equal to such Purchase Price. In the event an Account is charged back to Client prior to the payment by Goodman of the Purchase Price therefor, Goodman shall, in lieu of payment of the Purchase Price for any such Account, credit the Reserve Account with any Proceeds received by Goodman in respect of such Account on the Settlement Date therefor. Notwithstanding the repurchase of an Account by Client or the election by Goodman to chargeback to Client an  Account, Goodman shall retain  its security  interest in such Account as security for full payment and performance of all Obligations.


2.            Notation of Assignment, Remittances and Collections
 
(a)          Notice of Assignment. At the request of Goodman, all invoices evidencing Accounts purchased by Goodman hereunder shall prominently indicate that the Account evidenced thereby has been assigned to, is owned by and is payable directly and only to Goodman  at a lockbox account or other account designated  by Goodman  from time to time. Without limiting the foregoing, Client agrees that Goodman may and irrevocable authorizes Goodman to, at any time, notify Customers of the assignment to Goodman of(or security interest of Goodman in) the Accounts and that such Accounts are payable only to Goodman.
 
(b)          Remittances and Collections. Client shall cause all payments of Accounts to be remitted, and Client shall instruct and cause its Customers to remit all payments, to such lockbox or bank account as Goodman may from time to time designate (the "Collection  Accounts").If any Obligor receives payment of  an Account, Client shall cause such Obligor to, within one (I) Business Day of such receipt, remit such payment, in the same form received, to the Collection Accounts or as otherwise directed by Goodman. All checks, remittances and other Proceeds of Accounts purchased  by Goodman hereunder shall  be property of Goodman. Should Goodman receive a double payment on an Account or other payment which is not identifiable to an Account, Goodman shall account for such payment as an open item and, in Goodman's discretion, Goodman may return any duplicate or unidentified payment to the Customer or apply such  unidentified  payment pursuant 10  the Obligations  upon  proper identification and documentation acceptable to Goodman.
 
3.           lnterest and Certain Fees.
 
(a)          Interest. The outstanding Advances will bear interest at a variable per annum rate equal to the "Contract Rateset  forth on SchedulA.  Advances repaid  from the proceeds of thPurchase Price for an Account shall continue to accrue interest  through  the Settlement Date of such  Account.  All such interest will  be payable by Client  to Goodman  monthly in arrears on the first day of each month. Notwithstanding the foregoing, from and after the occurrence of an Event of Default, all Obligations shall, at the election of Goodman, bear interest at a rate per annum equal to eighteen percent (18%) (the "Default Rate") and such interest shall be accrued daily and  payable  by Client to Goodman  upon demand.   All interest  hereunder may be charged by Goodman to the Reserve Account as an Advance as and when due.
 
(b)          Select Fees. Client will pay to Goodman the fees set forth on Schedule A hereto. Such fees shall be fully earned, and may be charged by Goodman to the Reserve Account as an Advance, when due in accordance with such Schedule and shall not be subject to refund of any kind or pro-rated upon any termination of this Agreement.
 
(c)          Computation of Interest and Fees. Interest and fees will be computed on the basis of a three hundred sixty (360) day year for the actual number of days elapsed.
 
4.           Securitv Interest. As security  for the Obligations, Client hereby grantto Goodman a continuing security interest in and lien upon all of the Collateral. Client shall take all actions requested by Goodman from time to time to cause the attachment, perfection and, except as Goodman may otherwise agree in writing, first priority of Goodman's security interest in the Collateral.   Client  irrevocably and unconditionallauthorizes  Goodman  (or  Goodman's  agent) to complete and file, at any time and from time to  time, such  financing statements with respect to the Collateral  naming Goodman  as  the secured  party  and Client as debtor, as Goodman may require, together with all amendments and continuations with respect thereto. Without limiting the foregoing, Client shall, al the request of Goodman with respect to each or any Deposit Account of Client, deliver to Goodman a deposit account control agreement, in form and substance satisfactory to Goodman, duly executed by Client and the financial institution at which such Deposit Account is maintained.
 
5.            Representations and Warranties. Client hereby represents and warrants to Goodman that at all times:
 
(a)          Organization. Qualification: Compliance with Laws: Authority. Client (i) is duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization, (ii) is duly qualified to do business and is in good standing in each jurisdiction where its ownership of property or the conduct of its business requires such qualification, (iii) operates its business in material compliance  with all applicable local, state and federal laws, (iv) has all power and authority  under the laws of Client's jurisdiction of organization and its articles of organization to conduct Client's business and to enter into, execute and deliver this Agreement and  the Other Agreements and to  perform  its Obligationhereunder and  thereunder and (v) has taken all necessary action to authorize the execution and delivery of this Agreement and the Other Agreements and the performance of its Obligations hereunder and thereunder.
 
(b)          Solvency. Client  is solvent, is able to pay its debts as they  maturehas capital sufficient to carry on its business and all businesses in which it is about to engage and the fair saleable value of its assets (calculated on a going concern basis) is in excess of the amount of its liabilities.
 
(c)          Collateral. Client has good title to the Collateral, free and clear of all liens, claims and encumbrances other than those in favor of Goodman or with respect to which Goodman has consented in writing.
 
2

(d)          Accounts. Each Account submitted or sold by Client to Goodman  hereunder  (i) evidences  an absolute, bona fide sale of goods or rendition of services by Client in the ordinary course of  business, (ii) arises from the sale of goods or services that have been delivered or performed in full by Client and accepted in full by the Customer obligated thereon, (iii) is genuine, valid and enforceable against the Customer obligated thereon in the full amount set forth on the schedule and any invoice delivered by Client with respect to such Account, without ofTset, defense, counterclaim, deduction, credit, adjustment of any kind other than as disclosed by Client to Goodman in such schedule when such Account is first offered for sale by Client to Goodman hereunder, (iv) is not subject to Dispute (real or alleged) at the time such Account is first offered for sale by Client to Goodman hereunder, (v) is free and clear of all liens, claims or encumbrances other than in favor of Goodman or expressly permitted by Goodman in writing, (vi) is legally saleable and assignable by Client to Goodman; (vii) if arising from the sale of Inventory, such Inventory was owned by Client at all times prior to such sale and was not subject to any consignment arrangement, encumbrance, security interest or lien other than in favor of Goodman or as expressly permitted in writing by Goodman, and (viii) shall not be altered or modified without the prior written consent of Goodman. All invoices evidencing an Account submitted or sold by Client to Goodman hereunder, and all other documents delivered by Client to Goodman in connection therewith, are genuine and valid and are not mistaken, misleading, fraudulent. incorrect, incomplete or erroneous in any respect.
 
6.           Covenants
 
(a)          Certain Organizational Changes. Without giving Goodman at least thirty (30) days prior written notice, Client shall not (i) change Client's legal name, type of organization or jurisdiction of organization or (ii) chief executive office, mailing address or any location of Collateral. In addition, Client shall give Goodman prompt notice of, but in any event within five (5) days after, any change in any of the officers, principals, partners or owners of Client or any other Obligor.
 
(b)          Certain Negative Covenants. Client shall not, at any time, (i) be party to a merger or consolidation or acquire all or substantially all of the assets of, or equity interests in, any Person or any divisions of any Person, (ii) grant or permit to exist any lien, security interest or encumbrance other than in favor of Goodman or with the written consent of Goodman. (iii) sell or dispose of any Collateral other than the sale of lnventory in the ordinary course of Client's business, (iv) use the proceeds of the Purchase Price for any purpose other than the repayment of Advances or for working capital purposes in the ordinary course of Client's business, (v) conduct business or engage in any transaction with an affiliate of Client except in the ordinary course of business upon fair and reasonable terms no less favorable to Client than Client would obtain in a comparable arm•s length transaction with an un affiliated Person and, in all events, provided the same is fully disclosed to Goodman in writing in advance, (vi) make loans or advances to any Person other than advances to employees for travel and entertainment expenses in the ordinary course of Client's business, (vii) sell Accounts to, factor Accounts with or obtain financing secured by Collateral from any Person other than Goodman or with the prior written consent of Goodman or (viii) engage in any business, other than its business as conducted on the EfTective Date of this Agreement and any activities incidental thereto.
 
(c)          Financial Statements: Collateral Reports. Client shall provide to Goodman the financial and other information set forth on Schedule B hereto, in form and detail satisfactory to Goodman, within the time periods set forth on such Schedule.

(d)          Accounting Records: Inspections: Verifications. Client shall (i) maintain a system of accounting that enables Client to produce financial statements in accordance with GAAP, (ii) maintain complete and accurate records regarding the Collateral and (iii) permit Goodman and any Person designated by Goodman to, at any reasonable time, inspect, audit and examine the books and records of Client, make copies of the same, and inspect and appraise the Collateral and the other assets and properties of Client. Client authorizes Goodman to, in the name of Goodman or its nominee, communicate with any Customer of Client to verify the validity, amount or other matter relating to Accounts of Client.
 
(e)          Disputes. Client shall promptly, but in any event within five (5) days after Client has knowledge of the same, notify Goodman of each Dispute. lf a Dispute is not promptly settled by Client, Goodman may, if Goodman so elects in Goodman's sole discretion, settle, compromise, adjust or otherwise dispose any such Dispute, whether by litigation or otherwise, at Client's expense and upon such terms and conditions as Goodman in its sole discretion shall deem necessary or appropriate. Client shall promptly advise Goodman if Client settles any Dispute or grants any allowances, credits or adjustments to Customers, changes the selling terms to be issued to any Customer or accepts any return of goods. Any Account that is unpaid at the expiration of the Eligibility Period shall, unless the Customer thereof is subject to an insolvency proceeding at or prior to the expiration of such Eligibility Period, be deemed in Dispute.
 
(f)          Insurance. At Client's expense, Client shall maintain insurance with respect to such risks, in such amounts and with such insurance companies as ordinarily are insured against by other Persons engaged in the same or similar businesses and as are reasonably satisfactory to Goodman. Client shall, at the request of Goodman, cause Goodman to be named as an additional insured on all liability insurance policies of Client and as a lender's loss payee on all property insurance policies of Client, and deliver to Goodman such endorsements and certificates of insurance as Goodman may request with respect to Client's insurance policies.

3

(g)          Notice of Event of Default. Promptly, but in any event within five (5) days after Client has knowledge of any event or condition that constitutes an Event of Default, Client shall give Goodman notice of such event or condition and a statement of the curative action that Client proposes to take with respect thereto.
 
(h)          Anti-Monev Laundering and Anti-Corruption. Client shall maintain and comply at all times, and cause each affiliate of Client to maintain and comply at all times. with all applicable laws or regulations relating to money- laundering, any predicate crime to money laundering, bribery or corruption.
 
(i)          Taxes. Client shall pay and discharge all federal, state and local taxes (including payroll taxes) when due. Client shall, at the request of Goodman, furnish Goodman with proof of payment of all such taxes. Without limiting the foregoing, Client shall deliver to Goodman, at the request of Goodman, an Internal Revenue Service form 8821.
 
(U)      Further  Assurances and  Cooperation.   Client shall, at Goodman's  request and Client's expense. execute and deliver (or cause to be executed and delivered) to Goodman such further instruments and do and cause to be done such further acts as may be necessary or proper in the opinion of Goodman to effectuate the provisions and purposes of this Agreement. Without limiting the foregoing, Client acknowledges, confirms and  agrees  thatupon  Goodman's  request, Client shall cooperate and assist Goodman, at Client's expense, in connection with any effort by Goodman to (i) collect any Account or enforce any of Goodman's rights and remedies against third parties obligated on any Account or any other Collateral or (ii) defend any  claim or action commenced by any third party against Goodman in connection with Goodman's actions or the transactions hereunder.
 
7.            Termination and Default.
 
(a)          Term. This Agreement shall be effective commencing on the Effective Date and, unless sooner or otherwise terminated in accordance with the terms hereof, this Agreement shall remain in full force and effect for the "Initial Term" (as designated on Schedule A) and shall automatically  renew (and remain  in full force and effect) for successive "Renewal Terms" (as designated on  Schedule A) thereafter.    The Initial Term and each applicable  Renewal Term are collectively  referred  to herein as the "Term". Client  may elect to terminate this Agreement effective as of  the last day of  thapplicable  Term  by written  notice to Goodman no later than thirty (30) days prior to the expiration of such Term. Goodman may terminate this Agreement at any time upon at least thirty (30) dayprior written  notice to Client or  without  prior or other notice at  any time after the occurrence of an Event of Default.  All Obligations  hereunder shall become immediately due  and payable on the effective date of termination of this Agreement.    Notwithstanding any termination  of this Agreement, until such time as all Obligations shall have  been fully paid and satisfied in immediately available funds, this Agreement shall  remain  binding upon Client and, without limitinthe foregoing. all security interests and liens granted by Client in favor of Goodman hereunder shall remain in full force and effect.
 
(b)          Events of Default. Any one or more of the following shall constitute an "'Event of Default" hereunder: (i) Client shall fail to pay any of the Obligations when due; (ii) any statement, representation or warranty made by any Obligor in this Agreement or  any Other Agreement, or  in connection with  the  transactions contemplated  hereby or  therebyshall be untrue, incorrect or  misleading  when made or during thperiod covered  thereby; (iii) any breach or default  by any Obligor  in the performance of any covenant or other agreement of such Obligor in this Agreement or any Other Agreement; (iv) any corporate Obligor suspends or ceases operation of all or a material portion of such Obligor's business; (v) any breach or default by any Obligor under any document, instrument or agreement to which it is a party, or by which any of its properties are bound, if the maturity of any indebtedness of such Obligor may be accelerated or demanded due to such breach or default; (vi) there shall be issued or filed against any Obligor any judgment, order or award for the payment of money unless the same is discharged, satisfied, vacated or bonded pending appeal within fifteen (15) days after such issuance or filing; or enforcement proceedings are commenced upon any such judgment, order or award; (vii) a corporate Obligor is enjoined, restrained or in any way prevented by any governmental authority  from conducting  any  material  part of  its business; (viii)  any Obligor becomes insolvent, becomes  unable to pay its debts as they mature or  makes an assignment for the  benefit of creditors; a receiver is appointed  for any of the Collateral; or a petition under any provision of Title 11 of the United States Code, as amended or modified from time to time, is filed by or against any Obligor (a "Specified Default"); (ix) any Obligor that is a natural Person shall die or be declared incompetent; or the dissolution, merger or consolidation of any corporate Obligor; (x) any Obligor shall challenge the validity, enforceability or effectiveness of, terminate, seek or purport to seektermination of  this Agreement or  any Other Agreement; or (xi) from and  after the Effective  Date, the sale, transfer, or exchange, either directly or  indirectly, of  more than ten percent ( I0%)  in the aggregate of the equity interests in any corporate Obligor.
 
(c)          Remedies. At any time after the occurrence of an Event of Default, Goodman may: (i) declare the Obligations to bimmediately due and payable, at which time such Obligations shall be immediateldue and payable and Client shall be obligated  to immediatelrepay all of such Obligations in full; (ii) set off against, and appropriate and apply to the payment of the Obligations, any and all amounts owing by Goodman to Client and (iii) exercise any or all rights, powers and remedies available hereunder or under the Other Agreements, or accorded by law or equity, in each case, without presentment, demand, protest, notice of dishonor, or other notice of any kind, all of which are hereby expressly waived by Client. Notwithstanding the foregoing or anything to the contrary herein, immediately upon the occurrence of a Specified Default, all Obligations shall be automatically accelerated and this Agreement shall be automatically terminated, without notice or further action of any kind. Without limitinthe generality of  the foregoing, at any time after the occurrence of an Event of  Default, Goodman  shall  have all the rights and remedies of a secured party under the UCC and other applicable laws with respect to all Collateral, including the right to sell or cause to be sold any or all of such Collateral, in one or more sales or parcels, at such prices and upon such terms as Goodman shall elect, for cash or on credit or for future delivery, without assumption of any credit risk, and at a public or private sale as Goodman may deem appropriate. After application to the Obligations of the proceeds of any such sale or disposition of Collateral, Client shall remain liable for any deficiency.

4

8.           Indemnification and Taxes. Client hereby indemnifies and holds Goodman and its affiliates, subsidiaries, directors, officers, employees, representatives and agents (Good and all such Persons referred to herein each individually as an "Indemnified Person" and collectively as the "Indemnified Persons") harmless from and against any and all  suits, actions, proceedings, claims, damages, losses, liabilities and expenses of every kind and  nature  (includinattorneys'  costs, fees and expenses) which may be instituted or asserted against or incurred by any such Indemnified Person with respect to the execution. delivery, enforcement, performance or administration of, or in any other way arising out of or  relating to, this Agreement or  any Other Agreement, and any actions or inactions with respect to any of the foregoing, except to the extent that any such indemnified liability is determined  pursuant to a final, non-appealable order issued by a court of competent  jurisdiction to have resulted solely from such Indemnified Person's gross negligence or willful misconduct.   No Indemnified Person shall be responsible or liable to Client or to any other party for indirect,  punitive, special, exemplary or consequential damages which may be alleged as a result of any advance or other financial accommodation having been extended, denied, delayed, conditioned, suspended or terminated under this Agreement or any Other Agreement or as a result of any other event or transaction contemplated hereunder or thereunder. In addition, if any tax or fee by any governmental authority (other than income and franchise taxes owing by Goodman) is or may be imposed on or as a result of any transaction between Client and Goodman, or in respect to sales or the goods affected by such sales, which Goodman is or  may be required  to withhold  or pay, Client  acknowledges sole responsibility  for sucfee or  tax and agrees to indemnify and hold Goodman harmless in respect of such taxesClient will pay to Goodman, upon Goodman•s demand, the amount of any such taxes, which shall be charged to the Reserve Account as an Advance.

9.          Costs and Expenses. Client shall pay to Goodman all costs, fees and expenses, including attorneys' and other professionals" costs, fees and expenses, incurred by Goodman in connection with the preparation, execution, delivery, administration or enforcement of this Agreement or any Other Agreement, or the filing or perfecting of any security interest of Goodman in any Collateral. In addition, Client shall also reimburse Goodman for all costs, fees and expenses incurred by Goodman, including attorneys' and professionals' costs, fees and expenses, in connection with: (i) obtaining or enforcing payment or performance of any Obligation; (ii) the prosecution or defense of any action or proceeding concerning any matter arising out of or connected with this Agreement, any Other Agreement or any of the Collateral; (iii) any action or effort to inspect, appraise, examine, verify, protect, collect, sell, liquidate or otherwise dispose of any Collateral, including all costs incurred or payable in connection with periodic field examinations at such rates as shall be charged by Goodman to its clients from time to time. Client shall also pay to Goodman its standard and customary fees relating to bank services, wire transfers, special or additional reports, remittance expenses (including, without limitationincoming  wire charges, currency conversion fees and stop payment fees), and other services at such rates as shall be charged by Goodman to its clients from time to time. All such costs, fees and expenses, together with all filing, recording and search fees and taxes payable by Client to Goodman, shall be payable on demand and may be charged by Goodman to the Reserve Account as an Advance.
 
I0.          Miscellaneous Provision.
 
(a)          Power of AttorneyClient hereby appoints Goodman as Client's attorney-in-fact to (i) receive, open and dispose of all mail addressed to Client but received by Goodman, (ii) upon or after the occurrence of an Event of Default, notify Post Office authorities to change the address for delivery of mail addressed to the Client to such address as Goodman may designate,
(iii) endorse Client's name upon any notes, acceptances, checks, drafts, money orders, remittances and other items of payment of Accounts that come into Goodman's possession and to deposit or otherwise collect the same and (iv) upon or  after the occurrence of an Event of Default, do all other acts and things necessary to carry out  the terms of this Agreement. This power, being coupled with an interest, is irrevocable while this Agreement remains in effect or any Obligations remain outstanding. Goodman, as attorney-in-fact, shall not be liable for any errors of judgment or mistake of fact.
 
(b)          Waiverby Client.  Client waives any right to  require Goodman  to (i)  proceed against any Obligor or other Person, (ii) marshal assets or proceeagainst or exhaust any security  from any Obligor or any other Person, (iii) perform any obligation of any Obligor with respect to any Collateral and (iv) make any presentment or demand, or give any notice of nonpayment or non performance, protest, notice of protest or notice of dishonor hereunder or  in connection with the Obligations or any Collateral. Client further waives any  right tdirect the application of  payments or security for any Obligations of any  Obligor or indebtedness of customers of any Obligor.
 
(c)          Governing Law: Jurisdiction. The validity, construction and effect of this Agreement and, except as otherwise expressly stated therein, of the Other Agreements shall be governed  by, construed and enforced  in accordance with the laws of the State of Texas, without regard to conflicts of laws principles. Each of Client and Goodman hereby irrevocably and unconditionally submits, for itself and its property, to the exclusive jurisdiction of the state courts of Texas sitting in Dallas County and of the United States District Court for the Northern District of Texas, and any appellate court from any thereof, in any action or proceeding arising out of or  relating to  this Agreement, or for recognition or enforcement of  any judgment,  and each of Client and Goodman hereby irrevocably and unconditionally agrees that all claims in respect of  any such action or  proceeding shall be heard and determined in such state court or, to the fullest extent permitted by applicable law, in such federal court; provided, that Goodman may bring any action or proceeding against any Obligor relating to  this Agreement,  the Other Agreements or  the Collateral in the courts of any jurisdiction. Each of Client and Goodman irrevocably and unconditionally waives, to the fullest extent permitted by applicable law, any objection that it may now or hereafter have to the laying of  venue of  any action or proceeding arising out of or relating to this Agreement in any court referred to in this Section. Each party hereto hereby irrevocably waives, to the fullest extent permitted by applicable law, the defense of inconvenient forum to the maintenance of such action or proceeding in any such court.
 
5

(d)          WAIVER OF JURY TRJAL. GOODMAN AND CLIENT DO HEREBY WAIVE ANY AND ALL RJGHT TO  A TRIAL BY JURY IN ANY ACTION OR PROCEEDING OF ANY KIND ARJSING ON, OUT OF, BY REASON OF, OR RELATING IANY WAY TO, THIS AGREEMENT OR THE INTERPRETATION OR ENFORCEMENT  THEREOF OR TO ANY TRANSACTIONS HEREUNDER.

(e)          USA Patriot Act. Client shall provide and shall cause its affiliates to provide such information and take such actions as requested by Goodman from time to time in order to assist Goodman in maintaining compliance with all applicable "know your customer" and anti-money laundering rules and regulations, including the Patriot Act.
 
(f)          No Waiver of Rights. No failure or delay by Goodman in exercising any of its powers or rights hereunder shall operate as a waiver thereof; nor shall any single or partial exercise of any such power or right preclude other or further exercise thereof or the exercise of any other right or power. Goodman's rights, remedies and benefits hereunder are cumulative and not exclusive of any other rights, remedies or benefits which Goodman may have. No waiver by Goodman will be effective unless in writing and then only to the extent specifically stated.
 
(g)          Notices. All notices, requests and demands which any party is required or may desire to give to any other party under any provision of this Agreement must be in writing delivered to each party at the address for such party set forth below each party's name on the signature pages of this Agreement or to such other address as any party may designate by written notice to all other parties. Each such notice, request and demand will be deemed given or made as follows: (i) if sent by hand delivery or overnight courier, upon delivery; (ii) if sent by mailupon the earlier of the date of receipt or  three (3) days after deposit in the U.S. mail, first class and postage prepaid; (iii) if sent by telecopy, upon receipt; and (iv) if sent by electronic mail, upon sender's receipt of an acknowledgment from the intended  recipient (such as by "return  receipt requested" function, as available. return email or other written acknowledgment).
 
(h)          General. This Agreement will be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns; provided that Client may  not assign or  transfer any of its  interestsrights or  obligations under this Agreement without Goodman's prior written consent. This Agreement sets forth the entire understanding of the parties with respect to the matters seforth  herein and supersedes  in their entirety any  and all  understandings and agreements, whether  written or oral, of the parties with respect to the foregoing.  This Agreement cannot be changed, modified or amended  in any respect except by a writing executed  by the party to  be charged. This Agreement  is made and entered  into  for the solprotection and  benefit of the parties hereto and their respective permitted successors and assigns, and no other Person will be a third party beneficiary of, or have any direct or indirect cause of action or claim in connection  with, this Agreement.   If any provision of this Agreement is found to be unenforceable or otherwise invalid under applicable law, such provision shall be ineffective only to the extent of such invalidity and the  remaining  provisions of  this Agreement shall remain  in  full force and effect. This Agreement  may  be executed in counterparts, each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of an executed signature page by telecopy or electronic mail shall be effective as delivery of a manually executed counterpart of this Agreement. Each sale of  an Account  tGoodman  under this Agreement is an "Account Purchase  Transaction" as defined by Section 306.001(1) of the Texas Finance Code and is subject to such subtitle of the Texas Finance Code.
 
(i)          Savings Clause. No provision of this Agreement or of any Other Agreement shall require the payment or the collection of interest in excess of the maximum amount permitted by applicable law. In the event Goodman ever receives, collects or applies as  interest  hereunder or  under any Other Agreement  any amount in excess of the maximum  amount  permitted by applicable law, such excess shall be applied as a payment and reduction of the principal of the Obligations of Client and, if the principal of such Obligations has been paid in full, any remaining excess shall be paid to Client. In determining whether or not the interest paid or payable exceeds the maximum rate permitted  by applicable  law, Client and Goodman  shall, to the extent permitted by applicable law, including Section 306.00I (I) of  the  Texas Finance Code, (i) characterize any non-principal payment as an expense, fee, or premium  rather than as  interest, (ii) exclude voluntary prepayments and the effects thereof, and (iii) amortize, prorate, allocate, and spread in equal or unequal parts the total amount of interest throughout the entire contemplated term of this Agreement so that interest for the entire term does not exceed  the maximum rate permitted  by law.   If at any time the  interest rate set forth in this Agreement or any Other Agreement exceeds the maximum interest rate allowable under applicable law, the interest rate will be deemed to be such maximum interest rate allowable under applicable law.
 
(j)          Multiple Clients. Each Client acknowledges that the successful operation and condition of each Client individually is dependent on the successful operation and condition of all Clients collectively. Each Client further acknowledges that it expects to derive benefit from the successful operation and condition of each other Client and from any Advances or financial accommodations extended by Goodman to each or any other Client. Each Client agrees that it is jointly and severally liable for, and absolutely and unconditionally guarantees to Goodman the prompt payment and performance of, all Obligations. Each Client agrees that its guaranty obligations hereunder constitute a continuing guaranty of payment and not of collection, that such obligations shall not be discharged until cash payment in full of the Obligations, and that such obligations are absolute and  unconditional, irrespective of any action or circumstances that might otherwise constitute a legal or equitable discharge or defense of a surety or guarantor, except cash payment in full of all Obligations. Each Client agrees that it will not enforce any of its rights of contribution or subrogation against any olher Client with respect to any liability incurred by such Client hereunder or under any Other Agreement, any payments  made by it to  Goodman  with respect to any of the Obligations or any collateral security until such time as all of the Obligations have been paid in full in cash. Each reference to Client means each Client individually and all Clients collectively.
 
6

11.         Definitions.
 
Unless otherwise defined herein, the following terms are used herein as defined in the UCC: Accounts, Account Debtor, Chattel Paper, Commercial Tort Claims, Deposit Accounts, Documents, Equipment, General Intangibles, Goods, Instruments, Inventory, Investment Property, Letter-of-Credit Rights, Proceeds and Supporting Obligations.
 
As used in this Agreement, the following terms have the following meanings:
 
"Advance Rate" means 100% less the Reserve Percentage.
 
''Business Day" means any day other than a Saturday, Sunday or other day on which factors or commercial banks are authorized or required to close by law or under to the rules and regulations of the Federal Reserve System.
 
"Collateral" means, collectively. all of Client's existing and hereafter acquired (a) Accounts, Chattel Paper, Commercial Tort Claims, Deposit Accounts, Documents, General Intangibles, Goods (including Inventory and Equipment), lnstruments. Investment Property, Letter-of-Credit Rights and Supporting Obligations, (b) reserves, matured funds, credit balances and other property of Client in Goodman's possession, (c) Records and (d) insurance policies and Proceeds of any or all of the foregoing.
 
"Credit Risk'' means the risk of loss on an Account resulting solely and exclusively from the financial inability of the applicable Customer to pay the Account in full when due.
 
"Customer" means a Person that purchases goods or services from Client.
 
"Dispute" means any reason (regardless of merit) for nonpayment of an Account, including any alleged offset, defense or counterclaim.
 
"Effective Date" means the date designated by Goodman as 1he '•Effective Dale" as sci forth below Goodman's signature block on the signature page of1his Agreement
 
"Formula Amount" means an amount equal to (a) the Advance Rate multiplied by the gross amount of Accounts deemed eligible by Goodman, in its sole discretion, for borrowing purposes less (b) such reserves as it deems necessary as security for the payment and performance of the Obligations, to enhance the likelihood of repayment of the Obligations or to reflect events, conditions, contingencies or risks which might adversely affect the Collateral or the business of Client. In no event shall any Account be eligible for borrowing purposes or included in the Formula Amount if such Account is for any reason unpaid upon expiration of the ''Eligibility Period" set forth on Schedule A, subject to payment terms in excess of  maximum terms from time to time established by Goodman in its discretion, subject to Dispute or charged back to Client in accordance wilh the terms hereof.
 
"Funding Date" means, with respect to any Account that is at any time included in the Formula Amount, the date on which such Account is first included in such Formula Amount.
 
"Obligations" means all Advances, debts, liabilities, obligations, guaranties, covenants, duties and indebtedness of every nature at any time owing by Client to Goodman, whether evidenced  by or  arising under this Agreementthe Other Agreements or any note or other instrument or document, whether arising by law or otherwise, whether arising from an extension of credit, loan, guaranty, indemnification or otherwise, whether direct or indirect, absolute or contingent, due or to become due, contractual or tortious, liquidated or unliquidated, now existing or here afler arising (whether before or after the filing of any petition in bankruptcy by or against Client or the commencement of any other insolvency proceedings with respect to Client) including all interest, charges, expenses, fees, attorney's fees, consultant's fees, expert witness fees, field examination fees, loan fees, termination fees, minimum interest charges and any other sums chargeable to Client or incurred by Goodman under or in connection with this Agreement, the Other Agreements or the transactions contemplated hereby or thereby.
 
"Obligors" means, collectively, Client and any Person who now or hereafter executes in favor of  Goodman a guaranty of the prompt payment and performance payment of the Obligations.
 
"Other Agreement" means any agreement, guaranty, mortgage, note, instrument or document executed or delivered pursuant hereto or in connection with this Agreement.
 
"Person" means a natural person, corporation, limited liability company, limited partnership, general partnership, limited liability partnership, joint venture, trust, land trust, business trust or other organization, irrespective of whether it is a legal entity, or a government or agency or political subdivision thereof, and any reference herein to any Person shall be construed to include such Person's successors and assigns.
 
7

"Purchase Price" means, for any Account purchased under this Agreement, the gross amount of such Account determined by Goodman at the time such Account is first offered for sale to Goodman hereunder by delivery from Client to Goodman of a schedule for such Account in accordance with the terms hereof.
 
"Prime Rate" means the greater of (a) 0% per annum and (b) the rate published from time to time by The Wall Street Journal as the "Prime Rate" or, if at antime or for anreason such rate is not published, such rate  from timto  time  announced by Independent Bank as its "Prime Rate". Each change in the rate of interest will become effective on the date each Prime Rate change is published or announced, as the case may be.
 
"Reserve Account" means a ledger (or book-entry) account maintained by Goodman on its books and records in the name of Client.
 
"Settlement Date" means, for each Account, two (2) Business days after the Business Day on which payment of such
 
Account is posted by Goodman to the Reserve Account; provided, that if the Customer of a Non-Recourse Account for which the Settlement Date has not already occurred is subject to an insolvency proceeding at the expiration of the Eligibility Period for such Non-Recourse Account, the Settlement Date for such Non-Recourse Account shall be the Business Day following receipt by Goodman of the written acknowledgment of such Customer that no Dispute exists or the entry of an order by the court having jurisdiction over such insolvency proceeding that no Dispute exists.
 
"UCC" shall mean the Uniform Commercial Code as in effect from time to time in the State of Texas.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

8

IN WITNESS WHEREOF, the parties hereto have executed this Agreement effective as of the Effective Date.
 
GOODMAN:
 
INDEPENDENT BANK,
acting through its Goodman Capital Finance division

By
 
 
Name
   
Title    

Address:
Goodman Capital Finance,
30 IO LBJ Freeway, Suite 540
Dallas, TX 75234
Attention:
 
 
Fax No:
(972) 243-6285
 
Email:
 
 
Effective Date:June 17 ,2021
CLIENT:

SANUWAVE, INC.

By:
/s/ Kevin Richardson, II  
Name:
Kevin Richardson, II  
Title: CEO
 

By:
/S/ Lisa Sundstrom  
Name:
Lisa Sundstrom  
Title: CFO
 

SANUWAVE HEALTH, INC.

By:
/s/ Kevin Richardson, II  
Name:
Kevin Richardson, II  
Title: President  

By:
/s/ Lisa Sundstrom  
Name:
Lisa Sundstrom  
Title: Secretary  

Address:
3360 Martin Farm Rd., Suite 100
Suwanee, GA 30024
Attention: Kevin Richardson, II
Email: info@sanuwave.com

[Signature Page to Factoring Agreement}


SCHEDULE A TO
FACTORING AGREEMENT
 
 
Reserve
Percentage:
 
13.75%
 
Contract Rate:
 
NA
 
Eligibility Period
 
With respect to any Account, the earlier of 46 days from the original due date thereof or  90 days from the invoice date thereof.
 
Initial Term:
 
I month, commencing upon the Effective Date.
 
Renewal Term:
 
I month.
 
Facility
Maximum:
 
$3,000,000
 
Fees:
 
(a)          Initial Commissions. With respect to each Account of Client that is at  any time included in the Formula Amount, Client shall pay to Goodman a commission (with respect to each Account, the "Initial Commission") equal to 1.25% multiplied by the gross amount of such Account.  The Initial Commission for an Account shall be due and payable on the Funding Date for such Account.
 
(b)          Additional Commissions. In the event an  Account  remains unpaid  (in whole or in part) on the 30th day following the Funding  Date, Client shall pay to Goodman, on such 30th day and on each I day thereafter that such Account remains unpaid, an additional commission (with respect to each Account, the "Additional Commission") equal to 0.04% multiplied by the gross amount of such Account as of the Funding Date. For purposes of determining Additional Commissions, an Account shall be deemed to remain unpaid until the Settlement Date of such Account.
 
(c)          Misdirection  Fee.  Goodman may charge to Client a misdirected  payment fee in the amount of fifteen percent (15%) of the amount of any check, remittance or other item of payment constituting a payment of an Account which is received by an Obligor and not deposited into the Collection Account on the next Business Day following receipt by such Obligor.



SCHEDULE B TO
FACTORING AGREEMENT
 
on request of Goodman:
(a)
such other information as Goodman may request from time to time.
 



Exhibit 10.3

FUTURE RECEIVABLES AGREEMENT
 
This FUTURE RECEIVABLES AGREEMENT (this "Agreement"), dated September 27, 2021, is made by and between GCF Resources LLC, ("GCF") and SANUWAVE, INC. ("Merchant)".
 
Merchant's Legal Name: SANUWAVE, INC.
DBA Name: SANUWAVE
Legal Entity: Corporation
Address:  3360 MARTIN FARM RD #100



City: SUWANEE



State: GA



Zip: 30024
       

PURCHASE AND SALE OF FUTURE RECEIVABLES
 
Merchant hereby sells, assigns and transfers to GCF (making GCF the absolute owner) in consideration of the purchase price specified below (the Purchase Price), the specified percentage specified below (the Specified  Percentage)  of  all of Merchant's future accounts, contract  rights and other entitlements  arising from or relating to  the payment  of monies from Merchant's customers 'and/or other third party payors (collectively, the "Receipts", including all payments made by cash, check, electronic transfer or other form of monetary payment in the ordinary course of the  Merchant's business), for  the  payments due to Merchant as a result of Merchant's sale of goods or services (the "Transactions") until the receipts purchased amount specified below (the Purchased Amount) has been delivered by or on behalf of Merchant to GCF. Merchant hereby acknowledges and agrees that GCF may elect, in its sole discretion, to pay to Merchant a percentage of the full Purchase Price specified below. If GCF elects to pay to Merchant less than the full Purchase Price specified below then the amount actually paid by GCF shall be deemed the Purchase  Price for  purposes of  this transaction notwithstanding the Purchase Price specified below and the Purchased Amount shall automatically be reduced proportionately notwithstanding the Purchased amount specified below. By signing this Agreement, Merchant expressly consents to be bound to the terms of this Agreement whether GCF, in its sole discretion, elects to pay the full Purchase Price specified below or a percentage thereof. Merchant further acknowledges that if GCF elects to pay a percentage of the full Purchase Price specified below, that such payment shall not be deemed a default under this Agreement, and that all other terms and conditions, specifically including but not limited to the Daily Amount, shall remain in effect except as otherwise provided herein. The Purchased Amount shall be paid to GCF by...in consideration of the purchase price specified below (the Purchase Price), the specified percentage specified below (the Specified Percentage) of all of Merchants...until the receipts purchased amount specified below (the Purchased Amount) has been delivered by or on behalf of Merchant to GCF. Merchant hereby acknowledges and agrees that GCF may elect, in its sole discretion, to pay to Merchant a percentage of the full Purchase Price specified below. If GCF elects to pay to Merchant less than the full Purchase Price specified below then the amount actually paid by GCF shall be deemed the Purchase Price for purposes of  this transaction notwithstanding the Purchase Price specified below and the Purchased Amount shall automatically be reduced proportionately notwithstanding the Purchased Amount specified below. By signing this Agreement, Merchant expressly consents to  be bound to the terms of this Agreement whether GCF, in  its  sole discretion, elects to pay the  full Purchase Price specified below or a percentage thereof. Merchant further acknowledges that if GCF elects to pay a percentage of the full Purchase Price specified below, that such payment shall not be deemed a default under this  Agreement,  and that all other  terms and conditions, specifically  including but  not  limited  to the Daily Amount, shall remain  in effect except as otherwise provided herein. The Purchased Amount shall be paid to GCF by...paid to GCF by Merchant's irrevocably directing and authorizing that there be only one depositing bank account, which account must be acceptable to, and pre-approved by, GCF (the "Account") into which Merchant and Merchants customers shall remit the Specified Percentage of the Merchants settlement amounts due from each Transaction, until such time as GCF receives payment in full of thePurchased Amount. Merchant hereby authorizes GCF to ACH Debit the Daily Amount (as specified below) from the Merchants Account on a daily basis and will provide GCF with all required access codes, and monthly bank statements. Merchant understands that it is responsible for  ensuring that the specified  percentage  to  be debited by GCF remains in the  Account and will be held responsible for any fees incurred by GCF resulting from a rejected ACH attempt or an event of default. (See Appendix  A) GCF is not  responsible for  any overdrafts or rejected transactions that may result from GCF ACH debiting the specified amounts under the terms of this agreement. GCF will debit the specific daily amount each business day. The Merchant shall deliver to GCF, no later than the 18th date of each month the bank statement for the  Account in respect of  the  immediately  preceding month. Within three business  days of  GCF receipt of the Merchants monthly bank statements, GCF shall reconcile the  Merchants  Account  by either crediting or debiting the difference  from or back to  the  Merchants Account  so that the amount debited per month equals the  Specified  Percentage. If  the  Merchant fails to  deliver the  bank statement for  the Account for  any month, GCF shall consider that the specific remittances  were equal to the Specified Percentage of  the  settlement amount due from each Transaction for  such month. GCF may, upon Merchants request, adjust the amount of any payment due under this Agreement at GCF sole discretion  and as it  deems appropriate.  Notwithstanding anything to  the contrary  in this Agreement  or  any other agreement between GCF and Merchant, upon the violation of any provision contained in Section 1.11 of the MERCHANT AGREEMENT TERMS AND CONDITIONS or the occurrence of an Event of Default under Section 3 of the MERCHANT AGREEMENT TERMS AND CONDITIONS, the Specified percentage shall equal 100%. A list of all fees applicable under this Agreement is contained in Appendix A. For the avoidance of any doubt, each party to this Agreement acknowledges, agrees and understands that the transaction contemplated by this Agreement is a purchase and sale of future receivables and not a loan, and no party hereto intends for this Agreement to be, or to be deemed to be, a loan agreement. Accordingly, there is no interest payable  hereunder  and no mandated date on which amounts hereunder are due. Furthermore,  the failure of the Merchant to  make sales and the Merchant going out of business or bankrupt is, in and of itself, not an Event of Default under this Agreement. These are risks assumed by GCF. Neither the Merchant nor any affiliate of the Merchant, directly or indirectly, shall assert or attempt to assert at any time and in any forum that this Agreement is a loan agreement or that the transactions contemplated hereby are or should be characterized as loans.
 
Purchase Price
$1,000,000.00
Specified Percentage
10%
Estimated Daily Amount
$11,834.00
Receipts Purchased Amount
$1,420,000.00

THE TERMS AND CONDITIONS, THE "SECURITY AGREEMENT AND GUARANTY" AND THE "AUTHORIZATION AGREEMENT" ATTACHED HERETEO, ARE ALL HEREBY INCORPORATED IN AND MADE A PART OF THIS AGREEMENT.
 
MERCHANT
     
BY: KEVIN A RICHARDSON II
X
/s/ KEVIN A RICHARDSON II  

(SIGNATURE)
 
9/27/2021
CEO #1: KEVIN A RICHARDSON II
X
/s/ KEVIN A RICHARDSON II      

(SIGNATURE)
 
(DATE)
       
CEO#2:
X

   


 
(DATE)
 
GCF Resources LLC
(SIGNATURE)
   
BY:
X

   
(COMPANY OFFICER)
(SIGNATURE)
   

1
Merchant Initial

TERMS AND CONDITIONS
 
I. TERMS OF ENROLLMENT IN PROGRAM
 
1.1          Merchant Deposit Agreement. Merchant shall execute an agreement (the "Merchant Deposit Agreement") acceptable to GCF with a Bank acceptable to GCF to obtain electronic fund transfer services for the Merchant's account at the Bank approved by GCF (the "Account"). Merchant shall provide GCF and/or its authorized agent(s) with all of the information, authorizations and passwords necessary for verifying Merchant's receivables, receipts, deposits and withdrawals into and from the Account. Merchant hereby authorizes GCF and/or its agent(s) to deduct from the Account the amounts owed to GCF for the receipts as specified herein and to pay such amounts to GCF. Merchant also hereby authorizes GCF to withdraw from the Account the specified percentages and/or sums by GCF debiting the account. These authorizations apply not only to the approved Account but also to any subsequent or alternate account used by the Merchant for these deposits, whether pre-approved by GCF or not. This additional authorization is not a waiver of GCF entitlement to declare this Agreement breached by Merchant as a result of its usage of an account that GCF did not first pre-approve in writing prior to Merchant's usage thereof. The aforementioned authorizations shall be irrevocable without the written consent of GCF.

1.2      Term of Agreement. This Agreement shall remain in full force and effect until the entire "Purchased Amount" is received by GCF as per the terms of this Agreement, however, at any point during the term of this Agreement, Merchant may terminate this Agreement upon ninety days 'prior written notice (effective upon actual receipt) to GCF. The termination of this Agreement shall not affect Merchant's continuing obligation and responsibility to fully satisfy all outstanding obligations that are due to GCF simultaneous with the Notice of termination.

1.3           Future Purchases. GCF reserves the right to rescind the offer to make any purchase payments hereunder, in its sole and absolute discretion.

1.4          Financial Condition. Merchant and Guarantor(s) (as hereinafter defined and limited) authorize GCF and its agents to investigate their financial responsibility and history, and will provide to GCF any authorizations, bank or financial statements, tax returns, etc., as GCF deems necessary in its sole and absolute discretion prior to  or at any time after execution of  this Agreement. A photocopy of this authorization will be deemed as acceptable as an authorization for release of financial and credit reporting information. GCF is authorized to update such information and financial and credit profiles from time to time as it deems appropriate.

1.5           Transactional History. Merchant authorizes all of their banks and brokers to provide GCF with Merchant's banking, brokerage and/or processing history to determine qualification or continuation in this program.

1.6           Indemnification. Merchant and Guarantor(s) jointly and severally indemnify and hold harmless Processor, its officers, directors and shareholders against all losses, damages, claims, liabilities and expenses (including reasonable attorney's fees) incurred by Processor resulting from (a) claims asserted by GCF for monies owed to GCF from Merchant and (b) actions taken by Processor in reliance upon any fraudulent, misleading or deceptive information or instructions provided by GCF.

1.7          No Liability. In no event will GCF be liable for any claims asserted by Merchant or Guarantors under any legal theory for lost profits, lost revenues, lost business opportunities, exemplary, punitive, special, incidental, indirect or consequential damages, each of  which is waived by both Merchant and Guarantor(s). In the event these claims are nonetheless raised, Merchant and Guarantors will be jointly liable for all of GCF legal fees and expenses resulting there from.

1.8           Reliance on Terms. Section 1.1, 1.7, 1.8 and 2.5 of this Agreement are agreed to for the benefit of Merchant, GCF and Processor, and notwithstanding the fact that Processor is not a party of this Agreement, Processor may rely upon their terms and raise them as a defense in any action.

1.9        Sale of Receipts. Merchant and GCF agree that the Purchase Price under this Agreement is in exchange for the Purchased Amount, and that such Purchase Price is not intended to be, nor shall it be construed as a loan from GCF to Merchant. Merchant agrees that the Purchase Price is in exchange for the Receipts pursuant to this Agreement, and that it equals the fair market value of such Receipts. GCF has purchased and shall own all the Receipts described in this Agreement up to the full Purchased Amount as the Receipts are created. Payments made to GCF in respect to the full amount of the Receipts shall be conditioned upon Merchant's sale of products and services, and the payment therefore by Merchant's customers in the  manner provided in Section 1.1. In no event shall the aggregate of all amounts or any portion thereof be deemed as interest hereunder, and in the event it is found to be interest despite the parties hereto specifically  representing that it is NOT interest, it shall be found that no sum charged or collected hereunder shall exceed the highest rate permissible at law. In the event that a court nonetheless determines that GCF has charged or received interest hereunder in excess of the highest applicable rate, the rate in effect hereunder shall automatically be reduced to the maximum rate permitted by applicable law and GCF shall promptly refund to Merchant any interest received by GCF in excess of  the  maximum lawful rate, it being intended that Merchant not pay or contract to pay, and that GCF not receive or contract to receive, directly or indirectly in any manner whatsoever, interest in excess of that which may be paid by Merchant under applicable law. As a result thereof, Merchant knowingly and willingly waives the defense of Usury in any action or proceeding.
1.10          Power of Attorney. Merchant irrevocably appoints GCF as its agent and attorney in fact with full authority to take any action or execute any instrument or document to settle all obligations due to GCF from Processor, or in the case of a violation by Merchant of Section 1.12 or the occurrence of an Event of Default under Section 3.1 hereof, from Merchant, under this Agreement, including without limitation (i) to obtain and adjust insurance; (ii) to collect monies due or to become due under or in respect of any of the Collateral; (iii) to receive, endorse and collect any checks, notes, drafts, instruments, documents or chattel paper in connection  with clause (i) or clause (ii) above; (iv) to sign Merchant's name on any invoice, bill of lading, or assignment directing customers or account debtors to make payment directly to GCF; and (v) to file any claims or take any action or institute any proceeding which GCF may deem necessary for the collection of any of the unpaid Purchased Amount from the Collateral, or otherwise to enforce its rights with respect to payment of the Purchased Amount. In connection therewith, all costs, expenses and fees, including legal fees, shall be payable by and from Merchant, and GCF is authorized to use Merchant's funds to pay for the same.

1.11          Protections  against Default. The following Protections  1 through 7 may be invoked by GCF immediately and without notice to Merchant in the event: (a) Merchant takes any action to discourage the use of electronic check processing that are settled through Processor, or permits any event to occur that could have an adverse effect on the use, acceptance, or authorization of checks or other payments or deposits for the purchase of Merchant's services and products including but not limited to direct deposit of any checks into a bank account without scanning into the GCF electronic check processor; (b) Merchant changes its arrangements with Processor in any way that is adverse or unacceptable to GCF; (c) Merchant changes the electronic check processor through which the Receipts are settled from Processor to another electronic check processor, or permits any event to occur that could cause diversion of any of Merchant's check or deposit transactions to another processor; (d) Merchant interrupts the operation of this business (other than adverse weather, natural disasters or acts of God) transfers, moves, sells, disposes, or otherwise conveys its business and/or assets without (i) the express prior written consent of GCF, and (ii) the written agreement of any purchaser or transferee to the assumption of all of Merchant's obligations under this Agreement pursuant to documentation satisfactory to GCF; or (e) Merchant takes any action, fails to take any action, or offers any incentive-economic or otherwise-the result of which will be to induce any customer or customers to pay for Merchant's services with any means other than payments, checks or deposits that are settled through Processor. These protections are in addition to any other remedies available to GCF at law, in equity or otherwise pursuant to this Agreement.

Protection 1. The full un collected Purchase Amount plus all fees (including legal fees) due under this Agreement and the attached Security Agreement become due and payable in full immediately. Protection 2. GCF may enforce the provisions of the Validity Guaranty of Performance against the Guarantor(s). Protection 3. Merchant hereby authorizes GCF to execute in the name of the Merchant a Confession of Judgment in favor of GCF in  the amount of Purchase Amount stated in the Agreement. Upon breach of any provision in this paragraph 1.11, GCF may enter that Confession of Judgment as a Judgment with the Clerk of any Court and execute thereon. Protection 4. GCF may enforce its security interest in the Collateral identified in the attached Security Agreement and Guarantee. Protection 5. The entire Purchase Amount and all fees (including legal fees) shall become immediately refundable and payable to GCF from Merchant. Protection 6. GCF may proceed to protect and enforce its rights and remedies by lawsuit. In any such lawsuit, under which GCF shall recover Judgment against Merchant, Merchant shall be liable for all of GCF costs of the lawsuit, including but not limited to all reasonable attorneys 'fees and court costs. Protection 7. This Agreement shall be deemed Merchants Assignment of Merchant's Lease of Merchant's business premises to GCF. Upon breach of any provision in this Agreement, GCF may exercise its rights under this Assignment of Lease without prior Notice to Merchant. Protection 8. GCF may debit Merchant's depository accounts wherever situated by means of ACH debit or facsimile signature on a computer generated check drawn on Merchant's bank account or otherwise for all sums due to GCF.
 
2
Merchant Initial

1.12            Protection of Information. Merchant and each person signing this Agreement  on behalf of Merchant and/or as Owner or Guarantor, in respect of himself or herself personally, authorizes GCF to disclose information concerning Merchant's and each Owner's and each Guarantor's credit standing (including credit bureau reports that GCF obtains) and business conduct only to agents, affiliates, subsidiaries, and credit reporting bureaus. Merchant and each Owner and each Guarantor hereby and each waives to the maximum extent permitted by law any claim for damages against GCF or any of its affiliates relating to any (i) investigation undertaken by or on behalf of GCF as permitted by this Agreement or (ii) disclosure of information as permitted by this Agreement.
 
1.13             Confidentiality. Merchant understands and agrees that the terms and conditions of the products and services offered by GCF, including this Agreement and any other GCF documentations (collectively, "Confidential Information") are proprietary and confidential information of GCF. Accordingly unless disclosure is required by law or court order, Merchant shall not disclose Confidential Information of GCF to any person other than an attorney, accountant, financial advisor or employee  of Merchant  who needs to know such information for the purpose of advising Merchant ("Advisor"), provided such Advisor uses such information solely for the purpose of advising Merchant and first agrees in writing to be bound by the terms of this section. A breach hereof entitles GCF to not only damages and legal fees but also to both a Temporary Restraining Order and a Preliminary Injunction without Bond or Security.

1.14            Publicity. Merchant and each of Merchant's Owners and all Guarantors hereto all hereby authorizes GCF to use its, his or her name in listings of clients and in advertising and marketing materials.

1.15             D /B /A's. Merchant hereby acknowledges and agrees that GCF may be using "doing business as" or "d/b/a" names in  connection  with various matters relating to the transaction between GCF and Merchant, including the filing of UCC-1 financing statements and other notices or filings.
 
II. REPRESENTATIONS, WARRANTIES AND COVENANTS
 
Merchant represents warrants and covenants that, as of this date and during the term of this Agreement; and until GCF is fully paid:

2.1          Financial Condition and Financial Information. Merchant's and Guarantors 'bank and financial Statements, copies of which have been furnished to GCF, and future statements which will be furnished hereafter at the discretion of GCF, fairly represent the financial condition of Merchant at such dates, and since those dates there has been no material adverse changes, financial or otherwise, in such condition, operation or ownership of Merchant. Merchant and Guarantors have a continuing, affirmative obligation to advise GCF of any material adverse change in their financial condition, operation or ownership. GCF may request statements at any time during the performance of this Agreement and the Merchant and Guarantors shall provide them to GCF within 5 business days. Merchant's or Guarantors' failure to do so is a material breach of this Agreement.
2.2         Governmental Approvals. Merchant is in compliance and shall comply with all laws and has valid permits, authorizations and licenses to own, operate and lease its properties and to conduct the business in which it is presently engaged and/or will engage in hereafter.
 
2.3          Authorization. Merchant, and the person(s) signing this Agreement on behalf of Merchant, have full power and authority to incur and perform the obligations under this Agreement, all of which have been duly authorized.

2.4          Insurance. Merchant will maintain business-interruption insurance naming GCF as loss payee and additional insured in amounts and against risks as are satisfactory to GCF and shall provide GCF proof of such insurance upon request.

2.5          Electronic Check Processing Agreement. Merchant will not change its processor, add terminals, change its financial institution or bank account(s) or take any other action that could have any adverse effect upon Merchant's obligations under this Agreement, without GCF prior written consent. Any such changes shall be a material breach of this Agreement.

2.6           Change of Name or Location. Merchant will not conduct Merchant's businesses under any name other than as disclosed to the Processor and GCF, nor shall Merchant change any of its places of business without prior written consent by GCF.

2.7          Daily Batch Out. Merchant will batch out receipts with the Processor on a daily basis.
2.8              Estoppel Certificate. Merchant will at every and all times, and from time to time, upon at least one (1) day's prior notice from GCF to Merchant, execute, acknowledge and deliver to GCF and/or to any other person, firm or corporation specified by GCF, a statement certifying that this Agreement is unmodified and in full force and effect (or, if there have been modifications, that the same is in full force and effect as modified and stating the modifications) and stating the dates which the Purchased Amount or any portion thereof has been repaid.

2.9          No Bankruptcy. As of the date of this Agreement, Merchant is not insolvent and does not contemplate and has not filed any petition for bankruptcy protection under Title 11 of the United States Code and there has been no involuntary petition brought or pending against Merchant. Merchant further warrants that it does not anticipate filing any such bankruptcy petition and it does not anticipate that an involuntary petition will be filed against it. In the event that the Merchant files for bankruptcy protection or is placed under an involuntary filing Protections 2 and 3 are immediately invoked.

2.10          Working Capital Funding. Merchant shall not enter into any arrangement, agreement or commitment that relates to or involves the Receipts, whether in the form of a purchase of, a loan against, collateral against or the sale or purchase of credits against, Receipts or future check sales with any party other than GCF.

2.11          Unencumbered Receipts. Merchant has good, complete, unencumbered and marketable title to all Receipts, free and clear of any and all liabilities, liens, claims, changes, restrictions, conditions, options, rights, mortgages, security interests, equities, pledges and encumbrances of any kind or nature whatsoever or any other rights or interests that may be inconsistent with the transactions contemplated with, or adverse to the interests of GCF.

2.12         Business Purpose. Merchant is a valid business in good standing under the laws of the jurisdictions in which it  is organized and/or operates, and Merchant is entering into this Agreement for business purposes and not as a consumer for personal, family or household purposes.

2.13          Defaults under Other Contracts. Merchant's execution of, and/or performance under this Agreement, will not cause or create an event of default by Merchant under any contract with another person or entity.

2.14             Good Faith, Best Efforts and Due Diligence. Merchant and Guarantors hereby affirm that they will conduct the business in Good Faith and will expend their best efforts to maintain and grow its business, to ensure that GCF obtains the Purchased Amount. Furthermore, Merchant and Guarantors hereby agree, warrant and represent hereby that they will constantly perform all appropriate Due Diligence and credit checks of  all of the customers 'finances, cash flow, solvency, good faith, payment histories and business reputations (the "Due Diligence Requirements") as may suffice to ensure any and all products and/or services provided, sold or delivered by Merchant to said customers will be paid for by customers in full and on time, and will not result in the creation of an unpaid account. These Due Diligence Requirements must be performed prior to any sales to any customer, and repeated no less frequently than monthly for so long as any sums are due from those customers. Full documentation of all of Merchant's compliance with its Due Diligence Requirements  must be maintained in Merchant's files so long as GCF has not fully collected all sums due to it. This is not a guaranty of payment by customers, but is a guaranty of full, adequate and good faith Due Diligent investigation and credit check of customers before extending credit to them and continuing no less frequently than monthly so long as sums are still due.
 
Ill. EVENTS OF DEFAULT AND REMEDIES
 
3.1            Events of Default. The occurrence of any of the following events shall constitute an "Event of Default" hereunder: (a) Merchant or Guarantor shall violate any term or covenant in this Agreement; (b) Any representation or warranty by Merchant in this Agreement shall prove to have been incorrect, false or misleading in any material respect when made; (c) the sending of notice of termination by Merchant; (d) Merchant shall transport, move, interrupt, suspend, dissolve or terminate its business; (e) Merchant shall transfer or sell all or substantially all of its assets; (f) Merchant shall make or send notice of any intended bulk sale or transfer by Merchant; (g) Merchant shall use multiple depository accounts without the prior written consent of GCF (h) Merchant shall change its depositing account without the prior written consent of GCF; (i) Merchant shall perform any act that reduces the value of any Collateral granted under this Agreement; or (j) Merchant shall default under any of the terms, covenants and conditions of any other agreement with GCF.
 
3
Merchant Initial

3.2          Validity Guaranty. In the event of a Default under Sections 2.3, 2.5, 2.6, 2.9, 2.10, 2.11, 2.12, 2.13, and 2.14 or upon the occurrence of Event of Default as defined in Section 3.1, should GCF determine that the Purchased Amount cannot be obtained from the Merchant's business, GCF will enforce its rights against the Guarantors of this transaction. Said Guarantors will be jointly and severally liable to GCF for all of GCF losses and damages, in additional to all costs and expenses and legal fees associated with such enforcement.
 
3.3          Remedies. In case any Event of Default occurs and is not waived pursuant to Section 4.4.1 hereof, GCF may proceed to protect and enforce its rights or remedies by suit in equity of by action at law, or  both, whether  for the specific performance of any covenant, agreement or other provision contained herein, or to enforce the discharge of Merchant's obligations hereunder (including the Guaranty) or any other legal or equitable right or remedy. All rights, powers and remedies of GCF after the occurrence of an Event of Default, are cumulative and not exclusive and shall be in addition to any other rights, powers or remedies provided by law or equity. Simultaneous with the execution of this Agreement  Merchant  and Guarantor shall execute a Verified Confession of Judgment. In addition to the other remedies available to GCF upon any Event of Default, Merchant and Guarantor agree that GCF may file a Verified Confession of Judgment in New York (or an Agreed Judgment in Texas) without notice to Merchant and Guarantor and may seek to obtain a judgment for all amounts due and owing under this Agreement. In addition, GCF's remedies may include garnishment, or prejudgment garnishment, of Merchant's bank account.
 
3.4       Costs. Merchant shall pay to GCF all reasonable costs associated with (a) a breach by Merchant of the Covenants in this Agreement and the enforcement thereof, and (b) the enforcement of GCF remedies set forth in Section 4.2 below, including but not limited to court costs and attorneys 'fees.

3.5             Required Notifications. Merchant is required to give GCF written notice within 24 hours of any filing under Title 11 of the United States Code. Merchant is required to give GCF seven days 'written notice prior to the closing of any sale of all or substantially all of the Merchant's assets or stock.
 
IV. MISCELLANEOUS
 
4.1         Modifications; Agreements. No modification, amendment, waiver or consent of any provision of this Agreement shall be effective unless the same shall be in writing and signed by GCF.

4.2          Assignment. GCF may assign, transfer or sell its rights to receive the Purchased Amount or delegate its duties hereunder, either in whole or in part.

4.3               Notices. All notices, requests, consents, demands and other communications hereunder shall be delivered by certified mail, return receipt requested, to the respective parties to this Agreement at the addresses set forth in this Agreement. Notices to GCF shall become effective only upon receipt by GCF. Notices to Merchant shall become effective three days after mailing.

4.4              Waiver Remedies. No failure on the part of GCF to exercise, and no delay in exercising, any right under this Agreement shall operate as a waiver thereof, nor shall any single or partial exercise of any right under this Agreement preclude any other or further exercise thereof or the exercise of any other right. The remedies provided hereunder are cumulative and not exclusive of any remedies provided by law or equity.

4.5        Binding Effect; Governing Law, Venue and Jurisdiction. This Agreement shall be binding upon and inure to the benefit of Merchant, GCF and their respective successors and assigns, except that Merchant shall not have the right to assign its rights hereunder or any interest herein without the prior written consent of GCF, which consent may be withheld in GCF 'sole discretion. GCF reserves the rights to assign this Agreement with, or without written notice to Merchant. This Agreement shall be governed by and construed exclusively in accordance with the laws of the State of New York, without regards to any applicable principles of conflicts of law. If there is any suit, action, litigation or proceeding arising hereunder, or for the interpretation, performance or breach hereof, by either party, then such litigation shall only be instituted in any court sitting in the state of New York or Texas (the "Acceptable Forums"). The parties, including Merchant and Guarantor, agree that the Acceptable Forums are a convenient forum and submit to personal jurisdiction of the Acceptable Forums and waive any and all objections to jurisdiction or venue. Should any proceeding be initiated in any other state or forum, the parties waive any right to oppose any motion or application made by either party to transfer such proceeding to the Acceptable Forums. Additionally, Merchant and Guarantor hereby agree to waive any formal personal service of process and agree that any summons and/or complaint or other process to commence any litigation by GCF will be properly served if sent by certified mail, return receipt requested to the mailing address listed on page 1 of this Agreement.
4.6            Survival of Representation, etc. All representations, warranties and covenants herein shall survive the execution and delivery of this Agreement and shall continue in full force until all obligations under this Agreement shall have been satisfied in full and this Agreement shall have terminated.

4.7                Interpretation. All Parties hereto have reviewed this Agreement with attorney of their own choosing and have relied only on their own attorneys 'guidance and advice. No construction determinations shall be made against either Party hereto as drafter.

4.8            Severability. In case any of the provision in this Agreement is found to be invalid, illegal or unenforceable in any respect, the  validity, legality and enforceability of any other provision contained herein shall not in any way be affected or impaired.

4.9            Entire Agreement. Any provision hereof prohibited by law shall be ineffective only to the extent of such prohibition, without invalidating the remaining provisions hereof. This Agreement and the Security Agreement, Guaranty and Confession of Judgment hereto constitute and embody the entire agreement between Merchant and GCF and supersede all prior agreements and understandings relating to the subject matter hereof.

4.10          JURY TRIAL WAIVER. THE PARTIES HERETO WAIVE TRIAL BY JURY IN ANY COURT IN ANY SUIT, ACTION OR PROCEEDING ON ANY MATTER ARISINGIN CONNECTION WITH OR IN ANY WAY RELATED TO THE TRANSACTIONS ORTHE ENFORCEMENT HEREOF. THE PARTIES HERETO ACKNOWLEDGE THAT EACHMAKES THIS WAIVER KNOWINGLY, WILLINGLY AND VOLUNTARILY AND WITHOUTDURESS, AND ONLY AFTER EXTENSIVE CONSIDERATION OF THE RAMIFICATIONS OFTHIS WAIVER WITH THEIR ATTORNEYS.

4.11           CLASS ACTION WAIVER. THE PARTIES HERETO WAIVE ANY RIGHT TO ASSERT ANY CLAIMS AGAINST THE OTHER PARTY AS A REPRESENTATIVE OR MEMBER IN ANY CLASS OR REPRESENTATIVE ACTION, EXCEPT WHERE SUCH WAIVER IS PROHIBITED BY LAW AS AGAINST PUBLIC POLICY. TO THE EXTENT EITHER PARTY IS PERMITIED BY LAWOR COURT OF LAW TO PROCEED WITH A CLASS OR REPRESENTATIVE ACTION AGAINST THE OTHER, THE PARTIES HEREBY AGREE THAT: (1) THE PREVAILING PARTY SHALL NOT BE ENTITLED TO RECOVER ATTORNEYS 'FEES OR COSTS ASSOCIATED WITHPURSUING THE CLASS OR REPRESENTATIVE ACTION (NOTWITHSTANDING ANY OTHER PROVISION IN THIS AGREEMENT); AND (2) THE PARTY WHO INITIATES OR PARTICIPATES ASA MEMBER OF THE CLASS WILL NOT SUBMIT A CLAIM OR OTHERWISE PARTICIPATEIN ANY RECOVERY SECURED THROUGH THE CLASS OR REPRESENTATIVE ACTION.

4.12              Facsimile  Digital  Acceptance.   Facsimile  signatures  and Electronic Digital signatures hereon shall be deemed acceptable for all purposes.
 
4.13          Stacking Fee. $5,000.00 - When Merchant takes additional funding after getting funded by GCF while Merchant has a balance with GCF or any subsidiary or any other GCF associated entities. In the event GCF is stacked by another funder, GCF has the right to collect an additional daily payment per day.

 
4
Merchant Initial

SECURITY AGREEMENT AND GUARANTEE
 
Merchant's Legal Name: SANUWAVE, INC.
Address: 3360 MARTIN FARM RD #100
Federal Tax ID#: 20-3198616
DBA Name: SANUWAVE
City: SUWANEE

State: GA
Zip: 30024
       

SECURITY AGREEMENT
 
Security Interest. This Agreement will constitute a security agreement under the Uniform Commercial Code. Merchant grants to GCF a security interest in and lien upon: (a) all accounts, chattel paper, documents, equipment, general intangibles, instruments, and inventory, as those terms are defined in Article 9 of the Uniform Commercial Code (the "UCC"), now or hereafter owned or acquired by Merchant, (b) all proceeds, as that term is defined in Article 9 of the UCC (c) all funds at any time in the Merchant's Account, regardless of the source of such funds, (d) present and future Electronic Check Transactions, and (e) any amount which may be due to GCF under this Agreement, including but not limited to all rights to receive any payments or credits under this Agreement (collectively, the "Secured Assets"). Merchant agrees to provide other security to GCF upon request to secure Merchant's obligations under this Agreement. Merchant agrees that, if at any time there are insufficient funds in Merchant's Account to cover GCF entitlements under this Agreement, GCF is granted a further security interest in all of Merchant's assets of any kind whatsoever, and such assets shall then become Secured Assets. These security interests and liens will secure all of GCF entitlements under this Agreement and any other agreements now existing or later entered into between Merchant, GCF or an affiliate of GCF. GCF is authorized to file any and all notices or filings it deems necessary or appropriate to enforce its entitlements hereunder.
 
This security interest may be exercised by GCF without notice or demand of any kind by making an immediate withdrawal or freezing the Secured Assets. Pursuant to Article 9 of the Uniform Commercial Code, as amended from time to time, GCF has control over and may direct the disposition of the Secured Assets, without further consent of Merchant. Merchant hereby represents and warrants that no other person or entity has a security interest in the Secured Assets. With respect to such security interests and liens, GCF will have all rights afforded under the Uniform Commercial Code, any other applicable law and in equity. Merchant will obtain from GCF written consent prior to granting a security interest of any kind in the Secured Assets to a third party. Merchant agrees that this is a contract of recoupment and GCF is not required to file a motion for relief from a bankruptcy action automatic stay to realize on any of the Secured Assets. Nevertheless, Merchant agrees not to contest or object to any motion for relief from the automatic stay filed by GCF. Merchant agrees to execute and deliver to GCF such instruments and documents GCF may reasonably request to perfect and confirm the lien, security interest and right of setoff set forth in this Agreement. GCF is authorized to execute all such instruments and documents in Merchant's name.
 
Additional Collateral. To secure Guarantor's performance obligations to GCF under the Guaranty, the Guarantor hereby grants GCF a security interest in SANUWAVE SERVICES, LLC the   "Additional Collateral"). Guarantor understands that GCF will have a security interest in the aforesaid Additional Collateral upon execution of this Agreement. Merchant and Guarantor each acknowledge and agree that any security interest granted to GCF under any other agreement between Merchant or Guarantor and GCF (the "Cross-Collateral") will secure the obligations hereunder and under the Merchant Agreement.
 
Merchant and Guarantor each agrees to execute any documents or take any action in connection with this Agreement as GCF deems necessary to perfect or maintain GCF first priority security interest in the Collateral and the Additional Collateral, including the execution of any account control agreements. Merchant and Guarantor each hereby authorizes GCF to file any financing statements deemed necessary by GCF to perfect or maintain GCF security interest, which financing statement may contain notification that Merchant and/or Guarantor have granted a negative pledge to GCF with respect to the Collateral, and the Additional Collateral, and that any subsequent lien or may be tortuously interfering with GCF rights. Merchant and Guarantor shall be liable for, and GCF may charge and collect, all costs and expenses, including but not limited to attorney's fees, which may be incurred by GCF in protecting, preserving and enforcing GCF security interest and rights.
 
Negative Pledge. Merchant and Guarantor each agrees not to create, incur, assume, or permit to exist, directly or indirectly, any lien on or with respect to any of the Collateral or the Additional Collateral, as applicable.
 
Consent to Enter Premises and Assign Lease. GCF shall have the right to cure Merchant's default in the payment of rent on the following terms. In the event Merchant is served with papers in an action against Merchant for nonpayment of rent or for summary eviction, GCF may execute its rights and remedies under the Assignment of Lease. Merchant also agrees that GCF may enter into an agreement with Merchant's landlord giving GCF the right: (a) to enter Merchant's premises and to take possession of the fixtures and equipment therein for the purpose of protecting and preserving same; and/or (b) to assign Merchant's lease to another qualified business capable of operating a business comparable to Merchant's at such premises.
 
Remedies. Upon any Event of Default, GCF may pursue any remedy available at law (including those available under the provisions of the UCC), or in equity to collect, enforce, or satisfy any obligations then owing to GCF, whether by acceleration or otherwise.

VALIDITY GUARANTY
 
Validity Guaranty of Performance. The undersigned Guarantor(s) hereby guarantees to GCF, Merchant's good faith, truthfulness and performance of all of the representations, warranties, covenants made by Merchant in the Merchant Agreement in Sections thereof 2.3, 2.5, 2.6, 2.9, 2.10, 2.11, 2.12, 2.13 and 2.14, as each agreement may be renewed, amended, extended or otherwise modified (the "Guaranteed  Obligations"). Guarantor's obligations are due at the time of any breach by Merchant of any representation, warranty, or covenant made by Merchant in the Agreement.
 
Guarantor Waivers. In the event of a breach of the above, GCF may seek recovery from Guarantors for all of GCF losses and damages by enforcement of GCF rights under this Agreement without first seeking to obtain payment from Merchant, any other guarantor, or any Collateral or Additional Collateral GCF may hold pursuant to this Agreement or any other guaranty.
 

GCF does not  have to  notify Guarantor of any of the following events and Guarantor will not be released from its obligations under this Agreement if it is not notified of: (i) Merchant's failure to pay timely any amount owed under the Merchant Agreement; (ii) any adverse change in Merchant's financial condition or business; (iii) any sale or other disposition of any collateral securing the Guaranteed Obligations or any other guaranty of the Guaranteed Obligations; (iv) GCF acceptance of this Agreement; and (v) any renewal, extension or other modification of the Merchant Agreement or Merchant's other obligations to GCF. In addition, GCF may take any of the following actions without releasing Guarantor from any of its obligations under this Agreement: (i) renew, extend or otherwise modify the Merchant Agreement or Merchant's other obligations to GCF; (ii) release Merchant from its obligations to GCF; (iii) sell, release, impair, waive or otherwise fail to realize upon any collateral securing the Guaranteed Obligations or any other guaranty of the Guaranteed Obligations; and (iv) foreclose on any collateral securing the Guaranteed Obligations or any other guaranty of the Guaranteed Obligations in a manner that impairs or precludes the right of Guarantor to obtain reimbursement for payment under this Agreement. Until the Merchant Amount plus any accrued but unpaid interest and Merchant's other obligations to GCF under the Merchant Agreement and this Agreement are paid in full, Guarantor shall not seek reimbursement  from Merchant or any other guarantor for any amounts paid by it under this Agreement. Guarantor permanently waives and shall not  seek to exercise any of the following rights that it may have against Merchant, any other guarantor, or any collateral provided by Merchant or any other guarantor, for any amounts paid by it, or acts performed by it, under this Agreement: (i) subrogation; (ii) reimbursement; (iii) performance; (iv) indemnification; or (v) contribution. In the event that GCF must return any amount paid by Merchant or any other guarantor  of the Guaranteed Obligations because that person has become subject to a proceeding under the United States Bankruptcy Code or any similar law, Guarantor's obligations under this Agreement shall include that amount.
 
Guarantor Acknowledgement. Guarantor acknowledges that: (i) He/She understands the seriousness of the provisions of this Agreement; (ii) He/She has had a full opportunity to consult with counsel of his/her choice; and (iii) He/She has consulted with counsel of its choice or has decided not to avail himself/herself of that opportunity.
 
Joint and Several Liability. The obligations hereunder of the persons or entities constituting Guarantor under this Agreement are joint and several.
 
THE TERMS, DEFINITIONS, CONDITIONS AND INFORMATION SET FORTH IN THE "MERCHANT AGREEMENT", INCLUDING THE "TERMS AND CONDITIONS", ARE HEREBY INCORPORATED IN AND MADE A PART OF THIS SECURITY AGREEMENT AND GUARANTY. CAPITALIZED TERMS NOT DEFINED IN THIS SECURITY AGREEMENT AND GUARANTY, SHALL HAVE THE MEANING SET FORTH IN THE MERCHANT AGREEMENT, INCLUDING THE TERMS AND CONDITIONS.
 
MERCHANT
         
         
BY: KEVIN A RICHARDSON II
X
/s/ KEVIN A RICHARDSON II      
   
(SIGNATURE)
     
           
CEO #1: KEVIN A RICHARDSON II
X
/s/ KEVIN A RICHARDSON II  
9/27/2021
 
   
(SIGNATURE)
 
(DATE)
 
           
(SOCIAL SECURITY#)
         

 
(DRIVERS LICENSE)
     
           
CEO#2:
X

     

 
(SIGNATURE)
 
(DATE)
 
           
(SOCIAL SECURITY#)
         

 
(DRIVERS LICENSE)
     
 
ACKNOWLEDGMENT
 
I,     KEVIN A RICHARDSON II hereby acknowledge:
 
There has been no promise of additional capital in 30 days from funding by GCF Resources LLC or any ISO (broker)
 

o
Our policy is that merchants can seek additional capital from us when they have paid 50% of the Receipts Purchased Amount.
 
There has not been and will not be any contact from third party debt companies regarding this Future Receivables Agreement dated
 
September 27, 2021
 
I,the under signed, acknowledge that I am in agreement with these items, which are also described in detail within the pages of this

/s/ KEVIN A RICHARDSON II
  9/27/2021  
Signature
 
Date
 
        


Exhibit 10.4

NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY OTHER APPLICABLE SECURITIES LAWS AND MAY NOT BE SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED UNDER CIRCUMSTANCES THAT WOULD RESULT IN A VIOLATION OF SUCH LAWS. THIS NOTE IS SUBJECT TO FURTHER RESTRICTIONS ON TRANSFER AS SET FORTH IN THIS NOTE.
 
PROMISSORY NOTE

U.S. $150,000.00
Dated: October 27, 2021
 
FOR VALUE RECEIVED, the undersigned, SANUWAVE Health, Inc., a Nevada Corporation (the "Borrower"), HEREBY UNCONDITIONALLY PROMISES TO PAY to the order of A. Michael Stolarski (the "Lender"), the principal sum of ONE HUNDRED FIFTY THOUSAND UNITED STATES DOLLARS (U.S. $150,000.00) on June 30, 2022.
 
This Note is expressly subordinate and junior in right of payment and collection to the secured promissory notes issued pursuant to that certain Note and Warrant Purchase and Security Agreement (the "NWPSA") dated as of August 6, 2020 by and among NH Expansion Credit Fund Holdings, LP, the Borrower and the other parties thereto, as more particularly described in, and subject to the te1ms and conditions of, that certain Subordination Agreement dated as of the date hereof, by and between Agent and the Holder. The Borrower has provided a true and complete copy of the NWPSA to the Lender on the date hereof.
 
Section 1.        Definitions. The following terms when used herein shall have the following meanings:
 
"Default" means any Event of Default (as defined in Section 6) or any event or condition that constitutes or, with notice or lapse of time or both would constitute, an Event of Default.
 
"GAAP" means generally accepted accounting principles in the United States as in effect from time to time.
 
"Guarantor" means any guarantor hereof.
 
"Guaranty" means any guaranty hereof provided by a Guarantor.
 
"Indebtedness" means any indebtedness or obligation for borrowed money, the deferred purchase price of property or leases which would be capitalized in accordance with GAAP, any reimbursement and other obligations in respect of letters of credit and surety or performance bonds, and all net obligations in respect of derivative products; and any liability as a surety, guarantor, accommodation party or otherwise for or upon the indebtedness or obligation of any other Person of the nature described above.
 
"Lien" means any mortgage, deed of trust, pledge, security interest, assignment, deposit arrangement, charge or encumbrance, lien (statutory or other), or other preferential arrangement (including, without limitation, any conditional sale or other title retention agreement, any financing lease having substantially the same economic effect as any of the foregoing or any agreement to give any security interest).
 
"Loan Document" means this Note, each Guaranty and each document executed by Borrower or any Guarantor and delivered to Lender in connection with or pursuant to any of the foregoing.
 
"Material Adverse Effect" on any Person means a material adverse effect on the operations, properties, business or condition (financial or otherwise) of such Person.


"Person" means an individual, corporation, partnership, limited liability company, joint trust, unincorporated organization or any other entity of whatever nature, including any governmental agency or authority.
 
"Subsidiary" means any corporation, association, partnership, limited liability company, joint venture or other business entity of which more than 50% of the voting stock or other equity interest is owned directly or indirectly by any Person or one or more of the other Subsidiaries of such Person or a combination thereof. Unless otherwise defined or the context otherwise  requires, all  accounting  terms used herein shall be construed, and all accounting detern1inations and computations required hereunder shall be made, in accordance with GAAP, consistently applied.
 
Section 2.        Payments. (a) Interest. (i) The Borrower further promises to pay interest on the outstanding principal amount of this Promissory Note (this "Note") from the date hereof until maturity, in arrears, at maturity, at the rate of 15% (Fifteen percent) per annum.
 
(ii)          In the event that any amount of principal or interest, or any other amount payable hereunder, is not paid in full when due (whether at stated maturity, by acceleration or otherwise), the Borrower shall pay interest on such unpaid principal, interest or other amount, from the date such amount becomes due until the date such amount is paid in full, payable on demand, at a rate per annum which is 3% higher than the rate of interest set forth above; provided that payment of any such interest at such rate shall not constitute a waiver of any Event of Default and shall be without prejudice to the right of the Lender to exercise any of its rights and remedies hereunder. All computations  of  interest  shall be made on the basis of a year of 360 days for the actual number of days (including the first day but excluding the last day) occurring in the period for which such interest is payable.
 
(b)          Prepayment. (i) The Borrower may, at any time and from time to time, prepay the outstanding amount hereof in whole or in part, without premium or penalty.
 
(ii)          Together with any prepayment hereunder, the Borrower shall pay accrued interest to the date of such prepayment on the principal amount prepaid.

(c)          The Borrower agrees to make all payments under this Note without setoff or deduction and regardless of any counterclaim or defense.
 
(d)          In no event shall the Borrower be obligated to pay the Lender interest, charges or fees at a rate in excess of the highest rate permitted by applicable law.
 
Section 3.        Representations and Warranties. The Borrower represents and warrants to the Lender that:

(a)          The Borrower is duly organized or formed, as the  case may  be, validly  existing  and  in good standing  under the  laws of the jurisdiction  of its incorporation  or formation,  and  has all requisite power and authority to execute, deliver and perform its obligations under this Note and the other Loan Documents to which  it is a party.   Each of the Borrower  and  its Subsidiaries  is qualified  to do business and is in good standing in each jurisdiction in which the failure so to qualify or be in good standing would cause a  Material  Adverse  Effect on the Borrower and  its Subsidiaries  taken  as a whole, and  has all requisite power and authority to own its assets and carry on its business.
 
(b)          The execution, delive1y and performance by the Borrower of this Note have been duly authorized by all necessary action of the Borrower and do not and will not (i) contravene the terms of the articles or ce1iificate of incorporation, or bylaws, or other applicable organizational documents, of the Borrower, or result in a breach of or constitute a default under any material lease, instrument, contract or other agreement to which the Borrower is a party or by which it or its properties may be bound or affected; or (ii) violate any provision of any law, rule, regulation, order, judgment, decree or the like binding on or affecting the Borrower.
 
2

(c)          This Note constitutes the legal, valid and binding obligation of the Borrower, enforceable against the Borrower in accordance with its terms.

Section 4.        Affirmative Covenants. So long as any amount payable by the Borrower hereunder shall remain unpaid, the Borrower shall cause each of its Subsidiaries to take any action reasonably requested by the Lender to carry out the purpose and intent of this Note and the other Loan Documents.
 
Section 5.        Events of Default. Any of the following events which shall occur shall constitute an "Event of Default":
 
(a)          The Borrower shall fail to pay when due any amount of principal or interest hereunder or other amount payable hereunder, and, in the case of any non-payment of any amount other than principal, the continuation of such failure for five days.
 
(b)          The Borrower shall fail to perform or observe any term, covenant or agreement contained in Section 4.

(c)          The Borrower shall fail to perform or observe any other obligation of Borrower contained in any Loan Document and any such failure shall remain unremedied for a period of 15 days from the occurrence thereof (unless the Lender determines that such failure is not capable of remedy).
 
(d)          (i) The Borrower, any Guarantor or any of their respective Subsidiaries shall admit in writing its inability to, or shall fail generally or be generally unable to, pay its debts (including its payrolls) as such debts become due, or shall make a general assignment for the benefit of creditors, (ii) the Borrower, any Guarantor or any such Subsidiary shall file a voluntary petition in bankruptcy or a petition or answer seeking reorganization, to effect a plan or other arrangement with creditors or any other relief under the Bankruptcy Reform Act of 1978, as amended or recodified from time to time (the "Bankruptcy Code") or under any other state or federal law relating to bankruptcy or reorganization granting relief to debtors, whether now or hereafter in effect, or shall file an answer admitting the jurisdiction of the court and the material allegations of any involuntary petition filed against the Borrower, any Guarantor or any such Subsidiary pursuant to the Bankruptcy Code or any such other state or federal law, (iii) the Borrower, any Guarantor or any such Subsidiary shall be adjudicated a bankrupt, or shall make an assignment for the benefit of creditors, or shall apply for or consent to the appointment of any custodian, receiver or trustee for all or any substantial part of the Borrower's, any Guarantor's or any such Subsidiary's property, or shall take any action to authorize any of the actions or events set forth above in this Section 5(d), (iv) an involuntary petition seeking  any of the relief specified  in this Section 5(d) shall be filed against the BoITower, any Guarantor or any such Subsidia1y and shall not be dismissed within 30 days, or (v) any order for relief shall be entered against the Bo1rnwer, any Guarantor or any such Subsidiary in any involuntary proceeding under the Bankruptcy Code or any such other state or federal law referred to in this Section 5(d).
 
(e)          The Borrower, any Guarantor or any of their respective Subsidiaries shall (i) liquidate, wind up or dissolve (or suffer any liquidation, wind-up or dissolution), except to the extent expressly permitted by this Note, (ii) suspend its operations other than in the ordinary course of business, or (iii) take any action to authorize any of the foregoing actions or events.

3

Section 6.        Remedies. If any Event of Default shall occur and be continuing, the Lender may (i) by notice to the Borrower, declare the entire unpaid principal amount of this Note, all interest accrued and unpaid hereon and all other amounts payable hereunder to be forthwith due and payable, whereupon all unpaid principal under this Note, all such accrued interest and all such other amounts shall become and be forthwith due and payable, without presentment, demand, protest or further notice of any kind, all of which are hereby expressly waived by the Borrower, provided that upon the occurrence of an actual or deemed entry of an order for relief with respect to the Borrower under the Bankruptcy Code, the result which would otherwise occur only upon giving of notice by the Lender to the Borrower as specified above shall occur automatically, without the giving of any such notice; and (ii) whether or not the actions referred to in clause (i) have been taken, exercise any or all of the Lender's rights and remedies under the Loan Documents, and proceed to enforce all other rights and remedies available to the Lender under applicable law.
 
Section 7.        Miscellaneous. (a) No amendment or waiver of any provision of this Note or any other Loan Document, nor any consent to any departure by the Borrower therefrom, shall in any event be effective unless the same shall be in writing and signed by the Lender and then such amendment, waiver or consent shall be effective only in the specific instance and for the specific purpose for which given.
 
(b)          All notices and other communications provided for under any Loan Document shall, unless otherwise stated herein, be in writing (including by facsimile) and mailed (by certified or registered mail), sent or delivered to the respective parties hereto at or to the following addresses or facsimile numbers (or at or to such other address or facsimile number as shall be designated by Borrower or Lender to such other party):
 
 
If to the Lender:
[_______________]
 
    [_______________]  
    [_______________]  
    [_______________]  
   
 
 
If to the Borrower:
[_______________]  
 

[_______________]  
    [_______________]  
    [_______________]  

All such notices and communications shall be effective (i) if delivered by hand, sent by ce1tified or registered mail or sent by an overnight courier service, when received; and (ii) if sent by facsimile transmission, when sent.
 
(c)          This Note and the other Loan Documents reflect the entire agreement between Borrower and Lender with respect to the matters set forth therein and supersede any prior agreements, commitments, drafts, communication, discussions and understandings, oral or written, with respect thereto.
 
(d)          No failure on the part of the Lender to exercise, and no delay in exercising, any right, remedy, power or privilege under any Loan Document shall operate as a waiver thereof, nor shall any single or partial exercise of any such right, remedy, power or privilege preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege. The rights and remedies under this Note and the other Loan Documents are cumulative and not exclusive of any rights, remedies, powers and privileges that may otherwise be available to the Lender.

4

(e)          Time is of the essence for the performance of each and every obligation Under this Note and the other Loan Documents.
 
(f)          Whenever possible, each provision of this Note and the other Loan Documents shall be interpreted in such manner as to be effective and valid under all applicable laws and regulations. If, however, any provision of this Note or any other Loan Document shall be prohibited by or invalid under any such law or regulation in any jurisdiction, it shall, as to such jurisdiction, be deemed modified to conform to the minimum requirements of such law or regulation, or, if for any reason it is not deemed so modified, it shall be ineffective and invalid only to the extent of such prohibition or invalidity without affecting the remaining provisions of this Note, or the validity or effectiveness of such provision in any other jurisdiction.
 
(g)          This Note and each other Loan Document shall be binding upon, inure to the benefit of and be enforceable by the Borrower, the Lender and their respective successors and assigns.
 
(h)          The Borrower will maintain a register in which it will record the initial ownership of this Note and any changes in ownership of this Note which occur as permitted by and in compliance with the terms hereof.
 
(i)          The Borrower shall not have the right to assign its rights and obligations hereunder or any interest herein or therein without the prior written consent of the Lender. The Lender may sell, assign, transfer or grant participations in all or any portion of the Lender's rights and obligations hereunder. In the event of any such assignment, upon notice thereof to the Borrower, the assignee shall be deemed the "Lender" for all purposes of this Note and any other documents and instruments relating hereto with respect to the rights and obligations assigned to it. The Borrower agrees that in connection with any such grant or assignment, the Lender may deliver to the prospective participant or assignee financial statements and other relevant information relating to the Borrower and its Subsidiaries.
 
(i)           (i) THIS NOTE AND EACH OF THE OTHER LOAN DOCUMENTS SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF DELAWARE, WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAWS. (ii) THE BORROWER AND, BY ITS ACCEPTANCE HEREOF, THE LENDER, HEREBY WAIVE THEIR RESPECTIVE RIGHTS TO A TRIAL BY JURY OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF OR RELATED TO THIS NOTE OR ANY OTHER LOAN DOCUMENT.
 
(k)          The Borrower hereby (i) submits to the non-exclusive jurisdiction of the courts of the State of Delaware and the Federal courts of the United States sitting in the State of Delaware for the purpose of any action or proceeding arising out of or relating to this Note and any other Loan Document, (ii) agrees that all claims in respect of any such action or proceeding may be heard and determined in such courts, (iii) irrevocably waives (to the extent permitted by applicable law) any objection which it now or hereafter may have to the laying of venue of any such action or proceeding brought in any of the foregoing courts, and any objection on the ground that any such action or proceeding in any such court has been brought in an inconvenient forum and (iv) agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner permitted by law. Nothing herein shall limit the right of the Lender to bring any action or proceeding against the Borrower or its property in the courts of other jurisdictions.
 
5

IN WITNESS WHEREOF, the Borrower has duly executed this Note, as of the date first above written.

 
SANUWAVE HEALTH, INC.
 
 
 
 
By /s/ Kevin Richardson
 
 
Name:
Kevin Richardson
 
 
Title: CEO


6


Exhibit 10.5
 
THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY OTHER APPLICABLE SECURITIES LAWS AND MAY NOT BE SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED UNDER CIRCUMSTANCES THAT WOULD RESULT IN A VIOLATION OF SUCH LAWS. THIS NOTE IS SUBJECT TO FURTHER RESTRICTIONS ON TRANSFER AS SET FORTH IN THIS NOTE.
 
PROMISSORY NOTE
 
U.S. $25,000.00
Dated: October 27, 2021
 
FOR VALUE RECEIVED, the undersigned, SANUWAVE Health, Inc., a Nevada Corporation (the "Borrower"), HEREBY UNCONDITIONALLY PROMISES TO PAY to the order of NightWatch Capital Advisors, LLC, a Delaware Corporation (the "Lender"), the principal sum of TWENTY-FIVE THOUSAND UNITED STATES DOLLARS (U.S. $25,000.00) on June 30, 2022.
 
This Note is expressly subordinate and junior in right of payment and collection to the secured promissory notes issued pursuant to that certain Note and Warrant Purchase and Security Agreement (the "NWPSA") dated as of August 6, 2020 by and among NH Expansion Credit Fund Holdings, LP, the Borrower and the other parties thereto, as more particularly described in, and subject to the terms and conditions of, that ce1iain Subordination Agreement dated as of the date hereof, by and between Agent and the Holder. The Borrower has provided a true and complete copy of the NWPSA to the Lender on the date hereof.
 
Section 1.          Definitions. The following terms when used herein shall have the following meanings:
 
"Default" means any Event of Default (as defined in Section 6) or any event or condition that constitutes or, with notice or lapse of time or both would constitute, an Event of Default.
 
"GAAP" means generally accepted accounting principles in the United States as in effect from time to time.
 
"Guarantor" means any guarantor hereof.
 
"Guaranty" means any guaranty hereof provided by a Guarantor.
 
"Indebtedness" means any indebtedness or obligation for borrowed money, the deferred purchase price of prope1iy or leases which would be capitalized in accordance with GAAP, any reimbursement and other obligations in respect of letters of credit and surety or performance bonds, and all net obligations in respect of derivative products; and any liability as a surety, guarantor, accommodation party or otherwise for or upon the indebtedness or obligation of any other Person of the nature described above.
 
"Lien" means any mo1igage, deed of trust, pledge, security interest, assignment, deposit arrangement, charge or encumbrance, lien (statutory or other), or other preferential arrangement (including, without limitation, any conditional sale or other title retention agreement, any financing lease having substantially the same economic effect as any of the foregoing or any agreement to give any security interest).
 
"Loan Document" means this Note, each Guaranty and each document executed by Borrower or any Guarantor and delivered to Lender in connection with or pursuant to any of the foregoing.
 
"Material Adverse Effect" on any Person means a material adverse effect on the operations, properties, business or condition (financial or otherwise) of such Person.


"Person" means an individual, corporation, partnership, limited liability company, joint trust, unincorporated organization or any other entity of whatever nature, including any governmental agency or authority.
 
"Subsidiary" means any corporation, association, partnership, limited liability company, joint venture or other business entity of which more than 50% of the voting stock or other equity interest is owned directly or indirectly by any Person or one or more of the other Subsidiaries of such Person or a combination thereof. Unless otherwise defined or the context otherwise requires, all accounting terms used herein shall be construed, and all accounting determinations and computations required hereunder shall be made, in accordance with GAAP, consistently applied.
 
Section 2.         Payments. (a) Interest. (i) The Borrower further promises to pay interest on the outstanding principal amount of this Promissory Note (this "Note") from the date hereof until maturity, in arrears, at maturity, at the rate of 15% (Fifteen percent) per annum.
 
(ii)          In the event that any amount of principal or interest, or any other amount payable hereunder, is not paid in full when due (whether at stated maturity, by acceleration or otherwise), the Borrower shall pay interest on such unpaid principal, interest or other amount, from the date such amount becomes due until the date such amount is paid in full, payable on demand, at a rate per annum which is 3% higher than the rate of interest set f01ih above; provided that payment of any such interest at such rate shall not constitute a waiver of any Event of Default and shall be without prejudice to the right of the Lender to exercise any of its rights and remedies hereunder. All computations  of  interest  shall be made on the basis of a year of 360 days for the actual number of days (including the first day but excluding the last day) occurring in the period for which such interest is payable.
 
(b)          Prepayment. (i) The Borrower may, at any time and from time to time, prepay the outstanding amount hereof in whole or in party, without premium or penalty.
 
(ii)          Together with any prepayment hereunder, the Borrower shall pay accrued interest to the date of such prepayment on the principal amount prepaid.

(c)          The Borrower agrees to make all payments under this Note without setoff or deduction and regardless of any counterclaim or defense.
 
(d)          In no event shall the Borrower be obligated to pay the Lender interest, charges or fees at a rate in excess of the highest rate permitted by applicable law.
 
Section 3.        Representations and Warranties. The Borrower represents and warrants to the Lender that:

(a)          The Borrower  is duly organized  or formed, as the case may  be, validly existing  and  in good  standing  under the  laws of the jurisdiction  of its incorporation  or formation, and  has all requisite power and authority to execute, deliver and perform its obligations under this Note and the other Loan Documents  to which  it is a party.   Each  of the Borrower  and its Subsidiaries  is qualified  to do  business and is in good standing in each jurisdiction in which the failure so to qualify or be in good standing would cause  a Material  Adverse Effect on the Borrower  and  its Subsidiaries taken  as a whole,  and  has all requisite power and authority to own its assets and carry on its business.
 
(b)          The execution, delive1y and performance by the Borrower of this Note have been duly authorized by all necessary action of the Borrower and do not and will not (i) contravene the terms of the articles or ce1iificate of incorporation, or bylaws, or other applicable organizational documents, of the Borrower, or result in a breach of or constitute a default under any material lease, instrument, contract or other agreement to which Borrower is a party or by which it or its properties may be bound or affected; or (ii) violate any provision of any law, rule, regulation, order, judgment, decree or the like binding on or affecting the Borrower.
 
2

(c)          This Note constitutes the legal, valid and binding obligation of the Borrower, enforceable against the Borrower in accordance with its terms.
 
Section 4.         Affirmative Covenants. So long as any amount payable by the Borrower hereunder shall remain unpaid, the Borrower shall cause each of its Subsidiaries to take any action reasonably requested by the Lender to carry out the purpose and intent of this Note and the other Loan Documents.

Section 5.         Events of Default. Any of the following events which shall occur shall constitute an "Event of Default":
 
(a)          The Borrower shall fail to pay when due any amount of principal or interest hereunder or other amount payable hereunder, and, in the case of any non-payment of any amount other than principal, the continuation of such failure for five days.
 
(b)          The Borrower shall fail to perform or observe any term, covenant or agreement contained in Section 4.
 
(c)          The Borrower shall fail to perform or observe any other obligation of Borrower contained in any Loan Document and any such failure shall remain unremedied for a period of 15 days from the occmTence thereof (unless the Lender determines that such failure is not capable of remedy).
 
(d)          (i) The Borrower, any Guarantor or any of their respective Subsidiaries shall admit in writing its inability to, or shall fail generally or be generally unable to, pay its debts (including its payrolls) as such debts become due, or shall make a general assignment for the benefit of creditors, (ii) the Borrower, any Guarantor or any such Subsidia1y shall file a voluntary petition in bankruptcy or a petition or answer seeking reorganization, to effect a plan or other arrangement with creditors or any other relief under the Bankruptcy Reform Act of 1978, as amended or recodified from time to time (the "Bankruptcy Code") or under any other state or federal law relating to bankruptcy or reorganization granting relief to debtors, whether now or hereafter in effect, or shall file an answer admitting the jurisdiction of the court and the material allegations of any involuntary petition filed against the Borrower, any Guarantor or any such Subsidiary pursuant to the Bankruptcy Code or any such other state or federal law, (iii) the Borrower, any Guarantor or any such Subsidiary shall be adjudicated a bankrupt, or shall make an assignment for the benefit of creditors, or shall apply for or consent to the appointment of any custodian, receiver or trustee for all or any substantial part of the Borrower's, any Guarantor's or any such Subsidia1y's prope1iy, or shall take any action to authorize any of the actions or events set forth above in this Section S(d), (iv) an involuntary petition seeking any of the relief specified in this Section S(d) shall be filed against the Borrower, any Guarantor or any such Subsidiary and shall not be dismissed within 30 days, or (v) any order for relief shall be entered against the Borrower, any Guarantor or any such Subsidiary in any involuntary proceeding under the Bankruptcy Code or any such other state or federal law referred to in this Section S(d).
 
(e)          The Borrower, any Guarantor or any of their respective Subsidiaries shall (i) liquidate, wind up or dissolve (or suffer any liquidation, wind-up or dissolution), except to the extent expressly permitted by this Note, (ii) suspend its operations other than in the ordinary course of business, or (iii) take any action to authorize any of the foregoing actions or events.

3

Section 6.  Remedies        If any Event of Default shall occur and be continuing, the Lender may notice to the Borrower, declare the entire unpaid principal amount of this Note, all interest accrued and unpaid hereon and all other amounts payable hereunder to be forthwith due and payable, whereupon all unpaid principal under this Note, all such accrued interest and all such other amounts shall become and be forthwith due and payable, without presentment, demand, protest or further notice of any kind, all of which are hereby expressly waived by the Borrower, provided that upon the occurrence of an actual or deemed entry of an order for relief with respect to the Borrower under the Bankruptcy Code, the result which would otherwise occur only upon giving of notice by the Lender to the Borrower as specified above shall occur automatically, without the giving of any such notice; and (ii) whether or not the actions referred to in clause (i) have been taken, exercise any or all of the Lender's rights and remedies under the Loan Documents, and proceed to enforce all other rights and remedies available to the Lender under applicable law.

Section 7.         Miscellaneous. (a) No amendment or waiver of any provision of this Note or any other Loan Document, nor any consent to any departure by the Borrower therefrom, shall in any event be effective unless the same shall be in writing and signed by the Lender and then such amendment, waiver or consent shall be effective only in the specific instance and for the specific purpose for which given.
 
(b)          All notices and other communications provided for under any Loan Document shall, unless otherwise stated herein, be in writing (including by facsimile) and mailed (by ce1iified or registered mail), sent or delivered to the respective parties hereto at or to the following addresses or facsimile numbers (or at or to such other address or facsimile number as shall be designated by Borrower or Lender to such other party):

 
If to the Lender:
[_______________]
 
    [_______________]  
    [_______________]  
    [_______________]  
   
 
 
If to the Borrower:
[_______________]  
 

[_______________]  
    [_______________]  
    [_______________]  
 
All such notices and communications shall be effective (i) if delivered by hand, sent by ce1iified or registered mail or sent by an overnight courier service, when received; and (ii) if sent by facsimile transmission, when sent.
 
(c)          This Note and the other Loan Documents reflect the entire agreement between Borrower and Lender with respect to the matters set forth therein and supersede any prior agreements, commitments, drafts, communication, discussions and understandings, oral or written, with respect thereto.
 
(d)          No failure on the pa1i of the Lender to exercise, and no delay in exercising, any right, remedy, power or privilege under any Loan Document shall operate as a waiver thereof, nor shall any single or partial exercise of any such right, remedy, power or privilege preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege. The rights and remedies under this Note and the other Loan Documents are cumulative and not exclusive of any rights, remedies, powers and privileges that may otherwise be available to the Lender.

4

(e)          Time is of the essence for the performance of each and every obligation under this Note and the other Loan Documents.
 
(f)          Whenever possible, each provision of this Note and the other Loan Documents shall be interpreted in such manner as to be effective and valid under all applicable laws and regulations. however, any provision of this Note or any other Loan Document shall be prohibited by or invalid under any such law or regulation in any jurisdiction, it shall, as to such jurisdiction, be deemed modified to conform to the minimum requirements of such law or regulation, or, if for any reason it is not deemed so modified, it shall be ineffective and invalid only to the extent of such prohibition or invalidity without affecting the remaining provisions of this Note, or the validity or effectiveness of such provision in any other jurisdiction.
 
(g)          This Note and each other Loan Document shall be binding upon, inure to the benefit of and be enforceable by the Borrower, the Lender and their respective successors and assigns.
 
(h)          The Borrower will maintain a register in which it will record the initial ownership of this Note and any changes in ownership of this Note which occur as permitted by and in compliance with the terms hereof.
 
(i)          The Borrower shall not have the right to assign its rights and obligations hereunder or any interest herein or therein without the prior written consent of the Lender. The Lender may sell, assign, transfer or grant participations in all or any portion of the Lender's rights and obligations hereunder. In the event of any such assignment, upon notice thereof to the Borrower, the assignee shall be deemed the "Lender" for all purposes of this Note and any other documents and instruments relating hereto with respect to the rights and obligations assigned to it. The Borrower agrees that in connection with any such grant or assignment, the Lender may deliver to the prospective participant or assignee financial statements and other relevant information relating to the Borrower and its Subsidiaries.
 
(i)          (i) THIS NOTE AND EACH OF THE OTHER LOAN DOCUMENTS SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF DELAWARE, WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAWS. (ii) THE BORROWER AND, BY ITS ACCEPTANCE HEREOF, THE LENDER, HEREBY WAIVE THEIR RESPECTIVE RIGHTS TO A TRIAL BY JURY OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF OR RELATED TO THIS NOTE OR ANY OTHER LOAN DOCUMENT.
 
(k)          The Borrower hereby (i) submits to the non-exclusive jurisdiction of the courts of the State of Delaware and the Federal courts of the United States sitting in the State of Delaware for the purpose of any action or proceeding arising out of or relating to this Note and any other Loan Document, (ii) agrees that all claims in respect of any such action or proceeding may be heard and determined in such courts, (iii) irrevocably waives (to the extent permitted by applicable law) any objection which it now or hereafter may have to the laying of venue of any such action or proceeding brought in any of the foregoing courts, and any objection on the ground that any such action or proceeding in any such court has been brought in an inconvenient forum and (iv) agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner permitted by law. Nothing herein shall limit the right of the Lender to bring any action or proceeding against the Borrower or its property in the courts of other jurisdictions.

5

IN WITNESS WHEREOF, the Borrower has duly executed this Note, as of the date first above written.

 
SANUWAVE HEALTH, INC.
 
 
 
 
By /s/ Kevin Richardson
 
 
Name:
Kevin Richardson
 
 
Title: CEO


6


Exhibit 10.6

Leviston Resources LLC
78 SW 7th
Miami, Florida 33130

Sanuwave Health Inc.
May14, 2021
3360 Martin Farm Road

Suite 100

Suwanee, GA 30024

Attention: Kevin A. Richardson II


  Re:
Securities Purchase Agreement/Future Advance Convertible Promissory Note

Mr. Richardson:

We refer to that certain Securities Purchase Agreement, dated as of April 20, 2021 (as amended by this letter agreement and as may be further amended or restated from time to time, the "SPA"), made by and among (i) Sanuwave Health, Inc., a corporation incorporated under the laws of the State of Nevada (the "Company"), and (ii) Leviston Resources, LLC, a limited liability company organized and existing under the laws of the State of Delaware, as the sole initial purchaser thereunder (the "Purchaser"), pursuant to which the Purchaser agreed to purchase that certain Future Advance Convertible Promissory Note from the Company, in an aggregate principal amount of up to Three Million Four Hundred Two Thousand and no/100 United States Dollars (US$3,402,000.00) dated as of April 20, 2021 (as amended by this letter agreement and as may be further amended or restated from time to time, the "Note"), and in connection with which the Company and the Purchaser entered into that certain Registration Rights Agreement, dated as of April 20, 2021 (the "Registration Rights Agreement"). All capitalized terms used in this letter agreement shall have the same meaning ascribed to them in the SPA, except as otherwise specifically set forth herein.

The Company has requested and, for good and valuable consideration, the receipt of which is hereby acknowledged, the Purchaser has agreed to fund an additional disbursement under the SPA and Note of Seven Hundred Fifty Thousand and no/100 United States Dollars (US$750,000.00) (the "Second Disbursement"). In connection with the funding of the Second Disbursement the Company has agreed to amend the Note in certain respects.

The Company and the Purchaser hereby acknowledge, represent and warrant that, following the execution hereof and the funding of the Second Disbursement, the total outstanding amount due to the Purchaser pursuant to the Note and SPA shall be One Million Six Hundred Thirty-Three Thousand One Hundred Fifty-Two and no/100 United States Dollars (US$1,633,152).

The parties hereby agree to the following amendments to the Note and the SPA and the Transaction Documents:


a.
The Note, the SPA and each of the Transaction Documents  are hereby amended by removing each reference to  "$3,402,000" therein and replacing the same with "$4,217,217".



b.
Section 3(c)(iii) of the Note is hereby amended by deleting the first sentence thereof in its entirety and replacing it with the following:

Subject to the Holder's approval in its sole discretion, upon thirty (30) days' notice to the Holder, the Note may be redeemed by the Company at any time at an amount equal to one hundred and twenty-five percent (125%) of the outstanding Principal and accrued and unpaid Interest (the "Optional Redemption Price").


c.
Article 4 of the SPA is hereby amended by adding at the end thereof the following new Section 4.25:

4.25 Right of First Refusal. At any time the Note is outstanding, neither the Company nor any Subsidiary shall incur Indebtedness related to (i) the factoring of, or obtaining of financing through the sale of, accounts receivable or invoices, (ii) the financing of purchase orders, or (iii) the purchase of inventory or equipment unless the Company shall have provided the Holder with a right of first refusal to provide such factoring or financing on terms that are reasonably comparable to terms that are otherwise available to the Company or its Subsidiary.

As a condition precedent to the effectiveness of this letter agreement, the Company agrees: (i) to deliver a copy of resolutions of the Board of the Company authorizing the execution of this letter agreement, (ii) a signed and executed copy of the Security Agreement, and (iii) to pay to the Purchaser's counsel, as a legal fee in consideration for the preparation of this letter agreement and all transaction documents reviewed in connection herewith, immediately upon the execution hereof, Ten Thousand United States Dollars (US$10,000).

Other than as disclosed to the Purchaser in writing, the Company hereby confirms and affirms that all representations and warranties made by each of them under the SPA, the Note and the Registration Rights Agreement are true, correct and complete as of the date hereof, and hereby confirms and affirms that all such representations and warranties remain true, correct and complete as of the date hereof, and by this reference, the Company does hereby re-make each and every one of such representations and warranties herein as of the date hereof, as if each and every one of such representations and warranties was set forth and re-made in its entirety in this letter agreement by the Company.

The Company hereby affirms its respective obligations to the Purchaser under the SPA, the Note and the Registration Rights Agreement and agrees and affirms as follows: (i) other than as disclosed to the Purchaser in writing, that as of the date hereof, the Company has performed, satisfied and complied in all material respects with all the covenants, agreements and conditions under the SPA, the Note and the Registration Rights Agreement to be performed, satisfied or complied with by the Company; (ii) that the Company shall continue to perform each and every covenant, agreement and condition set forth in the SPA, the Note and the Registration Rights Agreement, and continue to be bound by each and all of the terms and provisions thereof and hereof; (iii) other than as disclosed to the Purchaser in writing, that as of the date hereof, no default or Event of Default has occurred or is continuing under the SPA, the Note and the Registration Rights Agreement, and no event has occurred that, with the passage of time, the giving of notice, or both, would constitute a default or an Event of Default under the SPA, the Note and the Registration Rights Agreement; and (iv) other than as disclosed to the Purchaser in writing, that as of the date hereof, no event, fact, or other set of circumstances has occurred which could reasonably be expected to have a Material Adverse Effect.

2

As of the date hereof, the Company hereby acknowledges and admits that: (i) the Purchaser has acted in good faith and has fulfilled and fully performed all of its obligations under or in connection with the SPA, the Note and the Registration Rights Agreement; and (ii) that there are no other promises, obligations, understandings or agreements with respect to the SPA, the Note and the Registration Rights Agreement, except as expressly set forth herein.

This letter agreement and the SPA, the Note and the Registration Rights Agreement and the documents executed in connection therewith, contain the entire understanding between and among the parties and supersedes any prior understandings and agreements among them respecting the subject matter of this letter agreement. This letter agreement shall be governed by and construed in accordance with the laws of the State of New York without regard to choice of law principles. Any dispute arising under or relating to or in connection with this letter agreement shall be subject to the exclusive jurisdiction and venue of the State courts located in the City of New York. This letter agreement may be executed in any number of counterparts, each of which shall be an original but all of which together shall constitute one and the same instrument. The parties hereby consent and agree that if this letter agreement shall at any time be deemed by the parties for any reason insufficient, in whole or in part, to carry out the true intent and spirit hereof or thereof, the parties will execute or cause to be executed such other and further assurances and documents as in the reasonable opinion of the parties may be reasonably required in order more effectively to accomplish the purposes of this letter agreement. In case any provision of this letter agreement shall be held to be invalid, illegal or unenforceable, such provision shall be severable from the rest of this letter agreement, and the validity legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.

Please indicate your agreement with and acceptance of the terms of this letter agreement by signing in the space provided and returning this letter agreement to our attention at the address above.

[ - signature page follows - ]

3


Very truly yours,



LEVISTON RESOURCES LLC



By:
/s/ R. Rogol  

Name:
R. Rogol

Title:
CFO

ACCEPTED AND AGREED:



SANUWAVE HEALTH, INC.



By:
/s/ Kevin A. Richardson II


Name:
Kevin A. Richardson II

Title:
Chief Executive Officer



4

EXHIBIT 31.1

Certification of Principal Executive Officer
Pursuant to Rule 13a-14(a) or Rule 15d-14(a)
Under the Securities Exchange Act of 1934

I, Kevin A Richardson II, certify that:
 
1.
I have reviewed this quarterly report on Form 10-Q of SANUWAVE Health, Inc.;
 
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
 
a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
  b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

  c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
  d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 

a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 

b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date:  December 13, 2021
   
/s/ Kevin A. Richardson II
 
Kevin A. Richardson II
 
Chief Executive Officer
 
(principal executive officer)




EXHIBIT 31.2

Certification of Chief Financial Officer
Pursuant to Rule 13a-14(a) or Rule 15d-14(a)
Under the Securities Exchange Act of 1934

I, Lisa E. Sundstrom, certify that:
 
1.
I have reviewed this quarterly report on Form 10-Q of SANUWAVE Health, Inc.;
 
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 

a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 

b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 

d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 

a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 

b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Date:  December 13, 2021
   
/s/Lisa E. Sundstrom
 
Lisa E. Sundstrom
 
Controller and Chief Financial Officer
 
(principal financial officer and principal accounting officer)
 



EXHIBIT 32.1
 
CERTIFICATION

In connection with the periodic report of SANUWAVE Health, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2021 as filed with the Securities and Exchange Commission (the “Report”), I, Kevin A. Richardson II, Chief Executive Officer (and principal executive officer) of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that:
 
1.
The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
 
2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.
 
Date:  December 13, 2021
   
/s/ Kevin A. Richardson II
 
Kevin A. Richardson II
 
Chief Executive Officer
 
(principal executive officer)




EXHIBIT 32.2
 
CERTIFICATION
 
In connection with the periodic report of SANUWAVE Health, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2021 as filed with the Securities and Exchange Commission (the “Report”), I, Lisa S. Sundstrom, Controller and Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that:
 
1.
The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
 
2.
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.
 
Date:  December 13, 2021
   
/s/ Lisa E. Sundstrom
 
Lisa E. Sundstrom
 
Controller and Chief Financial Officer
 
(principal financial officer and principal accounting officer)